From 3a4c7944e617ef7fd5ca020f66742f78c69fab85 Mon Sep 17 00:00:00 2001 From: Kamran Date: Tue, 10 Dec 2024 08:48:36 +0600 Subject: [PATCH] made cards fo external ear --- .obsidian/workspace.json | 8 +- .../2024-12-10T00_17_06.730Z.Desktop.md | 90 +++++++ .../2024-12-10T00_17_06.733Z.Desktop.md | 74 ++++++ .../2024-12-10T00_17_06.735Z.Desktop.md | 75 ++++++ .../2024-12-10T00_17_06.748Z.Desktop.md | 110 +++++++++ .../2024-12-10T00_17_06.750Z.Desktop.md | 103 ++++++++ .../2024-12-10T00_17_06.752Z.Desktop.md | 78 ++++++ .../2024-12-10T00_17_06.753Z.Desktop.md | 72 ++++++ .../2024-12-10T00_17_06.755Z.Desktop.md | 76 ++++++ .../2024-12-10T00_17_06.756Z.Desktop.md | 79 ++++++ .../2024-12-10T00_17_06.758Z.Desktop.md | 81 ++++++ .../2024-12-10T00_17_06.763Z.Desktop.md | 115 +++++++++ .../2024-12-10T00_17_06.763Z.Desktop.md | 6 + .../2024-12-10T00_17_06.764Z.Desktop.md | 70 ++++++ .../2024-12-10T00_17_06.765Z.Desktop.md | 72 ++++++ .../2024-12-10T00_17_06.766Z.Desktop.md | 69 ++++++ .../2024-12-10T00_17_06.767Z.Desktop.md | 72 ++++++ .../2024-12-10T00_17_06.768Z.Desktop.md | 74 ++++++ .../2024-12-10T00_17_06.775Z.Desktop.md | 96 ++++++++ .../2024-12-10T00_17_06.776Z.Desktop.md | 72 ++++++ .../2024-12-10T00_17_06.777Z.Desktop.md | 70 ++++++ .../COPD/2024-12-10T00_17_06.831Z.Desktop.md | 75 ++++++ .../2024-12-10T00_17_06.779Z.Desktop.md | 79 ++++++ .../2024-12-10T00_17_06.781Z.Desktop.md | 79 ++++++ .../2024-12-10T00_17_06.783Z.Desktop.md | 70 ++++++ .../2024-12-10T00_17_06.814Z.Desktop.md | 207 ++++++++++++++++ .../2024-12-10T00_17_06.815Z.Desktop.md | 73 ++++++ .../2024-12-10T00_17_06.816Z.Desktop.md | 71 ++++++ .../2024-12-10T00_17_06.818Z.Desktop.md | 92 +++++++ .../2024-12-10T00_17_06.820Z.Desktop.md | 83 +++++++ .../2024-12-10T00_17_06.821Z.Desktop.md | 79 ++++++ .../2024-12-10T00_17_06.822Z.Desktop.md | 74 ++++++ .../2024-12-10T00_17_06.823Z.Desktop.md | 75 ++++++ .../2024-12-10T00_17_06.825Z.Desktop.md | 85 +++++++ .../2024-12-10T00_17_06.827Z.Desktop.md | 80 ++++++ .../2024-12-10T00_17_06.828Z.Desktop.md | 71 ++++++ .../2024-12-10T00_17_06.828Z.Desktop.md | 73 ++++++ .../2024-12-10T00_17_06.829Z.Desktop.md | 71 ++++++ .../2024-12-10T00_17_06.830Z.Desktop.md | 73 ++++++ .../2024-12-10T00_17_06.832Z.Desktop.md | 75 ++++++ .../2024-12-10T00_17_06.833Z.Desktop.md | 75 ++++++ .../2024-12-10T00_17_06.834Z.Desktop.md | 74 ++++++ .../2024-12-10T00_17_06.836Z.Desktop.md | 75 ++++++ .../2024-12-10T00_17_06.837Z.Desktop.md | 70 ++++++ .../2024-12-10T00_17_06.839Z.Desktop.md | 79 ++++++ .../2024-12-10T00_17_06.845Z.Desktop.md | 155 ++++++++++++ .../2024-12-10T00_17_06.846Z.Desktop.md | 72 ++++++ .../2024-12-10T00_17_06.847Z.Desktop.md | 74 ++++++ .../2024-12-10T00_17_06.850Z.Desktop.md | 107 ++++++++ .../2024-12-10T00_17_06.851Z.Desktop.md | 70 ++++++ .../2024-12-10T00_17_06.852Z.Desktop.md | 76 ++++++ .../2024-12-10T00_17_06.853Z.Desktop.md | 75 ++++++ .../2024-12-10T00_17_06.854Z.Desktop.md | 72 ++++++ .../2024-12-10T00_17_06.856Z.Desktop.md | 75 ++++++ .../2024-12-10T00_17_06.857Z.Desktop.md | 79 ++++++ .../2024-12-10T00_17_06.861Z.Desktop.md | 126 ++++++++++ .../2024-12-10T00_17_06.862Z.Desktop.md | 77 ++++++ .../2024-12-10T00_17_06.863Z.Desktop.md | 76 ++++++ .../2024-12-10T00_17_06.864Z.Desktop.md | 74 ++++++ .../2024-12-10T00_17_06.864Z.Desktop.md | 12 + .../2024-12-10T00_17_06.865Z.Desktop.md | 70 ++++++ .../2024-12-10T00_17_06.866Z.Desktop.md | 73 ++++++ .../2024-12-10T00_17_06.867Z.Desktop.md | 77 ++++++ .../2024-12-10T00_17_06.870Z.Desktop.md | 104 ++++++++ .../2024-12-10T00_17_06.871Z.Desktop.md | 75 ++++++ .../2024-12-10T00_17_06.872Z.Desktop.md | 73 ++++++ .../2024-12-10T00_17_06.873Z.Desktop.md | 78 ++++++ .../2024-12-10T00_17_06.882Z.Desktop.md | 136 +++++++++++ .../2024-12-10T00_17_06.883Z.Desktop.md | 73 ++++++ .../2024-12-10T00_17_06.884Z.Desktop.md | 67 +++++ .../2024-12-10T00_17_06.885Z.Desktop.md | 81 ++++++ .../2024-12-10T00_17_06.886Z.Desktop.md | 75 ++++++ .../2024-12-10T00_17_06.887Z.Desktop.md | 70 ++++++ .../2024-12-10T00_17_06.888Z.Desktop.md | 75 ++++++ .../2024-12-10T00_17_06.889Z.Desktop.md | 70 ++++++ .../2024-12-10T00_17_06.890Z.Desktop.md | 80 ++++++ .../2024-12-10T00_17_06.893Z.Desktop.md | 85 +++++++ .../2024-12-10T00_17_06.893Z.Desktop.md | 10 + .../2024-12-10T00_17_06.894Z.Desktop.md | 74 ++++++ .../2024-12-10T00_17_06.922Z.Desktop.md | 230 ++++++++++++++++++ .../2024-12-10T00_17_06.924Z.Desktop.md | 75 ++++++ .../2024-12-10T00_17_06.925Z.Desktop.md | 70 ++++++ .../2024-12-10T00_17_06.928Z.Desktop.md | 111 +++++++++ .../2024-12-10T00_17_06.929Z.Desktop.md | 68 ++++++ .../2024-12-10T00_17_06.930Z.Desktop.md | 77 ++++++ .../2024-12-10T00_17_06.932Z.Desktop.md | 70 ++++++ .../2024-12-10T00_17_06.932Z.Desktop.md | 72 ++++++ .../2024-12-10T00_17_06.935Z.Desktop.md | 101 ++++++++ .../2024-12-10T00_17_06.936Z.Desktop.md | 75 ++++++ .../2024-12-10T00_17_06.937Z.Desktop.md | 72 ++++++ .../2024-12-10T00_17_06.940Z.Desktop.md | 114 +++++++++ .../2024-12-10T00_17_06.990Z.Desktop.md | 122 ++++++++++ .../2024-12-10T00_17_06.991Z.Desktop.md | 76 ++++++ .../2024-12-10T00_17_06.992Z.Desktop.md | 69 ++++++ .../2024-12-10T00_17_06.993Z.Desktop.md | 86 +++++++ .../2024-12-10T00_17_07.000Z.Desktop.md | 154 ++++++++++++ .../2024-12-10T00_17_07.001Z.Desktop.md | 75 ++++++ .../2024-12-10T00_17_07.002Z.Desktop.md | 70 ++++++ .../2024-12-10T00_17_07.003Z.Desktop.md | 68 ++++++ .../2024-12-10T00_17_07.004Z.Desktop.md | 79 ++++++ .../2024-12-10T00_17_07.005Z.Desktop.md | 74 ++++++ .../2024-12-10T00_17_07.006Z.Desktop.md | 70 ++++++ .../2024-12-10T00_17_07.007Z.Desktop.md | 75 ++++++ .../2024-12-10T00_17_07.007Z.Desktop.md | 72 ++++++ .../2024-12-10T00_17_07.008Z.Desktop.md | 74 ++++++ .../2024-12-10T00_17_07.009Z.Desktop.md | 76 ++++++ .../SLE/2024-12-10T00_17_07.016Z.Desktop.md | 112 +++++++++ .../2024-12-10T00_17_07.011Z.Desktop.md | 70 ++++++ .../2024-12-10T00_17_07.012Z.Desktop.md | 77 ++++++ .../2024-12-10T00_17_07.013Z.Desktop.md | 75 ++++++ .../2024-12-10T00_17_07.016Z.Desktop.md | 9 + .../Stye/2024-12-10T00_17_07.019Z.Desktop.md | 89 +++++++ .../2024-12-10T00_17_07.020Z.Desktop.md | 73 ++++++ .../2024-12-10T00_17_07.021Z.Desktop.md | 73 ++++++ .../2024-12-10T00_17_07.022Z.Desktop.md | 88 +++++++ .../2024-12-10T00_17_07.023Z.Desktop.md | 38 +++ .../2024-12-10T00_17_07.024Z.Desktop.md | 69 ++++++ .../2024-12-10T00_17_07.025Z.Desktop.md | 76 ++++++ .../2024-12-10T00_17_07.026Z.Desktop.md | 75 ++++++ .../2024-12-10T00_17_07.027Z.Desktop.md | 73 ++++++ .../2024-12-10T00_17_07.028Z.Desktop.md | 72 ++++++ .../Wax/2024-12-10T00_17_07.032Z.Desktop.md | 133 ++++++++++ .../2024-12-10T00_17_07.033Z.Desktop.md | 5 + .../2024-12-10T00_17_07.024Z.Desktop.md | 1 + pages/Carcinoma Esophagus.md | 100 ++++---- pages/Diptheria.md | 86 +++---- pages/External Ear.md | 1 - pages/Foreign Body in Ear.md | 55 ++++- pages/Furuncle.md | 92 +++++++ pages/Furunculosis.md | 96 ++++---- pages/Hematoma Auris.md | 101 ++++---- pages/Malignant Otitis Externa.md | 111 +++++---- pages/Otitis Externa.md | 27 +- pages/Otomycosis.md | 151 ++++++------ pages/Perichondritis.md | 164 ++++++------- pages/Syringing the Ear.md | 1 + pages/Wax.md | 201 +++++++-------- ...&_Head_and_Neck_Surgery_1730589599933_0.md | 37 +++ 138 files changed, 10479 insertions(+), 513 deletions(-) create mode 100644 logseq/bak/pages/Abruptio Placentae/2024-12-10T00_17_06.730Z.Desktop.md create mode 100644 logseq/bak/pages/Achalasia Cardia/2024-12-10T00_17_06.733Z.Desktop.md create mode 100644 logseq/bak/pages/Acoustic Neuroma/2024-12-10T00_17_06.735Z.Desktop.md create mode 100644 logseq/bak/pages/Acute Anterior Uveitis/2024-12-10T00_17_06.748Z.Desktop.md create mode 100644 logseq/bak/pages/Acute Dacrocystitis/2024-12-10T00_17_06.750Z.Desktop.md create mode 100644 logseq/bak/pages/Acute Epiglottitis/2024-12-10T00_17_06.752Z.Desktop.md create mode 100644 logseq/bak/pages/Acute Mastoiditis/2024-12-10T00_17_06.753Z.Desktop.md create mode 100644 logseq/bak/pages/Acute Maxillary Sinusitis/2024-12-10T00_17_06.755Z.Desktop.md create mode 100644 logseq/bak/pages/Acute Retropharyngeal Abscess/2024-12-10T00_17_06.756Z.Desktop.md create mode 100644 logseq/bak/pages/Acute Suppurative Otitis Media/2024-12-10T00_17_06.758Z.Desktop.md create mode 100644 logseq/bak/pages/Acute Tonsilitis/2024-12-10T00_17_06.763Z.Desktop.md create mode 100644 logseq/bak/pages/Adenoidectomy/2024-12-10T00_17_06.763Z.Desktop.md create mode 100644 logseq/bak/pages/Allergic Conjunctivitis/2024-12-10T00_17_06.764Z.Desktop.md create mode 100644 logseq/bak/pages/Allergic Rhinitis/2024-12-10T00_17_06.765Z.Desktop.md create mode 100644 logseq/bak/pages/Anticoantral Chronic Suppurative Otitis Media/2024-12-10T00_17_06.766Z.Desktop.md create mode 100644 logseq/bak/pages/Antrochoanal Polyp/2024-12-10T00_17_06.767Z.Desktop.md create mode 100644 logseq/bak/pages/Atrophic Rhinitis/2024-12-10T00_17_06.768Z.Desktop.md create mode 100644 logseq/bak/pages/Bacterial Ulcer/2024-12-10T00_17_06.775Z.Desktop.md create mode 100644 logseq/bak/pages/Brachial Cyst/2024-12-10T00_17_06.776Z.Desktop.md create mode 100644 logseq/bak/pages/Breast Cancer/2024-12-10T00_17_06.777Z.Desktop.md create mode 100644 logseq/bak/pages/COPD/2024-12-10T00_17_06.831Z.Desktop.md create mode 100644 logseq/bak/pages/Carcinoma Esophagus/2024-12-10T00_17_06.779Z.Desktop.md create mode 100644 logseq/bak/pages/Carcinoma Larynx/2024-12-10T00_17_06.781Z.Desktop.md create mode 100644 logseq/bak/pages/Carcinoma Parotid Gland/2024-12-10T00_17_06.783Z.Desktop.md create mode 100644 logseq/bak/pages/Cataract/2024-12-10T00_17_06.814Z.Desktop.md create mode 100644 logseq/bak/pages/Central Perforation/2024-12-10T00_17_06.815Z.Desktop.md create mode 100644 logseq/bak/pages/Cervical Lymphadenopathy/2024-12-10T00_17_06.816Z.Desktop.md create mode 100644 logseq/bak/pages/Chalazion/2024-12-10T00_17_06.818Z.Desktop.md create mode 100644 logseq/bak/pages/Cholesteatoma/2024-12-10T00_17_06.820Z.Desktop.md create mode 100644 logseq/bak/pages/Chronic Dacryocystitis/2024-12-10T00_17_06.821Z.Desktop.md create mode 100644 logseq/bak/pages/Chronic Maxillary Sinusitis/2024-12-10T00_17_06.822Z.Desktop.md create mode 100644 logseq/bak/pages/Chronic Retropharyngeal Abscess/2024-12-10T00_17_06.823Z.Desktop.md create mode 100644 logseq/bak/pages/Chronic Suppurative Otitis Media/2024-12-10T00_17_06.825Z.Desktop.md create mode 100644 logseq/bak/pages/Chronic Tonsilitits/2024-12-10T00_17_06.827Z.Desktop.md create mode 100644 logseq/bak/pages/Colon Cancer/2024-12-10T00_17_06.828Z.Desktop.md create mode 100644 logseq/bak/pages/Compensatory Hypertrophy of Inferior Turbinate/2024-12-10T00_17_06.828Z.Desktop.md create mode 100644 logseq/bak/pages/Congenital Dacryocystitis/2024-12-10T00_17_06.829Z.Desktop.md create mode 100644 logseq/bak/pages/Conjunctivitis/2024-12-10T00_17_06.830Z.Desktop.md create mode 100644 logseq/bak/pages/Cystic Hygroma/2024-12-10T00_17_06.832Z.Desktop.md create mode 100644 logseq/bak/pages/Dacryocystitis/2024-12-10T00_17_06.833Z.Desktop.md create mode 100644 logseq/bak/pages/Deviated Nasal Septum/2024-12-10T00_17_06.834Z.Desktop.md create mode 100644 logseq/bak/pages/Diarrhoea/2024-12-10T00_17_06.836Z.Desktop.md create mode 100644 logseq/bak/pages/Diptheria/2024-12-10T00_17_06.837Z.Desktop.md create mode 100644 logseq/bak/pages/Down Syndrome/2024-12-10T00_17_06.839Z.Desktop.md create mode 100644 logseq/bak/pages/Eclampsia/2024-12-10T00_17_06.845Z.Desktop.md create mode 100644 logseq/bak/pages/Encephalopathy/2024-12-10T00_17_06.846Z.Desktop.md create mode 100644 logseq/bak/pages/Enlarged Tonsil/2024-12-10T00_17_06.847Z.Desktop.md create mode 100644 logseq/bak/pages/Epistaxis/2024-12-10T00_17_06.850Z.Desktop.md create mode 100644 logseq/bak/pages/Esophageal Perforation/2024-12-10T00_17_06.851Z.Desktop.md create mode 100644 logseq/bak/pages/Ethmoidal Polyp/2024-12-10T00_17_06.852Z.Desktop.md create mode 100644 logseq/bak/pages/Foreign Body in Esophagus/2024-12-10T00_17_06.853Z.Desktop.md create mode 100644 logseq/bak/pages/Foreign Body in Larynx/2024-12-10T00_17_06.854Z.Desktop.md create mode 100644 logseq/bak/pages/Foreign Body in Nose/2024-12-10T00_17_06.856Z.Desktop.md create mode 100644 logseq/bak/pages/Furunculosis/2024-12-10T00_17_06.857Z.Desktop.md create mode 100644 logseq/bak/pages/Gestational Diabetes Mellitus/2024-12-10T00_17_06.861Z.Desktop.md create mode 100644 logseq/bak/pages/Glue Ear/2024-12-10T00_17_06.862Z.Desktop.md create mode 100644 logseq/bak/pages/Goiter/2024-12-10T00_17_06.863Z.Desktop.md create mode 100644 logseq/bak/pages/Hematoma Auris/2024-12-10T00_17_06.864Z.Desktop.md create mode 100644 logseq/bak/pages/Hoarseness of Voice/2024-12-10T00_17_06.864Z.Desktop.md create mode 100644 logseq/bak/pages/Hodgkin Lymphoma/2024-12-10T00_17_06.865Z.Desktop.md create mode 100644 logseq/bak/pages/Hypermetropia/2024-12-10T00_17_06.866Z.Desktop.md create mode 100644 logseq/bak/pages/Hypertensive Encephalopathy/2024-12-10T00_17_06.867Z.Desktop.md create mode 100644 logseq/bak/pages/Idiopathic Thrombocytopenic Purpura/2024-12-10T00_17_06.870Z.Desktop.md create mode 100644 logseq/bak/pages/Labyrinthitis/2024-12-10T00_17_06.871Z.Desktop.md create mode 100644 logseq/bak/pages/Laryngomalacia/2024-12-10T00_17_06.872Z.Desktop.md create mode 100644 logseq/bak/pages/Left Heart Failure/2024-12-10T00_17_06.873Z.Desktop.md create mode 100644 logseq/bak/pages/Leiomyoma of Uterus/2024-12-10T00_17_06.882Z.Desktop.md create mode 100644 logseq/bak/pages/Ludwig's Angina/2024-12-10T00_17_06.883Z.Desktop.md create mode 100644 logseq/bak/pages/Lung Cancer/2024-12-10T00_17_06.884Z.Desktop.md create mode 100644 logseq/bak/pages/Lymphoma/2024-12-10T00_17_06.885Z.Desktop.md create mode 100644 logseq/bak/pages/Malignant Otitis Externa/2024-12-10T00_17_06.886Z.Desktop.md create mode 100644 logseq/bak/pages/Marginal Perforation/2024-12-10T00_17_06.887Z.Desktop.md create mode 100644 logseq/bak/pages/Meniere's Disease/2024-12-10T00_17_06.888Z.Desktop.md create mode 100644 logseq/bak/pages/Multiple Papilloma of Larynx/2024-12-10T00_17_06.889Z.Desktop.md create mode 100644 logseq/bak/pages/Myopia/2024-12-10T00_17_06.890Z.Desktop.md create mode 100644 logseq/bak/pages/Nasal Polyp/2024-12-10T00_17_06.893Z.Desktop.md create mode 100644 logseq/bak/pages/Nasal Septum/2024-12-10T00_17_06.893Z.Desktop.md create mode 100644 logseq/bak/pages/Neovascular Glaucoma/2024-12-10T00_17_06.894Z.Desktop.md create mode 100644 logseq/bak/pages/Nephrotic Syndrome/2024-12-10T00_17_06.922Z.Desktop.md create mode 100644 logseq/bak/pages/Noise Induced Hearing Loss/2024-12-10T00_17_06.924Z.Desktop.md create mode 100644 logseq/bak/pages/Non Hodgkin Lymphoma/2024-12-10T00_17_06.925Z.Desktop.md create mode 100644 logseq/bak/pages/Obstructed Labor/2024-12-10T00_17_06.928Z.Desktop.md create mode 100644 logseq/bak/pages/Opthalmia Neonatorum/2024-12-10T00_17_06.929Z.Desktop.md create mode 100644 logseq/bak/pages/Ostosclerosis/2024-12-10T00_17_06.930Z.Desktop.md create mode 100644 logseq/bak/pages/Otitis Media with Effusion/2024-12-10T00_17_06.932Z.Desktop.md create mode 100644 logseq/bak/pages/Otogenic Brain Abscess/2024-12-10T00_17_06.932Z.Desktop.md create mode 100644 logseq/bak/pages/Otomycosis/2024-12-10T00_17_06.935Z.Desktop.md create mode 100644 logseq/bak/pages/Papillary Carcinoma of Thyroid/2024-12-10T00_17_06.936Z.Desktop.md create mode 100644 logseq/bak/pages/Parotid Tumor/2024-12-10T00_17_06.937Z.Desktop.md create mode 100644 logseq/bak/pages/Perichondritis/2024-12-10T00_17_06.940Z.Desktop.md create mode 100644 logseq/bak/pages/Placenta Praevia/2024-12-10T00_17_06.990Z.Desktop.md create mode 100644 logseq/bak/pages/Pleomorphic Adenoma/2024-12-10T00_17_06.991Z.Desktop.md create mode 100644 logseq/bak/pages/Pleural Effusion/2024-12-10T00_17_06.992Z.Desktop.md create mode 100644 logseq/bak/pages/Pneumonia/2024-12-10T00_17_06.993Z.Desktop.md create mode 100644 logseq/bak/pages/Pre-Eclampsia/2024-12-10T00_17_07.000Z.Desktop.md create mode 100644 logseq/bak/pages/Presbycusis/2024-12-10T00_17_07.001Z.Desktop.md create mode 100644 logseq/bak/pages/Ptosis/2024-12-10T00_17_07.002Z.Desktop.md create mode 100644 logseq/bak/pages/Purulent Conjunctivitis/2024-12-10T00_17_07.003Z.Desktop.md create mode 100644 logseq/bak/pages/Quinsy/2024-12-10T00_17_07.004Z.Desktop.md create mode 100644 logseq/bak/pages/Renal Failure/2024-12-10T00_17_07.005Z.Desktop.md create mode 100644 logseq/bak/pages/Retropharyngeal abscess/2024-12-10T00_17_07.006Z.Desktop.md create mode 100644 logseq/bak/pages/Rhinolith/2024-12-10T00_17_07.007Z.Desktop.md create mode 100644 logseq/bak/pages/Rhinoscleroma/2024-12-10T00_17_07.007Z.Desktop.md create mode 100644 logseq/bak/pages/Rhinosporidiosis/2024-12-10T00_17_07.008Z.Desktop.md create mode 100644 logseq/bak/pages/Ruptured Tympanic Membrane/2024-12-10T00_17_07.009Z.Desktop.md create mode 100644 logseq/bak/pages/SLE/2024-12-10T00_17_07.016Z.Desktop.md create mode 100644 logseq/bak/pages/Sensorineural Deafness/2024-12-10T00_17_07.011Z.Desktop.md create mode 100644 logseq/bak/pages/Septal Abscess/2024-12-10T00_17_07.012Z.Desktop.md create mode 100644 logseq/bak/pages/Septal Hematoma/2024-12-10T00_17_07.013Z.Desktop.md create mode 100644 logseq/bak/pages/Stridor/2024-12-10T00_17_07.016Z.Desktop.md create mode 100644 logseq/bak/pages/Stye/2024-12-10T00_17_07.019Z.Desktop.md create mode 100644 logseq/bak/pages/Thyroglossal Cyst/2024-12-10T00_17_07.020Z.Desktop.md create mode 100644 logseq/bak/pages/Thyroid Neoplasm/2024-12-10T00_17_07.021Z.Desktop.md create mode 100644 logseq/bak/pages/Tonsilitis/2024-12-10T00_17_07.022Z.Desktop.md create mode 100644 logseq/bak/pages/Tonsillectomy/2024-12-10T00_17_07.023Z.Desktop.md create mode 100644 logseq/bak/pages/Tubotympanic Chronic Suppurative Otitis Media/2024-12-10T00_17_07.024Z.Desktop.md create mode 100644 logseq/bak/pages/Uveitis/2024-12-10T00_17_07.025Z.Desktop.md create mode 100644 logseq/bak/pages/Varicella/2024-12-10T00_17_07.026Z.Desktop.md create mode 100644 logseq/bak/pages/Vertigo/2024-12-10T00_17_07.027Z.Desktop.md create mode 100644 logseq/bak/pages/Vocal Cord Nodule/2024-12-10T00_17_07.028Z.Desktop.md create mode 100644 logseq/bak/pages/Wax/2024-12-10T00_17_07.032Z.Desktop.md create mode 100644 logseq/bak/pages/White Patches on the tonsil/2024-12-10T00_17_07.033Z.Desktop.md create mode 100644 logseq/bak/pages/unanswered/2024-12-10T00_17_07.024Z.Desktop.md create mode 100644 pages/Furuncle.md create mode 100644 pages/Syringing the Ear.md diff --git a/.obsidian/workspace.json b/.obsidian/workspace.json index 4c1e5b6..ec794fb 100644 --- a/.obsidian/workspace.json +++ b/.obsidian/workspace.json @@ -13,12 +13,12 @@ "state": { "type": "markdown", "state": { - "file": "pages/Wax.md", + "file": "logseq/bak/pages/Acute Maxillary Sinusitis/2024-12-09T11_06_23.310Z.Desktop.md", "mode": "source", "source": false }, "icon": "lucide-file", - "title": "Wax" + "title": "2024-12-09T11_06_23.310Z.Desktop" } } ] @@ -52,7 +52,7 @@ "state": { "type": "search", "state": { - "query": "", + "query": "tag:#ent-prof-card", "matchingCase": false, "explainSearch": true, "collapseAll": false, @@ -165,6 +165,8 @@ }, "active": "e9eec337ac40e078", "lastOpenFiles": [ + "pages/Syringing the Ear.md", + "pages/Wax.md", "journals/2024_12_09.md", "pages/Perichondritis.md", "pages/Otomycosis.md", diff --git a/logseq/bak/pages/Abruptio Placentae/2024-12-10T00_17_06.730Z.Desktop.md b/logseq/bak/pages/Abruptio Placentae/2024-12-10T00_17_06.730Z.Desktop.md new file mode 100644 index 0000000..f1e044d --- /dev/null +++ b/logseq/bak/pages/Abruptio Placentae/2024-12-10T00_17_06.730Z.Desktop.md @@ -0,0 +1,90 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + id:: 6a809090-cfec-499d-8a53-72733578865f + - Painful per-vaginal Bleeding + - Dark Colored Blood + - Anemia out of proportion to the visible blood loss + - Often associated with Pre-eclampsia + - Uterus + - disproportionately enlarged in concealed type + - May be tense, tender and rigid + - Fetal Heart Sound absent in concealed type + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis #obspw #unanswered + background-color:: blue + - ### Clinical Diagnosis #obGyn-prof-OSPE + - Lower abdominal pain + - Per vaginal bleeding + - Uterus is hard and contracted + - FHS is absent + - ### Per Vaginal Examination + - Placenta is not felt on lower segment + - Blood clots are felt + - ### Laboratory Tests + - ### Imaging Studies + - [[Abdominal Ultrasonography]] : Placenta in upper segment + - ### Differential Diagnosis +- ## Management and Treatment #obspw #unanswered #obGyn-prof-OSPE + background-color:: blue + - Bishop's scoring + - If cervix favourable + - ### Medical Treatment + - Induction of labor by ARM and oxytocin + - if cervix is unfavourable + - ### Surgical Options + - [[Caesarean Section]] + - ### Lifestyle and Dietary Recommendations +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications #obspw #unanswered + background-color:: blue + - ### Possible Complications #obGyn-prof-OSPE + - Acute Renal Failure + - DIC + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Achalasia Cardia/2024-12-10T00_17_06.733Z.Desktop.md b/logseq/bak/pages/Achalasia Cardia/2024-12-10T00_17_06.733Z.Desktop.md new file mode 100644 index 0000000..45b8d96 --- /dev/null +++ b/logseq/bak/pages/Achalasia Cardia/2024-12-10T00_17_06.733Z.Desktop.md @@ -0,0 +1,74 @@ +- alias:: + ICD-11_Code:: +- ## Etiology #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 36de9f45-68c5-4331-8e37-c3daf391bb23 + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 52c64503-bf27-4d6a-8474-e752eb17a295 + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 2d2ff087-298c-43ec-a324-fce7ddfa9dfa + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Acoustic Neuroma/2024-12-10T00_17_06.735Z.Desktop.md b/logseq/bak/pages/Acoustic Neuroma/2024-12-10T00_17_06.735Z.Desktop.md new file mode 100644 index 0000000..345de7b --- /dev/null +++ b/logseq/bak/pages/Acoustic Neuroma/2024-12-10T00_17_06.735Z.Desktop.md @@ -0,0 +1,75 @@ +- alias:: + ICD-11_Code:: +- #definition {{c1 }} #ent-prof-card #card + deck:: #ENT + id:: 6756c304-3499-4275-8d91-49419983f0cc +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 55f72805-d6eb-4212-990f-cc2cd81152c3 + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: f9d9dedb-3efc-4deb-bde8-e714cd3afa45 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Acute Anterior Uveitis/2024-12-10T00_17_06.748Z.Desktop.md b/logseq/bak/pages/Acute Anterior Uveitis/2024-12-10T00_17_06.748Z.Desktop.md new file mode 100644 index 0000000..ae68df5 --- /dev/null +++ b/logseq/bak/pages/Acute Anterior Uveitis/2024-12-10T00_17_06.748Z.Desktop.md @@ -0,0 +1,110 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms #eye-prof-card #card + deck:: #Eye + id:: a8cc2e5c-90dd-4c82-8d22-14a5a66b12bb + - Mild pain + logseq.order-list-type:: number + - Photophobia + logseq.order-list-type:: number + - Redness + logseq.order-list-type:: number + - #### Signs #eye-prof-card #card + deck:: #Eye + id:: ad1ea991-9cc3-440f-9266-3be8950f0d2e + - Visual Acuity reduced + logseq.order-list-type:: number + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - [[Acute Angle Closure Glaucoma]] + id:: 67541f2a-f920-4139-bbd2-9e23ab3a42b2 + - id:: 67541f3e-5249-4a44-8402-70410e14efe4 + | Topic | AAU | AACG | + |------------------|--------------------------------|--------------------------------| + | Pain and vision loss | Mild pain and gradual loss of vision | Severe pain and sudden marked loss of vision | + | Circumcilliary | Mild | Moderate to severe | + | Cornea | Mild hazy | Hazy | + | Ant. Chamber | Depth Normal | Shallow | + | Cell | +++ | +/- | + | Flare | +++ | + | + | Pupil | Constricted | Mild dilated | + | IOP | Less/Normal | Increased | + | Treatment | Steroid, Mydriatics | Anti-Glaucoma Drugs | + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - Medications + - [[Mydriatics]] Topical [[Atropine 1% Sulphate]] [[TDS]] + logseq.order-list-type:: number + - [[Steroid]] -> Topical [[Dexamethasone]] + logseq.order-list-type:: number + - Mechanism of Action of the Medications + - [[Mydriatics]] #eye-prof-card #card + deck:: #Eye + id:: 6755b7b7-3a46-45a7-aa9b-82898d07b7df + - Relief Pain + logseq.order-list-type:: number + - Prevention and also breakdown of if existing Synachae + logseq.order-list-type:: number + - [[Steroid]] -> {{c1 Reduces Inflammation}} #eye-prof-card #card + deck:: #Eye + id:: 6755b7e5-3798-4191-a163-e41954f7ce45 + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Acute Dacrocystitis/2024-12-10T00_17_06.750Z.Desktop.md b/logseq/bak/pages/Acute Dacrocystitis/2024-12-10T00_17_06.750Z.Desktop.md new file mode 100644 index 0000000..4533dad --- /dev/null +++ b/logseq/bak/pages/Acute Dacrocystitis/2024-12-10T00_17_06.750Z.Desktop.md @@ -0,0 +1,103 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #eye-prof-written + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms #eye-prof-written #card + deck:: [[Eye]] + id:: a8ddd379-c7eb-43bf-b5c6-55cb70de2c56 + - Watering + logseq.order-list-type:: number + - Pain + logseq.order-list-type:: number + - #### Signs #eye-prof-written #card + deck:: [[Eye]] + id:: 455c396b-e575-43bc-97c9-9a788db9e227 + - Red tender tense swelling in medial canthus + logseq.order-list-type:: number + - Abscess in several cases + logseq.order-list-type:: number + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation #classical-presentation + probability:: 85-95% + - Painful Swelling and redness over the lacrimal sac area(medial canthus), with history [[Epiphora]], occasional discharge for last 2 years + - **Pain** and **erythema** over the lacrimal sac region + - **Swelling** and **tenderness** in the lacrimal sac area + - **Purulent discharge** with pressure over the sac (regurgitation test) + - **Systemic symptoms** like **fever** and **malaise** + - Acute onset of symptoms (usually within **hours to days**) + - #### Probable Diagnosis + - ### Differential Diagnosis + - [[Chronic Dacryocystitis]] + check-for:: intermittent mucopurulent discharge without acute pain or systemic symptoms, history of long-term obstruction + - [[Acute Sinusitis]] + check-for:: nasal symptoms (congestion, discharge), pain in the maxillary or ethmoid sinuses, and possible post-nasal drip + - ### Confirmation of Diagnosis + probability:: +0% (85-95%) + - [[Sac Patency Test]] is difficult as it is painful +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + recurrence:: 30-50% or even higher (if persistent nasolacrimal obstruction) + - Broad Spectrum Antibiotics + - Warm compression + - ### Surgical Options + recurrence:: 5-10% + - [[DCR]] + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications #eye-prof-written #card + deck:: [[Eye]] + id:: e901594a-f442-44c1-8dcb-52494a6b4f39 + - [[Chronic Dacryocystitis]] + logseq.order-list-type:: number + - [[Lacrimal Abscess]] + logseq.order-list-type:: number + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue +- SN: #eye-prof-written \ No newline at end of file diff --git a/logseq/bak/pages/Acute Epiglottitis/2024-12-10T00_17_06.752Z.Desktop.md b/logseq/bak/pages/Acute Epiglottitis/2024-12-10T00_17_06.752Z.Desktop.md new file mode 100644 index 0000000..23035cd --- /dev/null +++ b/logseq/bak/pages/Acute Epiglottitis/2024-12-10T00_17_06.752Z.Desktop.md @@ -0,0 +1,78 @@ +- alias:: + ICD-11_Code:: +- ## Etiology #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 679efe77-ff1d-4c8d-888c-abb551b9ada2 + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 594754be-5664-46ab-8213-ccbed28261b5 + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - [[Acute Laryngotracheobronchitis]] + - Differences #ent-prof-card #card + deck:: #ENT + id:: 6756b395-74e9-4b44-83bd-651dc5aeded1 + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 4ef3c41d-da98-42b2-ae51-71ddb4f116d4 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Acute Mastoiditis/2024-12-10T00_17_06.753Z.Desktop.md b/logseq/bak/pages/Acute Mastoiditis/2024-12-10T00_17_06.753Z.Desktop.md new file mode 100644 index 0000000..53faf92 --- /dev/null +++ b/logseq/bak/pages/Acute Mastoiditis/2024-12-10T00_17_06.753Z.Desktop.md @@ -0,0 +1,72 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - [[Furunculosis]] + - Differences #ent-prof-card #card + deck:: #ENT + id:: 6756bf74-1837-4386-b65d-01fd1761851d + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Acute Maxillary Sinusitis/2024-12-10T00_17_06.755Z.Desktop.md b/logseq/bak/pages/Acute Maxillary Sinusitis/2024-12-10T00_17_06.755Z.Desktop.md new file mode 100644 index 0000000..4276594 --- /dev/null +++ b/logseq/bak/pages/Acute Maxillary Sinusitis/2024-12-10T00_17_06.755Z.Desktop.md @@ -0,0 +1,76 @@ +- alias:: + ICD-11_Code:: +- ## Etiology #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 3fae41d5-d42b-4c21-9e86-58cedddcc339 + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 00ed145a-4123-46b2-8747-008133352fc0 + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: e0e6c817-331f-4915-8c21-e69e459165b0 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Complications #ent-prof-card #card + deck:: #ENT + id:: 481a1175-c18c-4f1f-9336-7f2707e71ffd + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Acute Retropharyngeal Abscess/2024-12-10T00_17_06.756Z.Desktop.md b/logseq/bak/pages/Acute Retropharyngeal Abscess/2024-12-10T00_17_06.756Z.Desktop.md new file mode 100644 index 0000000..42e5890 --- /dev/null +++ b/logseq/bak/pages/Acute Retropharyngeal Abscess/2024-12-10T00_17_06.756Z.Desktop.md @@ -0,0 +1,79 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 27392bbe-50d1-4650-837d-dccf4f455d4f + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Investigation #ent-prof-card #card + deck:: #ENT + id:: 6756b61f-4520-49bf-a222-e8244026dcf1 + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - [[Chronic Retropharyngeal Abscess]] + - Differences #ent-prof-card #card + deck:: #ENT + id:: 6756ae63-85c1-4975-92c6-81bccebb2bfb + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 32ecf5df-62d9-4669-bf18-94d0b5189c9d + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Acute Suppurative Otitis Media/2024-12-10T00_17_06.758Z.Desktop.md b/logseq/bak/pages/Acute Suppurative Otitis Media/2024-12-10T00_17_06.758Z.Desktop.md new file mode 100644 index 0000000..1d33616 --- /dev/null +++ b/logseq/bak/pages/Acute Suppurative Otitis Media/2024-12-10T00_17_06.758Z.Desktop.md @@ -0,0 +1,81 @@ +alias:: ASOM +ICD-11_Code:: + +- ## Etiology #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 6756cf32-3a7b-41ed-8fea-a0f681ae9e7d + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 782d278c-2df9-4263-8e34-97ecc224a950 + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: a75925d6-4e7c-4bb5-b330-4c6e4c33c818 + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: b1c1548a-73e5-4d11-9249-1f0f1b2b101e + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Complications #ent-prof-card #card + deck:: #ENT + id:: 06d1b4e7-12da-40c3-9f32-d0f47a801483 + - ##### Sequel #ent-prof-card #card + deck:: #ENT + id:: 6756cf32-6112-4fa1-81f0-3f85ea01f0ab + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Acute Tonsilitis/2024-12-10T00_17_06.763Z.Desktop.md b/logseq/bak/pages/Acute Tonsilitis/2024-12-10T00_17_06.763Z.Desktop.md new file mode 100644 index 0000000..4bfb3e8 --- /dev/null +++ b/logseq/bak/pages/Acute Tonsilitis/2024-12-10T00_17_06.763Z.Desktop.md @@ -0,0 +1,115 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### 3 important causes of unilateral tonsillar enlargement #ent-prof-written #card + deck:: #ENT + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 6733ccec-0fd5-4d94-a031-50fd073d4404 + - ### Signs and Symptoms + - #### Symptoms + - Severe sore throat + logseq.order-list-type:: number + - Dysphagia + logseq.order-list-type:: number + - Fever + logseq.order-list-type:: number + - Odynophagia + logseq.order-list-type:: number + - Unable to open mouth + logseq.order-list-type:: number + - Change of voice + logseq.order-list-type:: number + - Earache (referred pain or the result of acute otitis media as a complication) + logseq.order-list-type:: number + - #### Signs + - Temperature high (102ºF to 104ºF) + logseq.order-list-type:: number + - Tonsil - swollen, oedematous, congested, pus over the tonsil + logseq.order-list-type:: number + - Jugulo digastric lymph node - enlarged and tender + logseq.order-list-type:: number + - Surrounding soft tissue (pillar, soft palate, uvula) - congested + logseq.order-list-type:: number + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - ### Investigations + - CBC: Neutrophilic leukocytosis + - Throat swab for culture and sensitivity + - ### Imaging Studies + - ### Differential Diagnosis #ent-prof-written #card + deck:: #ENT + - ### Differential Diagnosis +- ## Management and Treatment #ent-prof-card #ent-prof-written #card + background-color:: blue + deck:: #ENT + id:: 6733ccec-59ce-49d1-91d1-710b3d517df6 + - ### Medical Treatment + - Broad spectrum antibiotics: [[Cefixime]] 200 mg / [[Cefuroxime]] 200 mg [[TDS]] + - Analgesics: [[Aspirin]], [[Paracetamol]] + - Antipyratics + - Nutrition maintain - liquid and soft solid food should be given + - Avoid cold + - Gurgling + - Bed rest + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications #ent-prof-written #card + deck:: #ENT + - #### Local + - [[Chronic Tonsilitits]] + - [[Peritonsillar abscess]] + - [[Retropharyngeal abscess]] + - [[Airway obstruction]] + - #### General + - [[Septicemia]] + - [[Rheumatic Fever]] + - [[AGN]] + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Adenoidectomy/2024-12-10T00_17_06.763Z.Desktop.md b/logseq/bak/pages/Adenoidectomy/2024-12-10T00_17_06.763Z.Desktop.md new file mode 100644 index 0000000..179a8b0 --- /dev/null +++ b/logseq/bak/pages/Adenoidectomy/2024-12-10T00_17_06.763Z.Desktop.md @@ -0,0 +1,6 @@ +# Indications #ent-prof-card #card +deck:: #ENT +id:: 6756b20d-4737-4be6-a805-51d67da83b14 +- # Postoperative Complications #ent-prof-card #card + deck:: #ENT + id:: 6756b219-4c90-4cd6-9ad0-94a78e34ae37 \ No newline at end of file diff --git a/logseq/bak/pages/Allergic Conjunctivitis/2024-12-10T00_17_06.764Z.Desktop.md b/logseq/bak/pages/Allergic Conjunctivitis/2024-12-10T00_17_06.764Z.Desktop.md new file mode 100644 index 0000000..bc18aa4 --- /dev/null +++ b/logseq/bak/pages/Allergic Conjunctivitis/2024-12-10T00_17_06.764Z.Desktop.md @@ -0,0 +1,70 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #eye-prof-written + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification #eye-prof-written + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #eye-prof-written + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Prevention and Treatment of Different Types of Conjunctivitis #eye-prof-written + - Vernal Conjunctivitis #eye-prof-written + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Allergic Rhinitis/2024-12-10T00_17_06.765Z.Desktop.md b/logseq/bak/pages/Allergic Rhinitis/2024-12-10T00_17_06.765Z.Desktop.md new file mode 100644 index 0000000..c6f11c9 --- /dev/null +++ b/logseq/bak/pages/Allergic Rhinitis/2024-12-10T00_17_06.765Z.Desktop.md @@ -0,0 +1,72 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: b1a89f71-c40c-4f6d-b9b5-94bd9c0b80de + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 72e3ee78-26ee-49d6-ab82-23fbaefdcc05 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Anticoantral Chronic Suppurative Otitis Media/2024-12-10T00_17_06.766Z.Desktop.md b/logseq/bak/pages/Anticoantral Chronic Suppurative Otitis Media/2024-12-10T00_17_06.766Z.Desktop.md new file mode 100644 index 0000000..1a87a13 --- /dev/null +++ b/logseq/bak/pages/Anticoantral Chronic Suppurative Otitis Media/2024-12-10T00_17_06.766Z.Desktop.md @@ -0,0 +1,69 @@ +alias:: Anticoantral variety CSOM +ICD-11_Code:: + +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Antrochoanal Polyp/2024-12-10T00_17_06.767Z.Desktop.md b/logseq/bak/pages/Antrochoanal Polyp/2024-12-10T00_17_06.767Z.Desktop.md new file mode 100644 index 0000000..50d99cc --- /dev/null +++ b/logseq/bak/pages/Antrochoanal Polyp/2024-12-10T00_17_06.767Z.Desktop.md @@ -0,0 +1,72 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: b60be11f-a8f7-4d59-bdc2-2b436cdbaa32 + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 984e2564-c66d-424d-9132-3312c25c965f + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Atrophic Rhinitis/2024-12-10T00_17_06.768Z.Desktop.md b/logseq/bak/pages/Atrophic Rhinitis/2024-12-10T00_17_06.768Z.Desktop.md new file mode 100644 index 0000000..72edc9f --- /dev/null +++ b/logseq/bak/pages/Atrophic Rhinitis/2024-12-10T00_17_06.768Z.Desktop.md @@ -0,0 +1,74 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 076f87a1-3352-4223-ab92-057fa79dcb5c + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 6c359ab4-206d-4b36-ac9e-9ccef443bae6 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications #ent-prof-card #card + deck:: #ENT + id:: cdac1bc9-1e05-45ba-8e84-2c8168f2a52c + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Bacterial Ulcer/2024-12-10T00_17_06.775Z.Desktop.md b/logseq/bak/pages/Bacterial Ulcer/2024-12-10T00_17_06.775Z.Desktop.md new file mode 100644 index 0000000..2cf2377 --- /dev/null +++ b/logseq/bak/pages/Bacterial Ulcer/2024-12-10T00_17_06.775Z.Desktop.md @@ -0,0 +1,96 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms #eye-prof-card #card + deck:: Eye + id:: c3f181b7-5dfb-4fd9-a503-6b6249eca219 + - Pain + - Photophobia + - Watering + - Diminished Vision + - #### Signs #eye-prof-card #card + deck:: Eye + id:: f8af9f1a-4fe3-48a6-a259-5fd572502c34 + - Ciliary Congestions (redness around cornea) + - [[Hypophon]] + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Investigations ‬‭ #eye-prof-card #card + deck:: Eye + id:: 6747af2c-41e7-4b9a-85c5-2d982358243b + - Corneal Scraping and the + logseq.order-list-type:: number + - Gram staining + logseq.order-list-type:: number + - Giemsa staining + logseq.order-list-type:: number + - KOH preparation + logseq.order-list-type:: number + - C/S + logseq.order-list-type:: number + - Fluorescein dye test + logseq.order-list-type:: number + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment #eye-prof-card #card + deck:: Eye + id:: 38be0f5c-2a09-4dd4-a846-791180fc9763 + - Board Spectrum Antibiotic (Topical) + - Systemic Antibiotic + - [[Atropine 1% Sulphate]] + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Brachial Cyst/2024-12-10T00_17_06.776Z.Desktop.md b/logseq/bak/pages/Brachial Cyst/2024-12-10T00_17_06.776Z.Desktop.md new file mode 100644 index 0000000..5753a33 --- /dev/null +++ b/logseq/bak/pages/Brachial Cyst/2024-12-10T00_17_06.776Z.Desktop.md @@ -0,0 +1,72 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: ec429dde-4fdb-4ee3-a333-de3148df1aa3 + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 981965ee-eeb0-4942-b9bc-8ef9e583b539 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Breast Cancer/2024-12-10T00_17_06.777Z.Desktop.md b/logseq/bak/pages/Breast Cancer/2024-12-10T00_17_06.777Z.Desktop.md new file mode 100644 index 0000000..ea17aa7 --- /dev/null +++ b/logseq/bak/pages/Breast Cancer/2024-12-10T00_17_06.777Z.Desktop.md @@ -0,0 +1,70 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + source:: ACOG + - Begin at age 40 ending at age 75 + exception:: start early if risk factors + - Annual Breast Exam : Annual Mammogram + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/COPD/2024-12-10T00_17_06.831Z.Desktop.md b/logseq/bak/pages/COPD/2024-12-10T00_17_06.831Z.Desktop.md new file mode 100644 index 0000000..7d12028 --- /dev/null +++ b/logseq/bak/pages/COPD/2024-12-10T00_17_06.831Z.Desktop.md @@ -0,0 +1,75 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - [[ECG]] + - Low voltage + - Poor R wave progression + - Tall P waves + - Unusual QRS axis + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Carcinoma Esophagus/2024-12-10T00_17_06.779Z.Desktop.md b/logseq/bak/pages/Carcinoma Esophagus/2024-12-10T00_17_06.779Z.Desktop.md new file mode 100644 index 0000000..c8bc25e --- /dev/null +++ b/logseq/bak/pages/Carcinoma Esophagus/2024-12-10T00_17_06.779Z.Desktop.md @@ -0,0 +1,79 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 464b6633-91a4-428a-b619-da2aa496c4e9 + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Investigation #ent-prof-card #card + deck:: #ENT + id:: 6756b5b4-3bc1-4867-9de8-8fa712fb4021 + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - [[Achalasia Cardia]] + - Differences #ent-prof-card #card + deck:: #ENT + id:: 6756aebe-94f6-4540-bb8d-48b5a674608e + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 1f402519-98a7-48ea-a65a-27f7915cd7ab + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Carcinoma Larynx/2024-12-10T00_17_06.781Z.Desktop.md b/logseq/bak/pages/Carcinoma Larynx/2024-12-10T00_17_06.781Z.Desktop.md new file mode 100644 index 0000000..b73479b --- /dev/null +++ b/logseq/bak/pages/Carcinoma Larynx/2024-12-10T00_17_06.781Z.Desktop.md @@ -0,0 +1,79 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: e7ef8278-394b-4031-81a4-7ae527bf7f6f + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Investigation #ent-prof-card #card + deck:: #ENT + id:: 6756ba70-7690-4493-9769-4bb8d8576e1b + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: f47ebcf7-3ddd-490a-ba70-306d4b3239be + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ##### Release a case of airway obstruction due to Carcinoma Larynx #ent-prof-card #card + deck:: #ENT + id:: 6756baf9-e01b-4bb0-8058-c9b6f7e146f1 + - [[Tracheostomy]] +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Carcinoma Parotid Gland/2024-12-10T00_17_06.783Z.Desktop.md b/logseq/bak/pages/Carcinoma Parotid Gland/2024-12-10T00_17_06.783Z.Desktop.md new file mode 100644 index 0000000..c142abd --- /dev/null +++ b/logseq/bak/pages/Carcinoma Parotid Gland/2024-12-10T00_17_06.783Z.Desktop.md @@ -0,0 +1,70 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: a9d8f1f0-97f2-425c-9f1d-36077e177008 + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Cataract/2024-12-10T00_17_06.814Z.Desktop.md b/logseq/bak/pages/Cataract/2024-12-10T00_17_06.814Z.Desktop.md new file mode 100644 index 0000000..4012fe2 --- /dev/null +++ b/logseq/bak/pages/Cataract/2024-12-10T00_17_06.814Z.Desktop.md @@ -0,0 +1,207 @@ +alias:: +ICD-11_Code:: + +- #definition {{c1 Any opacity in human crystalline lens}} #eye-prof-written #card + id:: 67542d36-5b17-40ac-b386-e03ef8bd4a2b + deck:: [[Eye]] +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + collapsed:: true + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification #eye-prof-written + - ##### Etiological Classificaton #eye-prof-written #card + deck:: #Eye + id:: 674ac82d-455f-4fbd-b556-e99abf5ff579 + - [[Developmental Cataract]] + id:: 674ac7a4-7bfe-4cd4-9c61-6ad349bdd3af + - [[Acquired Cataract]] + id:: 674ac7b5-20c1-41d8-b9e0-e338bfe7abcd + - ##### Depending on maturity #eye-prof-written #card + deck:: #Eye + id:: 674ac835-5aa6-4acd-8035-a1b5a218abdb + - [[Intumescent Cataract]] + - [[Immature Cataract]] + - [[Mature Cataract]] + - [[Hypermature Cataract]] + - Sclerotic Cataract + - Morgagnian Cataract + - ### Diagnostic Criteria + id:: 33644eee-3af2-4d56-8089-32a582fb4f8d + - | Traits | Immature Cataract | Mature Cataract | Hypermature Cataract | + | ------------- | ----------------- | --------------- | ----------------------- | + | Visual Acuity | upto 6/12, 6/18 | 6/36, 6/60 | Hand movement to PL, PR | + | Colour | Grayish white | Pearly white | Milky White | + | Iris shadow | present | absent | absent | + | Fundal glow | present | absent | absent | +- ## Diagnosis + background-color:: blue + collapsed:: true + - ### Clinical Diagnosis + - #### Classical Presentation #classical-presentation + - Old Age, above 60 + - Gradual Dimness of Vision for past few years + - Visual Acuity reduced to hand movement + - Color of lens milky white + - Iris shadow absent + - Follow ((33644eee-3af2-4d56-8089-32a582fb4f8d)) + - #### Probable Diagnosis + - ### Examination + - _General Examination of the patient should be done to determine the presence of serious systemic disease_ + - Visual Acuity + - Pupillary light reflex [Direct, consensual] + - Color of lens [Torch examination] + _grading of nucleus hardness_ by [[LOCS]] + - ((674f65c1-fc03-4bf1-ab74-bbb1463be2f2)) + - The grading of nucleus hardness is useful to the cataract surgeon in planning surgery by phacoemulsification + - [[Intraocular Pressure]] [Digitally] + - Retinal and Optic Nerve Function + _If the fundus cannot be seen, 5 tests are of value_ + - Detection of the projection of light + - Macular function + - Entopic view of the retina + - Ultrasonic investigation + - foveal electroretinogram + - Sac resucsitation test + - Additionally, + - Ocular Motility + - Fundoscopy + - ### Investigation + - #### Systemic Investigation + - ECG + - Blood Sugar profile, HbA1c + - #### Ocular Investigation + - [[Biometry]] + - [[Keratometry]] + - [[B scan]] + - ### Laboratory Tests + collapsed:: true + - For ((674f6390-1845-4e57-b843-880c24c49545)) + - ((674f63a7-3853-45ac-bd93-8acf9c9a7a49)) + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + collapsed:: true + - ### Medical Management + - ### Surgical Options + - ((674f748b-95b8-42e9-916f-1658f31beb7e)) + - ### Names of Cataract Surgeries #eye-prof-written #card + deck:: #Eye + id:: 67549996-1d4f-4213-80ba-ee798702508c + - [[SICS]] with [[Posterior Chamber Intraocular Lens Implantation]] + - [[Phaco-emulsification]] with [[Posterior Chamber Intraocular Lens Implantation]] + - [[Lensectomy]] + - [[Femtosecond Laser-Assisted Cataract Surgery]] + - ### Preoperative Investigations + Preoperative Clinical Evaluation + - Ocular #eye-prof-written #card + deck:: #Eye + id:: 674ff598-cb9b-4a1f-bd83-7cccdbfd5f2d + - [[Tonometry]] + logseq.order-list-type:: number + - [[Sac Patency Test]] + logseq.order-list-type:: number + - [[Biometry]] + logseq.order-list-type:: number + - [[B-Scan]] if Hypermature Cataract + logseq.order-list-type:: number + - Systemic #eye-prof-written #card + deck:: #Eye + id:: 674ff5c8-ce33-4f49-a8f6-bddb48164eb9 + - Blood Sugar, [[HbA1c]] + logseq.order-list-type:: number + - [[ECG]] + logseq.order-list-type:: number + - [[Chest X-Ray PA view]] if Respiratory problem + logseq.order-list-type:: number + - ### Lifestyle and Dietary Recommendations + - ### Follow-up + collapsed:: true + - Assess visual outcome + - [[ONFT]] + - [[MFT]] + - Tonometry + - Opthalmoscope +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - Due to anasthetics + collapsed:: true + - Retrobulbar hemorrhage + - Inadvertent perforation of the globe + - Oculocardiac reflex + - Accidental intracranial spread of the anaesthetic + - Per-operative complications #eye-prof-written #card + deck:: [[Eye]] + id:: 674acc2d-1181-4582-9238-eb1832535f0c + - Posterior Capsular Tear + logseq.order-list-type:: number + - Vitrous Prolapse, Iris Prolapse + logseq.order-list-type:: number + - Lens Drop + logseq.order-list-type:: number + - Injury to Surrounding Structures + logseq.order-list-type:: number + - Early Post-operative complication(first 3 weeks) #eye-prof-written #card + deck:: [[Eye]] + id:: 674acec8-b302-423c-a9be-3c186e75f46c + - [[Corneal edema]] + - Uveitis + - Late Post Operative Complication #eye-prof-written #card + deck:: [[Eye]] + id:: 674acf3c-c9f9-4d95-a09d-584c445d228d + - Macular Edema + - Posterior capsular opacification (2-3 years) + alias:: after cataract, secondary cataract + - [[Endophthalmitis]] + - Sublaxation + - Astigmatism + - #### Without Treatment + - ##### Possible Complications + - Progression of Immature to Mature and Mature to Hypermature Cataract + - ##### Long-Term Effects + - [[Lens Induced Glaucoma]] + - [[Immature Cataract]] , [[Mature Cataract]] -> [[Phacomorphic Glaucoma]] + - [[Hypermature Cataract]] -> [[Phacolytic Glaucoma]] , [[Phaco-anaphylactic glaucoma]] + - Retinal Detachment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + collapsed:: true + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + collapsed:: true + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + collapsed:: true + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Central Perforation/2024-12-10T00_17_06.815Z.Desktop.md b/logseq/bak/pages/Central Perforation/2024-12-10T00_17_06.815Z.Desktop.md new file mode 100644 index 0000000..9845054 --- /dev/null +++ b/logseq/bak/pages/Central Perforation/2024-12-10T00_17_06.815Z.Desktop.md @@ -0,0 +1,73 @@ +- alias:: + ICD-11_Code:: +- #definition {{c1 }} #ent-prof-card #card + deck:: #ENT + id:: 6756ce8c-7bd0-445c-bd5c-4d660a09f5a1 +- ## Etiology + background-color:: blue + - ### Causative Agents #ent-prof-card #card + deck:: #ENT + id:: c19ca376-1efb-4d4c-b236-f3b8c9ecea7a + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Cervical Lymphadenopathy/2024-12-10T00_17_06.816Z.Desktop.md b/logseq/bak/pages/Cervical Lymphadenopathy/2024-12-10T00_17_06.816Z.Desktop.md new file mode 100644 index 0000000..0e86a80 --- /dev/null +++ b/logseq/bak/pages/Cervical Lymphadenopathy/2024-12-10T00_17_06.816Z.Desktop.md @@ -0,0 +1,71 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 23733b98-e0a2-45fb-84fe-73d91f7c1a3e + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Investigation + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Chalazion/2024-12-10T00_17_06.818Z.Desktop.md b/logseq/bak/pages/Chalazion/2024-12-10T00_17_06.818Z.Desktop.md new file mode 100644 index 0000000..b9ac746 --- /dev/null +++ b/logseq/bak/pages/Chalazion/2024-12-10T00_17_06.818Z.Desktop.md @@ -0,0 +1,92 @@ +alias:: +ICD-11_Code:: + +- #definition {{c1 It is a chronic granulomatous non-infections lesion in [[Meibomian Gland]] due to occlusion of its duct.}} #eye-prof-written #eye-prof-card #card + deck:: #Eye + id:: 67542e6e-8422-4c0a-9aaf-8d258b53e746 +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - Cardinal Features #eye-prof-card #card + deck:: #Eye + id:: 6755ecef-3719-432c-9179-1e5f38e3c300 + - Non-Tender,painless + logseq.order-list-type:: number + - Firm ,Tense + logseq.order-list-type:: number + - Nodular swelling of eyelid away from margin + logseq.order-list-type:: number + - No signs of inflammation + logseq.order-list-type:: number + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #eye-prof-written + background-color:: blue + - ### Medical Management + id:: 4b839cd7-0d9e-432d-a908-0e842ff94c1b + - Initially {{c1 Antibiotic}} & {{c1 Hot Compression}} #eye-prof-card #card + deck:: #Eye + id:: 6755e6f6-49cd-45a8-a276-c802dc9732ba + - ### Surgical Treatment + id:: 991b1321-eec2-4363-b81c-cd94158ea089 + - {{c1 Incision}} and {{c1 Curettage}} ( {{c2 vertical}} incision to the lid margin) #eye-prof-card #card + id:: 6755e72e-388d-4f4e-af82-6779b34321e0 + deck:: #Eye + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment #eye-prof-written + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue +- SN: #eye-prof-written \ No newline at end of file diff --git a/logseq/bak/pages/Cholesteatoma/2024-12-10T00_17_06.820Z.Desktop.md b/logseq/bak/pages/Cholesteatoma/2024-12-10T00_17_06.820Z.Desktop.md new file mode 100644 index 0000000..22a3338 --- /dev/null +++ b/logseq/bak/pages/Cholesteatoma/2024-12-10T00_17_06.820Z.Desktop.md @@ -0,0 +1,83 @@ +- alias:: + ICD-11_Code:: +- #definition {{c1 }} #ent-prof-card #card + deck:: #ENT + id:: 6756c713-60be-453c-8b30-ab4c6d5335e0 +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease #ent-prof-card #card + deck:: #ENT + id:: b4a881f1-bb60-4a39-8c4d-af04161a135e + - ### Affected Systems/Organs + - Intracranial Complications + - Mechanism #ent-prof-card #card + deck:: #ENT + id:: 6756ce3a-2ab7-4c2c-8a0a-1cc353422dd0 +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 6756cf34-077e-4771-9169-584c3f362368 + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 2e0078c6-cf6c-4b3d-8223-0ca14f393bf2 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications #ent-prof-card #card + deck:: #ENT + id:: b23de92e-4657-4264-824c-24fa3cad1f05 + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Chronic Dacryocystitis/2024-12-10T00_17_06.821Z.Desktop.md b/logseq/bak/pages/Chronic Dacryocystitis/2024-12-10T00_17_06.821Z.Desktop.md new file mode 100644 index 0000000..696b922 --- /dev/null +++ b/logseq/bak/pages/Chronic Dacryocystitis/2024-12-10T00_17_06.821Z.Desktop.md @@ -0,0 +1,79 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #eye-prof-written + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - Constant [[Epiphora]] + - [[Chronic Conjunctivitis]] + - #### Signs + - Painless swelling at medial canthas + - Positive Sac Regurgitation test + - Matted eyelash + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation #classical-presentation + probability:: 70-90% + - [[Epiphora]] and intermittent mucopurulent Discharge + - Positive [[Regurgitation Test]] showing mucopurulent discharge + - #### Probable Diagnosis + - ### Differential Diagnosis + - [[Acute Dacrocystitis]] + check-for:: marked pain, erythema, swelling, and absence of mucopurulent discharge or occasional and only on [[Regurgitation Test]] + - ### Confirmation of Diagnosis + *clinical diagnosis* +- ## Management and Treatment + background-color:: blue + for [[Congenital Dacryocystitis]] in Congenital Dacryocystitis + - ### Medical Treatment + - ### Surgical Options + - + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Chronic Maxillary Sinusitis/2024-12-10T00_17_06.822Z.Desktop.md b/logseq/bak/pages/Chronic Maxillary Sinusitis/2024-12-10T00_17_06.822Z.Desktop.md new file mode 100644 index 0000000..441cf18 --- /dev/null +++ b/logseq/bak/pages/Chronic Maxillary Sinusitis/2024-12-10T00_17_06.822Z.Desktop.md @@ -0,0 +1,74 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 2b3fabc1-bcd2-478c-9359-217b0ccfec52 + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 1010e57a-e0f8-4c59-b704-25ab11c34937 + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 5f482ed7-2c91-4a3c-b7e2-a07a17eb328b + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Chronic Retropharyngeal Abscess/2024-12-10T00_17_06.823Z.Desktop.md b/logseq/bak/pages/Chronic Retropharyngeal Abscess/2024-12-10T00_17_06.823Z.Desktop.md new file mode 100644 index 0000000..ef79200 --- /dev/null +++ b/logseq/bak/pages/Chronic Retropharyngeal Abscess/2024-12-10T00_17_06.823Z.Desktop.md @@ -0,0 +1,75 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 25d8cef9-d646-4c62-a329-59dc6819cf92 + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Investigation #ent-prof-card #card + deck:: #ENT + id:: 6756b622-96b5-44c0-8b11-0d31e5b0a86e + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: b74bd004-ee30-4dd4-abc5-fa18e986569f + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Chronic Suppurative Otitis Media/2024-12-10T00_17_06.825Z.Desktop.md b/logseq/bak/pages/Chronic Suppurative Otitis Media/2024-12-10T00_17_06.825Z.Desktop.md new file mode 100644 index 0000000..a4152ce --- /dev/null +++ b/logseq/bak/pages/Chronic Suppurative Otitis Media/2024-12-10T00_17_06.825Z.Desktop.md @@ -0,0 +1,85 @@ +alias:: CSOM +ICD-11_Code:: + +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - [[Tubotympanic Chronic Suppurative Otitis Media]] + - [[Anticoantral Chronic Suppurative Otitis Media]] + - Differences between [[Tubotympanic variety CSOM]] and [[Anticoantral variety CSOM]] #ent-prof-card #card + deck:: #ENT + id:: 6756c6d1-5755-4374-91b1-8f5ec4f8f6ef + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Investigation + - deck:: #ENT + id:: 6756bff6-4066-4836-ad06-539a7077b1ca + |Test|Interpretation| + |[[Rinne's Test]]|{{c1 }}| + |[[Weber Test]]|{{c2 }}| + #ent-prof-card #card + deck:: #ENT + id:: 6756bff6-4066-4836-ad06-539a7077b1ca + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications #ent-prof-card #card + deck:: #ENT + id:: c93f1a22-c346-4a1e-9be1-67b2db2bca1c + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Chronic Tonsilitits/2024-12-10T00_17_06.827Z.Desktop.md b/logseq/bak/pages/Chronic Tonsilitits/2024-12-10T00_17_06.827Z.Desktop.md new file mode 100644 index 0000000..3e17d27 --- /dev/null +++ b/logseq/bak/pages/Chronic Tonsilitits/2024-12-10T00_17_06.827Z.Desktop.md @@ -0,0 +1,80 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - Mild pain/sore throat + - Mild fever + - Odynophagia + - Change of voice + - Sleep apnoea + - Helitosis + - bad taste + - Cough + - #### Signs + - Tonsil enlarged not so congested + - Pus/debris/ cheesy material out if anterior pillar is pressed may come tonsillar crypt (Crypt of Magna) + - Congestion of anterior pillar + - Jugulo-digastric palpable but not tender + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - ### Laboratory Tests + - CBC: increased lymphocyte count + - ### Imaging Studies + - ### Differential Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment : failure + - ### Surgical Options + - [[Tonsillectomy]] + - ### Lifestyle and Dietary Recommendations +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Colon Cancer/2024-12-10T00_17_06.828Z.Desktop.md b/logseq/bak/pages/Colon Cancer/2024-12-10T00_17_06.828Z.Desktop.md new file mode 100644 index 0000000..68f0f59 --- /dev/null +++ b/logseq/bak/pages/Colon Cancer/2024-12-10T00_17_06.828Z.Desktop.md @@ -0,0 +1,71 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - Begin at age : 50 + exception:: if 1st degree relative with colon cancer, then begin 10 years prior to the youngest known diagnosis in the family or age 40 whichever is earlier + - Colonoscopy + - [[FOBT]] + - FIT + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Compensatory Hypertrophy of Inferior Turbinate/2024-12-10T00_17_06.828Z.Desktop.md b/logseq/bak/pages/Compensatory Hypertrophy of Inferior Turbinate/2024-12-10T00_17_06.828Z.Desktop.md new file mode 100644 index 0000000..2c61a8c --- /dev/null +++ b/logseq/bak/pages/Compensatory Hypertrophy of Inferior Turbinate/2024-12-10T00_17_06.828Z.Desktop.md @@ -0,0 +1,73 @@ +- alias:: + ICD-11_Code:: +- #definition {{c1 }} #ent-prof-card #card + deck:: #ENT + id:: 6756bdb7-a31c-443d-b8eb-a34f8e72da6f +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: a52df07d-fc55-46a1-b2c1-3690d2f23591 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Congenital Dacryocystitis/2024-12-10T00_17_06.829Z.Desktop.md b/logseq/bak/pages/Congenital Dacryocystitis/2024-12-10T00_17_06.829Z.Desktop.md new file mode 100644 index 0000000..4a92415 --- /dev/null +++ b/logseq/bak/pages/Congenital Dacryocystitis/2024-12-10T00_17_06.829Z.Desktop.md @@ -0,0 +1,71 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #eye-prof-written + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation #classical-presentation + - infant with persistent watering(epiphora) and mild discharge from both eyes since birth + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - only in case of newborn which later is to be corrected surgically if 9 months to 1 year elapses without marked improvement + - ### Surgical Options + - [[Therapeutic Syringing and Probing]] + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Conjunctivitis/2024-12-10T00_17_06.830Z.Desktop.md b/logseq/bak/pages/Conjunctivitis/2024-12-10T00_17_06.830Z.Desktop.md new file mode 100644 index 0000000..78738b7 --- /dev/null +++ b/logseq/bak/pages/Conjunctivitis/2024-12-10T00_17_06.830Z.Desktop.md @@ -0,0 +1,73 @@ +alias:: +ICD-11_Code:: + +- #definition [[Conjunctiva]] #eye-prof-written +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification #eye-prof-written + - [[Purulent Conjunctivitis]] + - [[Allergic Conjunctivitis]] + - [[Phylectenular Conjunctivitis]] + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Cystic Hygroma/2024-12-10T00_17_06.832Z.Desktop.md b/logseq/bak/pages/Cystic Hygroma/2024-12-10T00_17_06.832Z.Desktop.md new file mode 100644 index 0000000..e6b8e13 --- /dev/null +++ b/logseq/bak/pages/Cystic Hygroma/2024-12-10T00_17_06.832Z.Desktop.md @@ -0,0 +1,75 @@ +- alias:: + ICD-11_Code:: +- #definition {{c1 }} #ent-prof-card #card + deck:: #ENT + id:: 6756b7cb-0e39-419c-9e5a-5d0676a0e1a0 +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 637ecf91-1409-4a8b-92a1-32d975883843 + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 872e3283-b66f-480b-b243-c1ff1f9e6d18 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Dacryocystitis/2024-12-10T00_17_06.833Z.Desktop.md b/logseq/bak/pages/Dacryocystitis/2024-12-10T00_17_06.833Z.Desktop.md new file mode 100644 index 0000000..502fce1 --- /dev/null +++ b/logseq/bak/pages/Dacryocystitis/2024-12-10T00_17_06.833Z.Desktop.md @@ -0,0 +1,75 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #eye-prof-written + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - [[Congenital Dacryocystitis]] + - ### Clinical Features #eye-prof-written + - [[Acute Dacrocystitis]] + - ### Clinical Features #eye-prof-written + - [[Chronic Dacryocystitis]] + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation #eye-prof-written + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis #eye-prof-written + - ### Confirmation of Diagnosis +- ## Management and Treatment #eye-prof-written + background-color:: blue + - ### Medical Treatment + - Adult #eye-prof-written + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up + - ## Management of Lacrimal Abscess #eye-prof-written +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment #eye-prof-written + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Deviated Nasal Septum/2024-12-10T00_17_06.834Z.Desktop.md b/logseq/bak/pages/Deviated Nasal Septum/2024-12-10T00_17_06.834Z.Desktop.md new file mode 100644 index 0000000..a9b715d --- /dev/null +++ b/logseq/bak/pages/Deviated Nasal Septum/2024-12-10T00_17_06.834Z.Desktop.md @@ -0,0 +1,74 @@ +- alias:: + ICD-11_Code:: +- ## Etiology #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: a12b2c41-66a3-47f3-955c-f74a8fd201f4 + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 54938744-188d-4ab1-aa09-32bef16d24a4 + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 79b6dbbe-38f6-4e65-98ab-4b95f3dade21 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Diarrhoea/2024-12-10T00_17_06.836Z.Desktop.md b/logseq/bak/pages/Diarrhoea/2024-12-10T00_17_06.836Z.Desktop.md new file mode 100644 index 0000000..0f00ae1 --- /dev/null +++ b/logseq/bak/pages/Diarrhoea/2024-12-10T00_17_06.836Z.Desktop.md @@ -0,0 +1,75 @@ +alias:: +ICD-11_Code:: +tags:: #Paediatrics + +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - [[Acute Diarrhoea]] #fahim + - [[Chronic Diarrhoea]] #fahim + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue + - [[IMCI]] ((6735a5bf-cd0b-41fc-a864-7045ca6fac5c)) \ No newline at end of file diff --git a/logseq/bak/pages/Diptheria/2024-12-10T00_17_06.837Z.Desktop.md b/logseq/bak/pages/Diptheria/2024-12-10T00_17_06.837Z.Desktop.md new file mode 100644 index 0000000..6ed9267 --- /dev/null +++ b/logseq/bak/pages/Diptheria/2024-12-10T00_17_06.837Z.Desktop.md @@ -0,0 +1,70 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis #ent-prof-written #card + deck:: #ENT + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue +- SN : #ent-prof-written #card + deck:: #ENT \ No newline at end of file diff --git a/logseq/bak/pages/Down Syndrome/2024-12-10T00_17_06.839Z.Desktop.md b/logseq/bak/pages/Down Syndrome/2024-12-10T00_17_06.839Z.Desktop.md new file mode 100644 index 0000000..49dd4c1 --- /dev/null +++ b/logseq/bak/pages/Down Syndrome/2024-12-10T00_17_06.839Z.Desktop.md @@ -0,0 +1,79 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - 1 case in 800 live briths + - 6000 children each year + - ### Prevalence + - ### Demographics + - Down syndrome accounts for about one third of all moderate and severe mental handicaps in school-aged children. + - Age Related Demographics + - 15-29 years - 1 case in 1500 live births + - 30-34 years - 1 case in 800 live births + - 35-39 years - 1 case in 270 live births + - 40-44 years - 1 case in 100 live births + - Older than 45 years - 1 case in 50 live births + - Sex Related Demographics + - male to female ration in free trisomy 21 - 1.15:1 + - 50% females having trisomy 21 are fertile and have a 50% chance of having a child with trisomy 21(However, many affected fetuses abort spontaneously.) + - On the other hand, men with Down syndrome are usually infertile, except for those with mosaicism. + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Eclampsia/2024-12-10T00_17_06.845Z.Desktop.md b/logseq/bak/pages/Eclampsia/2024-12-10T00_17_06.845Z.Desktop.md new file mode 100644 index 0000000..69eb189 --- /dev/null +++ b/logseq/bak/pages/Eclampsia/2024-12-10T00_17_06.845Z.Desktop.md @@ -0,0 +1,155 @@ +alias:: Antepartum Eclampsia +source:: ((671a2fe1-638a-434d-895f-ddf00e3932c9)) [[Dutta Obs]] +ICD-11_Code:: + +- #definition [[Pre-Eclampsia]] when complicated with grand mal seizures (generalized tonic-clonic convulsions) and/or coma is called eclampsia #obspc +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification #obspc + collapsed:: true + - # Premonitory Stage + duration:: 30 seconds + - The patient becomes unconscious. + - There is twitching of the muscles of the face, tongue and limbs + - Eyeballs roll or are turned to one side become fixed. + - # Tonic Stage + duration:: 30 seconds + - The whole body goes into a tonic spasm the trunk-opisthotonus, limbs and hands clenched. + - Respiration ceases and the tongue protrudes between the teetch + - Cyanosis appears + - Eyeballs become fixed + - # Clonic Stage + duration:: 1-4 minutes + - All the voluntary muscles undergo alterate contraction and relaxation. + - The twitchings start in the face then involve one side of the extremities and ultimately the whole body is involved in the convulsion. + - Biting of the tongue occurs. + - Breathing is stertorous and blood stained frothy secretions fill the mouth; cyanosis gradually disappears. + - # Stage of Coma + - Following the fit, the patient passes on to the stage of coma. + - It may last for a brief period or in others deep coma persists till another convulsion. + - On occasion, the patient appears to be in a confused state following the fit and fails to remember the heppenings. + - Rarely, the coma occurs without prior convulsion + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - Near Term, Term + - Repeated Convulsions + - BP raised significantly + - Urine albumin +++ + - #### Probable Diagnosis + - nth Gravid at 36 weeks of pregnancy with Eclampsia + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis #18obGyn + - Epilepsy + - Encephalitis + - Meningitis + - Puerperal cerebral thrombosis + - Hypertensive encephalopathy + - Cerebral malaria in topics + - PRES + - Intracranial tumors + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Principle of Management #obGyn-prof-OSPE #18obGyn + - General nursing Care + - Control of convuslion : Injection Magnesium Sulphate #obGyn-prof-OSPE + - Obstetric management + - Management of complications + - ### Emergency Management + collapsed:: true + - Call for extra help, multiple personel are required to simultaneously manage different aspects + - Put the patient in bed and prevent falling to prevent injury + - Put the patient in left lateral recumbent position + - Tongue blade/mouth gag is placed between the teeth + - prevent aspiration + - vomitus and oral secretions removed by frequent suctioning + - Oxygenation is maintained through a face mask(8-10 L/minute) , Intubate if required + - Monitor Saturation with Pulse Oximetry : Arterial Blood Gas analysis is needed when $\ce{O2}$ saturation falls below 92% + - Fluid correction if required, $\ce{NaHCO3}$ if pH<7.1 + - Perform cannulation at both hands to maintain two channels + - $\ce{MgSO4}$ in one channel + - Loading Dose : 4-6 g IV slow over 15-20 minute + - Maintenance Dose : 1-2 g/h IV infusion + - [[Labetalol]] in another channel (add dosage and all) + - Urinary Catheterization + - Diuretics if pulmonary edema + - Fluid Balance, if urine output <30 ml/hour + - Antibiotics to prevent secondary infection + - Monitor + - {{embed ((671631f9-3f4a-4e5a-9a64-5af96c5b26d0))}} + - Fetal Status : Heart Rate + - Delivery (Obstetric Management of Eclampsia) + - ((671634c1-4afb-4d67-b1d2-e6166497fa8d)) + - ### Drugs + collapsed:: true + - Magnesium Sulphate + - Dosage #obGyn-prof-OSPE + - Loading Dose : 10 gm + - 4 gm (8 ml) diluted with 12 ml distilled water slow I/V + - 3 gm I/M in each buttock (total 6 gm) + - Maintainance Dose + - 2.5 gm I/M 4 hourly in alternate buttock for 24 hours from the delivery or last convulsion which ever is last + - Magnesium Toxicity #obGyn-prof-OSPE + id:: 671631f9-3f4a-4e5a-9a64-5af96c5b26d0 + - Respiratory Rate : >12 breath/min + - Knee Jerk (Deep Tendon Reflex) + - Oligouria (normal : >30 ml/hour) + - ### Lifestyle and Dietary Recommendations + - ### Follow-up + - check hypertension & proteinuria by 6 weeks time in postnatal clinic + - if continued then further investigation and consultation with a [[Primary Care Physician]] +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Prediction and Preventions + - generally, it's preventable in [[Pre-Eclampsia]] but some cases(20-40%) occur without pre-eclamptic state + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Encephalopathy/2024-12-10T00_17_06.846Z.Desktop.md b/logseq/bak/pages/Encephalopathy/2024-12-10T00_17_06.846Z.Desktop.md new file mode 100644 index 0000000..010d9fb --- /dev/null +++ b/logseq/bak/pages/Encephalopathy/2024-12-10T00_17_06.846Z.Desktop.md @@ -0,0 +1,72 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - [[Hepatic Encephalopathy]] + - [[Hypertensive Encephalopathy]] + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Enlarged Tonsil/2024-12-10T00_17_06.847Z.Desktop.md b/logseq/bak/pages/Enlarged Tonsil/2024-12-10T00_17_06.847Z.Desktop.md new file mode 100644 index 0000000..73a4f2d --- /dev/null +++ b/logseq/bak/pages/Enlarged Tonsil/2024-12-10T00_17_06.847Z.Desktop.md @@ -0,0 +1,74 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: f6ecbf7b-81e7-4ae2-bfd8-0d050dbf8b32 + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis #ent-prof-card #card + deck:: #ENT + id:: 84affb2e-e6cf-40ec-9f0d-f28cf4a6a623 + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 75364eb0-108c-4a79-8736-378d2cc5d49a + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Epistaxis/2024-12-10T00_17_06.850Z.Desktop.md b/logseq/bak/pages/Epistaxis/2024-12-10T00_17_06.850Z.Desktop.md new file mode 100644 index 0000000..ede1bb4 --- /dev/null +++ b/logseq/bak/pages/Epistaxis/2024-12-10T00_17_06.850Z.Desktop.md @@ -0,0 +1,107 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents #ent-prof-card #card + deck:: #ENT + id:: 6733ccec-688c-4457-840d-2ffaa6f77b4b + - ### Risk Factors + - | Most Commons | Coagulopathy | Inflammatory | Iatrogenic(medication induced) | Neoplastic | Traumatic | Vascular | + | ---------------------------------- | --------------------------- | -------------------------------------------------- | -------------------------------------------- | ------------------------ | ------------------------------------------ | ----------------------------------------------------------------- | + | Nose Picking (most common) | Thrombocytopenia (ITP, TTP) | Granulomatosis with polyangitis (GPA or Wegener's) | Anticoagulation (warfarin, heparin, etc) | Sq. C. C | Anatomical deformities (e.g. septal spurs) | Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease) | + | foreign object (children) | Von Willebrand's Disease | SLE | Insufflated drugs (particularly cocaine) | Melanoma | Blunt trauma (e.g. a punch in the face) | carotid artery aneurysm | + | blunt trauma (MVA) | Hemophilia | | Nasal sprays (nasal steroids: prolonged use) | Adenoid Cystic Carcinoma | Foreign bodies (or nose picking) | Angioma | + | RTIs (chronic sinusitis, rhinitis) | Leukemia | | | Nasopharyngeal carcinoma | Nasal bone fracture | Anigofibroma | +- ## Epidemiology + background-color:: blue + - ### Incidence + - A bimodal age distribution + - most commonly affecting those: + - younger than 10 and + logseq.order-list-type:: number + - older than 50 + logseq.order-list-type:: number + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - blood coming out of the nostrils + - blood coming out of the lacrimal ducts (shedding tears of blood) + - blood coming out of the mouth (vomiting) + - blood coming out of the anus(with stool... Very rare(dark blood because it has passed by the stomach acid) + - blood is cathartic -> diarrhea + - rule of thumb: blood is [[Cathartic]] whereas iron is constipating + - #### Signs + - ### Types + - Anterior Epistaxis + - Posterior Epitaxis + - #### Differences between ((6708e6ef-4496-4512-8dec-a10fa7e9b655)) and ((6708e6f5-25c3-4bfe-8839-db3a63ee7ac1)) + - | Posterior Epistaxis | Anterior Epistaxis | + | ------------------- | -------------------------------------- | + | Less Common | More Common | + | Older Patient | Younger Patient | + | HTN | Mucosal Dryness/ Foreign Body/ Picking | + | More Significant | Less Significant | + - ### Diagnostic Criteria +- ## Diagnosis & Treatment + background-color:: blue + - Child -> picking his nose -> bleeding from anterior septum -> local pressure and phenylephrine spray will save the day [+antrior packing if severe] + logseq.order-list-type:: number + - Youth/young adult -> cocaine (will perforate the nasal septum) -> posterior packing "mnemonic: cocaine comes in packages, so you should pack the nose" + logseq.order-list-type:: number + - Youth/young adult -> [[juvenile nasopharyngeal angiofibroma]] -> surgical resection is a MUST "mnemonic: oma means mass, and you should remove it" + logseq.order-list-type:: number + collapsed:: true + - eventhough [[angiofibroma]] is a benign tumor (not cancer), it eats and erodes the surrounding structure + - {{query #benign_but_eroding}} + query-table:: true + - Elderly Hypertensive -> Huge amount of bleeding [life threatening] -> BP controlling, posterior packing and vessel ligation + logseq.order-list-type:: number + - Hemorrhages that are life-threatening occur in the posterior segment (sphenopalatine artery, a branch of maxillary artery) + - Common causes include foreign body, trauma, allergic rhinitis, and nasal angiofibromas (common in adolescent males) +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 6733ccec-105f-48ff-ba7c-1b3af590ed12 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Esophageal Perforation/2024-12-10T00_17_06.851Z.Desktop.md b/logseq/bak/pages/Esophageal Perforation/2024-12-10T00_17_06.851Z.Desktop.md new file mode 100644 index 0000000..c0f988c --- /dev/null +++ b/logseq/bak/pages/Esophageal Perforation/2024-12-10T00_17_06.851Z.Desktop.md @@ -0,0 +1,70 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 1e979a08-37ac-4cd4-934f-370c1fd01f0b + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Ethmoidal Polyp/2024-12-10T00_17_06.852Z.Desktop.md b/logseq/bak/pages/Ethmoidal Polyp/2024-12-10T00_17_06.852Z.Desktop.md new file mode 100644 index 0000000..022e631 --- /dev/null +++ b/logseq/bak/pages/Ethmoidal Polyp/2024-12-10T00_17_06.852Z.Desktop.md @@ -0,0 +1,76 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 146ed908-262b-45bb-a3c9-ee89813aaaa7 + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - [[Antrochoanal Polyp]] + - Differences #ent-prof-card #card + deck:: #ENT + id:: 6756c3ac-94e0-4b01-9b59-15fa3ea7206c + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 191b8483-4607-4bb9-821e-207baa7e562c + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Foreign Body in Esophagus/2024-12-10T00_17_06.853Z.Desktop.md b/logseq/bak/pages/Foreign Body in Esophagus/2024-12-10T00_17_06.853Z.Desktop.md new file mode 100644 index 0000000..646d0e3 --- /dev/null +++ b/logseq/bak/pages/Foreign Body in Esophagus/2024-12-10T00_17_06.853Z.Desktop.md @@ -0,0 +1,75 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - # Common Foreign Bodies that may introduced in the Oesophagus #ent-prof-card #card + deck:: #ENT + id:: 6756b3d0-6307-466a-a856-af9b4a6ef67c + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: fcaf4274-5a62-4051-bb53-6838993f76b1 + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 6dfa3abe-e61f-4f44-bf88-55cc2d38780e + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Foreign Body in Larynx/2024-12-10T00_17_06.854Z.Desktop.md b/logseq/bak/pages/Foreign Body in Larynx/2024-12-10T00_17_06.854Z.Desktop.md new file mode 100644 index 0000000..aba6ca2 --- /dev/null +++ b/logseq/bak/pages/Foreign Body in Larynx/2024-12-10T00_17_06.854Z.Desktop.md @@ -0,0 +1,72 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 52956cb8-b56e-4fa6-afcb-a8c6b2693452 + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 41b76876-2a54-446b-97b6-537746e31f1d + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Foreign Body in Nose/2024-12-10T00_17_06.856Z.Desktop.md b/logseq/bak/pages/Foreign Body in Nose/2024-12-10T00_17_06.856Z.Desktop.md new file mode 100644 index 0000000..ed4b7ee --- /dev/null +++ b/logseq/bak/pages/Foreign Body in Nose/2024-12-10T00_17_06.856Z.Desktop.md @@ -0,0 +1,75 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Names of Foreign Bodies in Nose #ent-prof-card #card + deck:: #ENT + id:: 6756c608-aef3-4c0d-a3a3-ecc8abd74751 + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 2825038c-36a6-4d14-bc37-11cff7ba062a + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 75f55c1e-b022-41f2-864f-518b3d6e6db5 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Furunculosis/2024-12-10T00_17_06.857Z.Desktop.md b/logseq/bak/pages/Furunculosis/2024-12-10T00_17_06.857Z.Desktop.md new file mode 100644 index 0000000..a3939c3 --- /dev/null +++ b/logseq/bak/pages/Furunculosis/2024-12-10T00_17_06.857Z.Desktop.md @@ -0,0 +1,79 @@ +- alias:: + ICD-11_Code:: +- #definition {{c1 }} #ent-prof-card #card + deck:: #ENT + id:: 6756a8ab-4837-43bd-8f2a-5e5a48df80fa +- ## Etiology #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 6756cf33-62f1-4697-b808-6abef9e42e55 + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: f0515a7d-e1eb-4340-981b-5b843b5bb246 + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: e445fb66-0f09-4bbf-a956-f1602db091af + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 0103a3c3-347d-4f75-8dfc-57f0e330cc30 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Gestational Diabetes Mellitus/2024-12-10T00_17_06.861Z.Desktop.md b/logseq/bak/pages/Gestational Diabetes Mellitus/2024-12-10T00_17_06.861Z.Desktop.md new file mode 100644 index 0000000..20004a3 --- /dev/null +++ b/logseq/bak/pages/Gestational Diabetes Mellitus/2024-12-10T00_17_06.861Z.Desktop.md @@ -0,0 +1,126 @@ +alias:: GDM +ICD-11_Code:: + +- #definition GDM is defined as carbohydrate intolerance of variable severity with onset or first recognition during the present pregnancy #obspc +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors #obspc + - Positive family history of diabetes(parents or sibling). Family history should include uncles, aunts and grandparents. + - Having a still birth with pancreatic islet hyperplasia revealed on autopsy + - Unexplained perinatal loss + - Presence of polyhydramnios or recurrent vaginal candidiasis in present pregnancy + - Persistent glycosuria + - Age over 30 years + - Obesity + - Ethnic group (East Asian, Pacific Island ancestry) +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis +- ## Management and Treatment #obspc + background-color:: blue + - ### Medical Treatment + - [[Insulin]] + - Indication + - plasma glucose level exceeds 90 mg% and 2 hours postprandial value is greater than 120 mg% (repetitive) even on diet control + - Nearly 25% women with GDM need insulin therapy + - ### Lifestyle and Dietary Recommendations + - #### Diet + - 2000-2500 Kcal/day for normal weight woman and restriction to 1200-1800 Kcal/day for overweight woman is recommended. + - Carbohydrate should be 40-50% of total calories. + - Commplex Carbohydrate + - Excercie + - Aerobic + - Brisk Walking + - may obviate the need of insulin therapy + - Monitoring + - Women should perform self-blood glucose monitoring using reflectance meter. + - ### Obstetric Management + - #### Time of Termination of Pregnancy #obspc + - Women with good glycemic control and who do not require insulin may wait for spontaneous onset of labor. However, elective delivery (induction or cesarean section) is considered in patients requiring insulin or with complications (macrosomia) at around 38 weeks +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - Follow-up + - The patient needs more frequent antenatal supervision with periodic checkup of fasting plasma glucose level which should be less than 90 mg%. + - Maintenance of mean plasma glucose level between 105 mg% and 110 mg% is desirable for good fetal outcome + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications in pregnancy #obspc + - Maternal + - During Pregnancy + collapsed:: true + - Abortion + - Preterm labor (26%) + - Urinary Tract Infection and vulvovaginitis + - Increased incidence of preeclampsia (25%) + - Polyhydramnios(25-50%) + - Maternal Distress + - Diabetic Retinopathy + - Diabetic Nephropathy + - Coronary Artery Disease + - Ketoacidosis + - During Labor + collapsed:: true + - Prolongation of labor due to big baby + - [[Shoulder Dystocia]] + - Perineal injuries + - Postpartum hemorrhage + - Operative interference + - Peurperium + collapsed:: true + - Puerperal sepsis + - Lactation failure + - Fetal + collapsed:: true + - Fetal macrosomia (40-50%) + - Congenital malformation (6-10%) + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs #obspc + - WHO screening method + - Random blood sugar, Urine for sugar, $\ce{HbA1C}$ + - We follow [[OGTT]] + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Glue Ear/2024-12-10T00_17_06.862Z.Desktop.md b/logseq/bak/pages/Glue Ear/2024-12-10T00_17_06.862Z.Desktop.md new file mode 100644 index 0000000..ad86679 --- /dev/null +++ b/logseq/bak/pages/Glue Ear/2024-12-10T00_17_06.862Z.Desktop.md @@ -0,0 +1,77 @@ +- alias:: + ICD-11_Code:: +- #definition {{c1 }} #ent-prof-card #card + deck:: #ENT + id:: 6756ac3f-1083-4687-90f9-a2cdab6b164a +- ## Etiology #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 6756cf31-1f68-4244-96cc-dfd7e64c4524 + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: ac1bf438-7d4d-491b-8b45-ec06249d8f79 + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 97b8658f-ca53-4b25-a8cc-6afa90810b3c + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Goiter/2024-12-10T00_17_06.863Z.Desktop.md b/logseq/bak/pages/Goiter/2024-12-10T00_17_06.863Z.Desktop.md new file mode 100644 index 0000000..744d843 --- /dev/null +++ b/logseq/bak/pages/Goiter/2024-12-10T00_17_06.863Z.Desktop.md @@ -0,0 +1,76 @@ +- alias:: + ICD-11_Code:: +- #definition {{c1 }} #ent-prof-card #card + deck:: #ENT + id:: 6756b42a-f01e-49f9-9607-950a21bc25a5 +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification #ent-prof-card #card + deck:: #ENT + id:: 7a4bfba6-3f71-4029-8dde-b27bfa1527a7 + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Investigation #ent-prof-card #card + deck:: #ENT + id:: 6756b615-65e1-4d94-9a47-ceca69322c22 + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Hematoma Auris/2024-12-10T00_17_06.864Z.Desktop.md b/logseq/bak/pages/Hematoma Auris/2024-12-10T00_17_06.864Z.Desktop.md new file mode 100644 index 0000000..9422fd2 --- /dev/null +++ b/logseq/bak/pages/Hematoma Auris/2024-12-10T00_17_06.864Z.Desktop.md @@ -0,0 +1,74 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents #ent-prof-card #card + deck:: #ENT + id:: 267a035d-50dd-44af-9166-b7cd518c61af + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 675e005b-0dc4-4250-8c48-872b210a4b86 + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: f7071a4f-91ab-45e9-a9ee-7701520e4996 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Hoarseness of Voice/2024-12-10T00_17_06.864Z.Desktop.md b/logseq/bak/pages/Hoarseness of Voice/2024-12-10T00_17_06.864Z.Desktop.md new file mode 100644 index 0000000..959d268 --- /dev/null +++ b/logseq/bak/pages/Hoarseness of Voice/2024-12-10T00_17_06.864Z.Desktop.md @@ -0,0 +1,12 @@ +tags:: #Signs + +- #definition {{c1 }} #ent-prof-card #card + deck:: #ENT + id:: 6756b9d6-95e7-4d4d-8242-b64272a3182e +- # Causes #ent-prof-card #card + deck:: #ENT + id:: 6756cf30-17c0-4743-b3cd-1caf89df239d + - [[Vocal Cord Nodule]] +- # Diagnosis #ent-prof-card #card + deck:: #ENT + id:: 6756b9f1-8182-4a72-ab0f-96a81cdc2482 \ No newline at end of file diff --git a/logseq/bak/pages/Hodgkin Lymphoma/2024-12-10T00_17_06.865Z.Desktop.md b/logseq/bak/pages/Hodgkin Lymphoma/2024-12-10T00_17_06.865Z.Desktop.md new file mode 100644 index 0000000..073fd89 --- /dev/null +++ b/logseq/bak/pages/Hodgkin Lymphoma/2024-12-10T00_17_06.865Z.Desktop.md @@ -0,0 +1,70 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 888ce7a8-ddf9-4350-a425-d9ffda8e9adb + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Hypermetropia/2024-12-10T00_17_06.866Z.Desktop.md b/logseq/bak/pages/Hypermetropia/2024-12-10T00_17_06.866Z.Desktop.md new file mode 100644 index 0000000..275306e --- /dev/null +++ b/logseq/bak/pages/Hypermetropia/2024-12-10T00_17_06.866Z.Desktop.md @@ -0,0 +1,73 @@ +alias:: Hyperopia + +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation #eye-prof-written + - oldage onset, problem with reading book, but his distance vision was 6/6 in both eyes + - he never used glasses + - Tailor by profession(any profession requiring focus in near vision), painless gradual dimness of near vision + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #eye-prof-written + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Hypertensive Encephalopathy/2024-12-10T00_17_06.867Z.Desktop.md b/logseq/bak/pages/Hypertensive Encephalopathy/2024-12-10T00_17_06.867Z.Desktop.md new file mode 100644 index 0000000..1b38c61 --- /dev/null +++ b/logseq/bak/pages/Hypertensive Encephalopathy/2024-12-10T00_17_06.867Z.Desktop.md @@ -0,0 +1,77 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - Headache + - #### Signs + - Blurred vision + - Convulsions + - Papilloedema + - Nausea, Vomiting + - Restlessness + - Alterad sensoriu + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Idiopathic Thrombocytopenic Purpura/2024-12-10T00_17_06.870Z.Desktop.md b/logseq/bak/pages/Idiopathic Thrombocytopenic Purpura/2024-12-10T00_17_06.870Z.Desktop.md new file mode 100644 index 0000000..f300cec --- /dev/null +++ b/logseq/bak/pages/Idiopathic Thrombocytopenic Purpura/2024-12-10T00_17_06.870Z.Desktop.md @@ -0,0 +1,104 @@ +alias:: ITP, Immune Thrombocytopenic Purpura +tags:: #Paediatrics +ICD-11_Code:: + +- ## Etiology + background-color:: blue + - ### Causative Agents + - Autoimmune + - Primary : unknown cause | idiopathic + - Secondary : known cause (following infection) + - SLE + - CLL + - APS (antiphospholipid syndrome) + - Viruses + - HIV + - HCV + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - antibody against GPIIb/IIIa + id:: 674736e2-8fe7-4418-85aa-e7de99f38eaa + - platelet won't be able to aggregate with each other + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria + - Purpura is Blanchable + - Platelet count : low + - BT : prolonged + - Peripheral smear : macro thrombocytopenia + - PT : normal + - aPTT : normal +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - a child afebrile presenting with purpura having a history of fever 2-3 weeks back + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - No symptoms ⇒ No Tx : "observation" + - IVIG (or anti-D immune globulin if Rh+ & DAT+ (positive comb's test)) + - Platelet transfusion + - Rituximab, eltrombopag, Romiplostim + - ### Surgical Options + - ### Splenectomy + - not for children | because it is a major immune organ + - vaccinate (pre-op) + - strept pneumo + - H. influenza + - Nisseria meningitidis + - antibodies (post-op) + - advantages (the following functions of spleen are rectified) + - platelets hide within the spleen + - plasma cells in spleen produce ((674736e2-8fe7-4418-85aa-e7de99f38eaa)) + - platelets get destroyed by splenic macrophages + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Labyrinthitis/2024-12-10T00_17_06.871Z.Desktop.md b/logseq/bak/pages/Labyrinthitis/2024-12-10T00_17_06.871Z.Desktop.md new file mode 100644 index 0000000..5da8b27 --- /dev/null +++ b/logseq/bak/pages/Labyrinthitis/2024-12-10T00_17_06.871Z.Desktop.md @@ -0,0 +1,75 @@ +- alias:: + ICD-11_Code:: +- #definition {{c1 }} #ent-prof-card #card + deck:: #ENT + id:: 6756c289-999e-43b8-a165-6b05d19fb679 +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: ccad68e3-86a7-49e5-b518-9b79c6ceb88c + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 3eaca97b-c9d9-4609-8891-97b901e2b1fe + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Laryngomalacia/2024-12-10T00_17_06.872Z.Desktop.md b/logseq/bak/pages/Laryngomalacia/2024-12-10T00_17_06.872Z.Desktop.md new file mode 100644 index 0000000..4f6a8c4 --- /dev/null +++ b/logseq/bak/pages/Laryngomalacia/2024-12-10T00_17_06.872Z.Desktop.md @@ -0,0 +1,73 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Investigation #ent-prof-card #card + deck:: #ENT + id:: 6756bbbc-9731-4257-87a4-df3fc932e43a + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 578709b2-13ab-41d6-8b76-7c809f270a82 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Left Heart Failure/2024-12-10T00_17_06.873Z.Desktop.md b/logseq/bak/pages/Left Heart Failure/2024-12-10T00_17_06.873Z.Desktop.md new file mode 100644 index 0000000..724bf63 --- /dev/null +++ b/logseq/bak/pages/Left Heart Failure/2024-12-10T00_17_06.873Z.Desktop.md @@ -0,0 +1,78 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - Severe respiratory distress, orthopnoea, feeding difficulties, tachypnoea + - Pulse : Tachycardia + - Jugular Venous Pressure : Raised + - Precordium : Hyperdyamic + - Apex beat : May be shifted to the left + - Gallop rhythm : May be present + - Lung bases : Crepitations on ascultation + - Liver : Enlarged and tender + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Leiomyoma of Uterus/2024-12-10T00_17_06.882Z.Desktop.md b/logseq/bak/pages/Leiomyoma of Uterus/2024-12-10T00_17_06.882Z.Desktop.md new file mode 100644 index 0000000..26beb5f --- /dev/null +++ b/logseq/bak/pages/Leiomyoma of Uterus/2024-12-10T00_17_06.882Z.Desktop.md @@ -0,0 +1,136 @@ +alias:: Fibroid Uterus, Uterine Leiomyoma, Uterine myoma, Uterine fibromyoma +ICD-11_Code:: + +- ## Etiology + background-color:: blue + - ### Causative Agents + - unknown + - ### Risk Factors + - |Risk Factors|Protective Factors| + |--|--| + |Increasing age|| + |Early menarche|Multiparity| + |Nulliparity|Multiparity| + |Obesity, ↑ body mass index (BMI)|Menopause| + |Polycystic Ovary Syndrome (PCOS)|Combined Oral Contraceptives (COCs) use| + |Black Women|Smoking| + |High fat diet|| + |Family History|| +- ## Epidemiology + background-color:: blue + - ### Incidence + - [[Leiomyoma]]s are the most common benign tumors of the uterus and also the most common benign solid tumor in female + - hospital outpatient : 3% + - ### Prevalence + - 20% women at age 30 + - 50% of these remain asymptomatic + - high between 35 and 45 years + - ### Demographics + - ### Para Distribution + - more common in [[nulliparous]] or those having one child infertility +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - arises from the neoplastic single smooth muscle of the myometrium + - Each myomama is monoclona + - The stimulus for initial neoplastic myocyte transformation is not known + - Initial Sitmulus is unknown but following are implicated + - #### Chromosomal abnormality + - 40% of cases, there is a varying type of chromosomal abnormality particularly the chromosome seven (17%) or twelve (12%) (rearrangements, deletions) + - #### Role of polypeptide growth factors + - Epidermal growth factor (EFG) + - Insuline-like growth factor-1 (IGF-1) + - Transforming growth factor-ß (TGF-ß) + - these stimulate the growth of leiomyoma either directly or via estrogen. + - ### Growth of Leiomyomas + - Both estrogen and progesterone receptors are found in higher concentrations in myomas. + - Myomas cells have higher levels of the enzyme [[aromatase]]. This increases the high local levels of estrogen. + - Are rare before menarche and majority decreases in size following menopause. + - They often enlarge during pregnancy. + - Hypoestrogenic conditions (GnRH agonist use) reduces the size of myomas. + - Hypercellularity of myomas (cellular leiomyomotas) are less common (<5%). Cellular myomas are often larger in size. Clinical presentation is more close to a sarcoma(leiomyosarcoma). + - However, most cellular leiomyomata have a benign course and prognosis. + - Myoma cell contains more estrogen receptors than the adjacent myometrium. + - Frequent association of anovulation. +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - Asymptomatic - majority (75%) + - Dysmenorrhea + - Dyspareunia + - Subfertility + - Pressure symptoms (bladder, ureter and rectum) + - Recurrent pregnancy loss (miscarriage, preterm labor) + - Lower abdominal or pelvic pain + - Abdominal enlargement + - #### Signs + - #### Presentation + - Progressive Uterine Bleeding + - ### Stages or Classification + - ((671cc330-e3bb-4093-9d8b-4b8b6f5ab621)) + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation #classical-presentation #gyn-prof-card + - Progressive menorrhagia + - lump in lower abdomen + - ### Confirmation of Diagnosis #gyn-prof-card + - Biopsy and Histopathology + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis +- ## Management and Treatment #gyn-prof-card + background-color:: blue + - ### Medical Treatment + goal:: minimize blood loss + - Antiprogesterones (Mifepristone) + - Antigoandotropins : Danazol, gestrinone + - GnRH analogs + - Agonists + - Antagonists + - LNG-IUS + - Combined oral contraceptives + - Prostaglandin synthetase inhibitors + - Selective progesterone receptor modulators + - ### Surgical Options + - Family complete : Hysterectomy + - Family incomplete : Myomectomy open, Laparoscopy or Hysteroscopy + - Embolotherapy + - Laparoscopic uterine artery ligation + - Myolysis + - Endometrial ablation + - ### Lifestyle and Dietary Recommendations +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Ludwig's Angina/2024-12-10T00_17_06.883Z.Desktop.md b/logseq/bak/pages/Ludwig's Angina/2024-12-10T00_17_06.883Z.Desktop.md new file mode 100644 index 0000000..1670014 --- /dev/null +++ b/logseq/bak/pages/Ludwig's Angina/2024-12-10T00_17_06.883Z.Desktop.md @@ -0,0 +1,73 @@ +- alias:: + ICD-11_Code:: +- #definition {{c1 }} #ent-prof-card #card + deck:: #ENT + id:: 6756b8b1-7ab0-4520-b4a3-4cda026d234c +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: bde4b4a6-a339-4cd2-8e9a-5718408a868d + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Lung Cancer/2024-12-10T00_17_06.884Z.Desktop.md b/logseq/bak/pages/Lung Cancer/2024-12-10T00_17_06.884Z.Desktop.md new file mode 100644 index 0000000..f74f7bf --- /dev/null +++ b/logseq/bak/pages/Lung Cancer/2024-12-10T00_17_06.884Z.Desktop.md @@ -0,0 +1,67 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - age : 55-80 with 30 pack-year, annual low-dose CT + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Lymphoma/2024-12-10T00_17_06.885Z.Desktop.md b/logseq/bak/pages/Lymphoma/2024-12-10T00_17_06.885Z.Desktop.md new file mode 100644 index 0000000..3ca55fa --- /dev/null +++ b/logseq/bak/pages/Lymphoma/2024-12-10T00_17_06.885Z.Desktop.md @@ -0,0 +1,81 @@ +- alias:: + ICD-11_Code:: +- #definition {{c1 }} #ent-prof-card #card + deck:: #ENT + id:: 6756b8d3-824a-4c28-9c1a-6b41a25652cf +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification #ent-prof-card #card + deck:: #ENT + id:: 39750d8e-d114-4734-bed3-85921884aeba + - [[Hodgkin Lymphoma]] + - [[Non Hodgkin Lymphoma]] + - Differences between [[Hodgkin Lymphoma]] & [[Non Hodgkin Lymphoma]] #ent-prof-card #card + deck:: #ENT + id:: 6756b90e-1c9b-4d4e-985f-541498e0373c + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Investigation #ent-prof-card #card + deck:: #ENT + id:: 6756b8f7-9adc-4f99-908f-3f82f85fb5d7 + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Malignant Otitis Externa/2024-12-10T00_17_06.886Z.Desktop.md b/logseq/bak/pages/Malignant Otitis Externa/2024-12-10T00_17_06.886Z.Desktop.md new file mode 100644 index 0000000..e0a6528 --- /dev/null +++ b/logseq/bak/pages/Malignant Otitis Externa/2024-12-10T00_17_06.886Z.Desktop.md @@ -0,0 +1,75 @@ +- alias:: + ICD-11_Code:: +- #definition {{c1 }} #ent-prof-card #card + deck:: #ENT + id:: 6756ab5c-a4c8-488c-abee-6ae8f0386aa9 +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 7cb04bbd-1833-4b20-951c-15e69c28556d + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 28d9b3b0-29e5-42da-ae87-1173fb90808d + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Marginal Perforation/2024-12-10T00_17_06.887Z.Desktop.md b/logseq/bak/pages/Marginal Perforation/2024-12-10T00_17_06.887Z.Desktop.md new file mode 100644 index 0000000..ca82148 --- /dev/null +++ b/logseq/bak/pages/Marginal Perforation/2024-12-10T00_17_06.887Z.Desktop.md @@ -0,0 +1,70 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents #ent-prof-card #card + deck:: #ENT + id:: 18f2a957-0d99-4e3d-932f-0e4c7ca716fc + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Meniere's Disease/2024-12-10T00_17_06.888Z.Desktop.md b/logseq/bak/pages/Meniere's Disease/2024-12-10T00_17_06.888Z.Desktop.md new file mode 100644 index 0000000..b0f3989 --- /dev/null +++ b/logseq/bak/pages/Meniere's Disease/2024-12-10T00_17_06.888Z.Desktop.md @@ -0,0 +1,75 @@ +- alias:: + ICD-11_Code:: +- #definition {{c1 }} #ent-prof-card #card + deck:: #ENT + id:: 6756c23f-2e59-47e9-b177-c10af5c95e12 +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: cacace2a-0212-4b4f-8198-80c2164bb44f + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 3abf9902-4436-4be6-ad4c-1ad09cab3a65 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Multiple Papilloma of Larynx/2024-12-10T00_17_06.889Z.Desktop.md b/logseq/bak/pages/Multiple Papilloma of Larynx/2024-12-10T00_17_06.889Z.Desktop.md new file mode 100644 index 0000000..e93216f --- /dev/null +++ b/logseq/bak/pages/Multiple Papilloma of Larynx/2024-12-10T00_17_06.889Z.Desktop.md @@ -0,0 +1,70 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 042c3d7d-5137-411a-9c18-72e8dc5973c7 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Myopia/2024-12-10T00_17_06.890Z.Desktop.md b/logseq/bak/pages/Myopia/2024-12-10T00_17_06.890Z.Desktop.md new file mode 100644 index 0000000..7cfb4dd --- /dev/null +++ b/logseq/bak/pages/Myopia/2024-12-10T00_17_06.890Z.Desktop.md @@ -0,0 +1,80 @@ +alias:: Nearsightedness +ICD-11_Code:: + +- #definition #eye-prof-written +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification #eye-prof-written + - [[Pathological Myopia]] + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - ### Classical Presentation #eye-prof-written + - School Child with complaints of unable to read the blackboard in his classroom if he seat at last row + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis +- ## Management and Treatment #eye-prof-written #eye-prof-card + background-color:: blue + - ### Non-Surgical #eye-prof-card #card + deck:: #Eye + id:: 6733ccee-981c-4557-b8e8-0e700c1e3f74 + - EyeGlasses + - Contact Lenses + - ### Surgical Options #eye-prof-card #card + deck:: #Eye + id:: 6733ccee-438a-4ecd-8a30-9c7a0f83ff97 + - [[Laser Vision Correction]] + - Phakic Intraocular Lens + - Refractive Lens Exchange + - ### Lifestyle and Dietary Recommendations +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Nasal Polyp/2024-12-10T00_17_06.893Z.Desktop.md b/logseq/bak/pages/Nasal Polyp/2024-12-10T00_17_06.893Z.Desktop.md new file mode 100644 index 0000000..8d076a6 --- /dev/null +++ b/logseq/bak/pages/Nasal Polyp/2024-12-10T00_17_06.893Z.Desktop.md @@ -0,0 +1,85 @@ +- alias:: + ICD-11_Code:: +- #definition soft tissue masses (teardrop-shaped, non-neoplastic) that arises from the mucous membranes of the nose and paranasal sinuses. #ent-prof-card #card + deck:: #ENT + id:: 6733ccee-38eb-4cfd-b655-5edb891d4701 +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors + - In adults: commonly associated w/allergic rhinitis (IgE-mediated) -> mast cell degranulation) + - In kids: it's NOT allergic -> suspect cystic fibrosis + - cystic fibrosis -> thick secretions -> inflammatory nasal polyps (chronic inflammation) +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - Most common in adults: 40 years or older + - Male > female + - ### Geographic Distribution +- Bilateral (usually) +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - usually due to chronic inflmmation + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - History of [[Samter's triad]] + - #### Signs + - ### Stages or Classification #ent-prof-card #card + deck:: #ENT + id:: a3130458-2726-4c0b-9ebd-085ec2810978 + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - [[Inferior Turbinate]] + - Differentiate #ent-prof-card #card + deck:: #ENT + id:: 6756beab-f1ec-4c13-95d1-2ac4ef1b90f1 + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Nasal Septum/2024-12-10T00_17_06.893Z.Desktop.md b/logseq/bak/pages/Nasal Septum/2024-12-10T00_17_06.893Z.Desktop.md new file mode 100644 index 0000000..22ae14b --- /dev/null +++ b/logseq/bak/pages/Nasal Septum/2024-12-10T00_17_06.893Z.Desktop.md @@ -0,0 +1,10 @@ +# Anatomy #ent-prof-card #card +deck:: #ENT +id:: 6756bca9-74c8-443b-8071-33282805d64f + +deck:: #ENT +id:: 6756bca9-74c8-443b-8071-33282805d64f +- # Blood Supply #ent-prof-card #card + deck:: #ENT + id:: 6756cf38-6d8c-4d69-a647-fe6d82ad218c +- [[Littles Area]] \ No newline at end of file diff --git a/logseq/bak/pages/Neovascular Glaucoma/2024-12-10T00_17_06.894Z.Desktop.md b/logseq/bak/pages/Neovascular Glaucoma/2024-12-10T00_17_06.894Z.Desktop.md new file mode 100644 index 0000000..f68fd82 --- /dev/null +++ b/logseq/bak/pages/Neovascular Glaucoma/2024-12-10T00_17_06.894Z.Desktop.md @@ -0,0 +1,74 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - [[Atropine 1% Sulphate]] + - Reason #eye-prof-card #card + deck:: #Eye + id:: 67541e08-11bf-4d94-8ab7-cff391949cc8 + - **Reduces ciliary muscle spasm**: By inducing **cycloplegia**, atropine alleviates **pain** associated with ciliary muscle spasm. + - **Keeps the pupil fixed and dilated**: Atropine induces **mydriasis**, preventing further angle closure and reducing the risk of complications from **neovascularization** of the iris (rubeosis iridis). + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Nephrotic Syndrome/2024-12-10T00_17_06.922Z.Desktop.md b/logseq/bak/pages/Nephrotic Syndrome/2024-12-10T00_17_06.922Z.Desktop.md new file mode 100644 index 0000000..b2f029e --- /dev/null +++ b/logseq/bak/pages/Nephrotic Syndrome/2024-12-10T00_17_06.922Z.Desktop.md @@ -0,0 +1,230 @@ +alias:: NS +source:: ((67391705-7e88-4abf-84ec-c43365722458)) [[Nelson Textbook of Pediatrics]] +ICD-11_Code:: +tags:: #Paediatrics +Here by Nephrotic Syndrome, [[Minimal Change Nephrotic Syndrome]] is meant for most of the parts + +- ## Etiology + background-color:: blue + - ## Idiopathic Nephrotic Syndrome + - Minimal Change Disease + - Mesangial Proliferation + - Focal Segmental glomerulosclerosis + - Membranous nephropathy + - Glomerulonephritis associated with nephrotic syndrome membranoproliferative glomerulonephritis, crescentic glomerulonephritis, immunoglobulin A nephropathy + - ## Secondary causes + - ### Infections + - Endocarditis + - Post- streptococcal + - Hepatitides B, C + - HIV- 1 + - Infectious mononucleosis + - Cytomegalovirus + - Malaria + - Syphilis (congenital and secondary) + - Toxoplasmosis + - Tuberculosis + - Schistosomiasis + - Filariasis + - ### Drugs + - [[Captopril]] + - [[Penicillamine]] + - [[Gold]] + - [[NSAIDS]] + - [[Pamidronate]], other bisphosphates + - [[Interferon]] + - [[Mercury]] + - [[Heroin]] + - [[Lithium]] + - [[Rifampicin]] + - [[Sulfasalazine]] + - ### Immunological or Allergic Disorders + - [[Vasculitis Syndromes]] + - [[Castleman Disease]] + - [[Kimura Disease]] + - [[Bee Sting]] + - [[Snake Venom]] + - Food Allergens + - [[Serum Sickness]] + - Poison ivy + - Poison oak + - ### Associated with Malignant Disease + - *[[Wilms Tumor]]* + - [[Lymphoma]] + - [[Pheochromocytoma]] + - [[Leukemia]] + - [[Thymoma]] + - Solid Tumors +- ## Epidemiology + background-color:: blue + - ### Incidence + - The commonest kidney problem in children + - Incidence: 2-7 per 100, 000 children <16 years of age + - Common in between 2 to 8 years + - Peak age of onset: Around 3 year + - 85% of total nephrotic syndrome in children is [[MCNS]] + - ((673919e2-2a88-45ae-ba9f-a2b48d3e4a8e)) + ((67391a0f-8b9c-4d27-950e-64c7a30f6688)) + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - Pathogenesis + - Immune-mediated + logseq.order-list-type:: number + - Systemic circulating factors (eg, suPAR) + logseq.order-list-type:: number + - Podocyte related factors (eg, ANGPTL4) + logseq.order-list-type:: number + - Genetic Variants + logseq.order-list-type:: number + - Mutant proteins play roles in + - Nucleus + logseq.order-list-type:: number + - Mitochondria + logseq.order-list-type:: number + - Lysosomes + logseq.order-list-type:: number + - Actin + logseq.order-list-type:: number + - Slit diaphragm + logseq.order-list-type:: number + - Basement membrane + logseq.order-list-type:: number + - ### Affected Systems/Organs + - Damage to the podocytes (effacement of foot process) + - Increase permeability of GFB + - ↑↑passage of albumin across GFB into the urinary space + - This massive albumin loss in urine(Albuminuria) gives rise to hypoalbuminemia with fall of plasma Colloidal osmotic pressure. As a result, fluid shifts from plasma to interstitial space, resulting in + - [[Generalized Edema]] + - [[Haemoconcentration]] as reduced blood colloidal osmotic pressure + - Further retaining of fluid leading to Edema + - The Haemoconcentration in turn activates the renin angiotensin aldosterone system and promotes release of ADH + - This causes the body to retain more fluid, reduced GFR and oligouria + - Raised Cholesterol and Triglycerides + - Hypoalbuminaemia induces lipoprotein synthesis in liver which causes elevation of cholesterol and triglycerides in blood +- # Essential Characteristics of MCNS + - No appreciable glomerular pathology, noted in light microscopy but effacement of foot processes of podocytes in GBM seen under electron microscope + - Prompt respose to steroid but high tendency to relapse + - Not associated with hypertension, hematuria and azoteaemia +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - The affected children may present as initial case or may present with History of recurrent attacks(replapse) with + - #### Symptoms + - Anorexia + - Irritability + - Abdominal pain + - Diarrhoea + - Scanty urination (color usually normal) + - #### Signs + - Facial puffiness, massive peri-orbital swelling + - Generalized oedema + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - Following minor infections and uncommonly reactions to insect bites, bee stings, or poison ivy + - Mild edema, initially periorbital which decreases throughout the day and the edema becomes generalized + possibly misdiagnosed as allergic disorder + - Anorexia, irritability, abdominal pain, diarrhoea + - #### Probable Diagnosis + - Diagnosis other than [[MCNS]] should be considered in children <1 year of age, with a positive family history of nephrotic syndrome, and/or presence of extrarenal findings (e.g., arthritis, rash, anemia), hypertension or pulmonary edema, acute or chronic renal insufficiency, and gross hematuria + - ### Laboratory Tests + - Urine RME with the first morning urine : 3+ or 4+ (20% sensitive) + - 24 hour timed collection of urine for protein quantification + - spot Urine Protein : Creatinine ratio >2.0 + - Creatinine : normal + may be abnormally elevated if there is diminished renal perfusion from contractiion of teh intravascular volume + - Serum Albumin : < 2/5 g/dL + - Serum Cholesterol and Triglycerides : elevated + - complement C3 and C4 levels : normal + (decreased C3 in glomerulonephritis) + - CBC + - Serum electrolytes + - BUN + - Glomerular filtration rate + - Antinuclear and anti-streptococcal antibodies + - Antineutrophilic cytoplastic antibodies + - ### Imaging Studies + - Kidney ultrasound may be considered to exclude renal maformations and venous thrombosis but is not mandatory + - ### Renal Biopsy + - Renal biopsy is not routinely performed if the patient fits the standard clinical picture of MCNS + - should be considered for renal biopsy if + - Age <1 year or >12 years + - Persistent or sustained elevation in creatinine + - Significant hematuria or gross hematuria + - sustained hypertension + - Hypocomplementemia + - Findings indicative of another autoimmune disease + - Infection with Hepatitis B or C, HIV, or tuberculosis + - Glucocorticoid resistance + - [[AKI]] + - Arthritis + - Rash + - ### Differential Diagnosis + - #### Differential Diagnosis + *child with marked edema* + - Protein losing enteropathy + - Hepatic Failure + - Heart Failure + - Acute or chronic glomerulonephritis + - Protein malnutrition + - ### Confirmation of Diagnosis + - labs, imaging and biopsy not necessary +- ## Management and Treatment + background-color:: blue + - First episode of nephrotic syndroem and mild to moderate edema may be managed as outpatients. + - But, not practiced as outpatient, as educating parents regarding all aspects of the condition can require a short period of hospitalization + - The child's parents must be able to recognize the signs and symptoms of the complications of the disease and may be taught how to use a dipstick and interpret the results to monitor for the degree of proteinuria + - ### Medical Treatment + - More than 95% of children with minimal change disease respond to corticosteroid therapy + - Tuberculosis must be ruled out before starting immunosuppressive therapy with corticosteoids by placing a purified protein derivative skin test or obtaining an interferon-gamma release assay and confirming a negative result + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - Cough & respiratory distress (pneumonia, pleural effusion, huge ascites) + - Abdominal pain(gut ischemia, peritonitis, renal vein thrombosis) + - Pain, redness & tendreness of skin(cellulitis) + - Fever & dysuria (UTI) + - Diarrhoea(impaired absorption of foods due to oedema of the bowel wall) + - Neurodeficit like hemiplegia (stroke from thrombo-embolism due to haemoconcentration) + - ### Survival Rates + - #### With Treatment + - Remission achieved after 8 week of oral corticosteroid therapy : 90% + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Noise Induced Hearing Loss/2024-12-10T00_17_06.924Z.Desktop.md b/logseq/bak/pages/Noise Induced Hearing Loss/2024-12-10T00_17_06.924Z.Desktop.md new file mode 100644 index 0000000..9f7da3d --- /dev/null +++ b/logseq/bak/pages/Noise Induced Hearing Loss/2024-12-10T00_17_06.924Z.Desktop.md @@ -0,0 +1,75 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs + - Type of Hearing Loss -> {{c1 }} #ent-prof-card #card + deck:: #ENT + id:: 6756c2ba-5a45-4230-9ecc-74d47ef2a9f1 +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 6aa171cb-2b6f-4ba0-a0fb-eb9ad65c1128 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: a83dd02c-18dc-4a85-9135-5828e63a46eb + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Non Hodgkin Lymphoma/2024-12-10T00_17_06.925Z.Desktop.md b/logseq/bak/pages/Non Hodgkin Lymphoma/2024-12-10T00_17_06.925Z.Desktop.md new file mode 100644 index 0000000..7af86db --- /dev/null +++ b/logseq/bak/pages/Non Hodgkin Lymphoma/2024-12-10T00_17_06.925Z.Desktop.md @@ -0,0 +1,70 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 2dc7b291-39a2-4ac0-96ef-b78ef55b2d50 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Obstructed Labor/2024-12-10T00_17_06.928Z.Desktop.md b/logseq/bak/pages/Obstructed Labor/2024-12-10T00_17_06.928Z.Desktop.md new file mode 100644 index 0000000..fd94897 --- /dev/null +++ b/logseq/bak/pages/Obstructed Labor/2024-12-10T00_17_06.928Z.Desktop.md @@ -0,0 +1,111 @@ +- #definition Obstructed Labor is one where in spite of good uterine contractions, the progressive descent of the presenting part is arrested due to mechanical obstruction #obspc +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents #obspc + collapsed:: true + - Fault in the passage + - Bony : Cephalopelvic disproportion + - Soft tissue obstructions + - Cervical Dystocia due to prolapse or previous operative scarring + - Certical or broad ligament fibroid + - Impacted ovarian tumor or the nongravid horn of bicornuate uterus below the presenting part + - Fault in the passanger + - Transverse lie + - Brow presentation + - Congenital malformations of hte fetus-hydrocephalus(commonest), fetal ascites, double monsters + - Big baby, occipitoposterior position + - Compound presentation + - Locked twins + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis +- ## Management #obspc + background-color:: blue + - ### Medical Management + - Fluid Electrolyte Balance and correction of dehydration and ketoacidosis + - A vaginal swab is taken and sent for culture and sensitivity test + - Blood sample is sent for group and cross matching and a bottle of blood should be at hand prior to any operative intervention + - Antibiotic: [[ceftriaxone]] 1 g IV is administered + - IV infusion, [[metronidazole]] is given for anaerobic infection + - ### Obstetric management + - [[Vaginal Delivery]] + - The baby is invariably dead in most of the neglected cases and destructive operative operation is the best choice to relieve the obstruction + - If the head is low down and vaginal delivery is not risky, forceps extraction may be done in a living baby + - Cesarean Section + - If the case is detected early with good fetal condition, [[Caesarean Section]] gives the best result +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications #obspc + - #### Maternal + - ###### Immediate + - Exhaustion + - Dehydration + - Metabolic acidosis + - Genital sepsis + - Injury to the genital tract includes rupture of the uterus + - Postpartum hemorrhage and shock + - ###### Death + - Rupture of Uterus + - Shock + - Sepsis with metabolic change + - #### Fetal + - Asphyxia + - Acidosis + - Intracranial hemorrhage + - Infection + - ### Long-term Effects + - [[Genitourinary Fistula]] or [[Rectovaginal Fistula]] + - Variable degree of vaginal atresia + - Secondary amenorrhea following hysterectomy due to rupture or due to Sheehan's syndrome +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue +- [[Obstructed Labor with Ruptured Uterus]] \ No newline at end of file diff --git a/logseq/bak/pages/Opthalmia Neonatorum/2024-12-10T00_17_06.929Z.Desktop.md b/logseq/bak/pages/Opthalmia Neonatorum/2024-12-10T00_17_06.929Z.Desktop.md new file mode 100644 index 0000000..1917669 --- /dev/null +++ b/logseq/bak/pages/Opthalmia Neonatorum/2024-12-10T00_17_06.929Z.Desktop.md @@ -0,0 +1,68 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #eye-prof-written + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Ostosclerosis/2024-12-10T00_17_06.930Z.Desktop.md b/logseq/bak/pages/Ostosclerosis/2024-12-10T00_17_06.930Z.Desktop.md new file mode 100644 index 0000000..e8de707 --- /dev/null +++ b/logseq/bak/pages/Ostosclerosis/2024-12-10T00_17_06.930Z.Desktop.md @@ -0,0 +1,77 @@ +- alias:: + ICD-11_Code:: +- #definition {{c1 }} #ent-prof-card #card + deck:: #ENT + id:: 6756c839-670c-4475-8257-1519f21e88b3 +- ## Etiology #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 6756cf3a-1a9f-4d2a-a472-b8758ec4dc5e + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: b3dc5b3d-6350-4a81-99c5-6eace147331c + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 50b4d3aa-2afc-4659-8402-a810ca1e5960 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Otitis Media with Effusion/2024-12-10T00_17_06.932Z.Desktop.md b/logseq/bak/pages/Otitis Media with Effusion/2024-12-10T00_17_06.932Z.Desktop.md new file mode 100644 index 0000000..3ddfd7f --- /dev/null +++ b/logseq/bak/pages/Otitis Media with Effusion/2024-12-10T00_17_06.932Z.Desktop.md @@ -0,0 +1,70 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease #ent-prof-card #card + deck:: #ENT + id:: e5e8984f-91b9-4523-b5d1-00400bfb2a81 + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Otogenic Brain Abscess/2024-12-10T00_17_06.932Z.Desktop.md b/logseq/bak/pages/Otogenic Brain Abscess/2024-12-10T00_17_06.932Z.Desktop.md new file mode 100644 index 0000000..02da687 --- /dev/null +++ b/logseq/bak/pages/Otogenic Brain Abscess/2024-12-10T00_17_06.932Z.Desktop.md @@ -0,0 +1,72 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: de4b90d5-6491-4ba7-b943-9e3d9ce1ec88 + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: fd126f41-2d06-4734-b6c0-f2ad365af147 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Otomycosis/2024-12-10T00_17_06.935Z.Desktop.md b/logseq/bak/pages/Otomycosis/2024-12-10T00_17_06.935Z.Desktop.md new file mode 100644 index 0000000..6300736 --- /dev/null +++ b/logseq/bak/pages/Otomycosis/2024-12-10T00_17_06.935Z.Desktop.md @@ -0,0 +1,101 @@ +- #definition It is a fungal infection of external auditory canal +- alias:: AA03 + ICD-11_Code:: [[AA03]] +- ## Etiology + background-color:: blue + - ### Causative Agents + - _[[Aspergillus niger]]_ (black fungal ball) + - _[[Aspergillus fumigatus]]_ (green) + - _[[Candida albicans]]_ (whitish) + - ### Risk Factors + - Hot and humid climate + - More in summer, DM, topical use of antibiotics + - Secondary to bacterial infection diffuse otitis externa and suppurative otitis media + - At that time antibiotic should not be given because antibiotic solution support the growth of fungus +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 6733ccee-2abe-4542-a82e-a7e5755b34d6 + - ### Signs and Symptoms + - #### Symptoms + - Intense itching & irritation + - Mild pain associated with secondary bacterial infection + - Blockage of ear + - Otorrhoea-straw coloured serous discharge due to increase secretion of gland of external auditory canal + - Blockage & heaviness in the ear + - Impairment of hearing(conductive type) + - #### Signs + - Aural discharge-watery or purulent + - Peculiar musty odor + - On auriscopic findings + - Fungal ball or otomycotic plug - wet filter paper/ newspaper color of the ball + - Mucous membrane **swollen**, **reddish**, **congested** + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis : S/S + - ### Laboratory Tests + - Wet film preparation + - Hyphae are found in aspergillus + - Small ovoid budding is found in candida + - Aural swab for C/S + - ### Imaging Studies + - ### Differential Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Surgical Options + - For blockage: {{c1 Removal of the fungal mass by forceps, suction or by syringe}} #ent-prof-card #card + deck:: #ENT + id:: 6733ccee-7980-4895-ad56-952edb6147b4 + - ### Medical Treatment #ent-prof-card #card + deck:: #ENT + id:: 6756cf36-e0de-4456-8c77-c1efbe134db8 + - For itching : Antihistamine (Chlorpheniramine) + - If pain: Tab. Paracetamol(500 mg) three times daily till pain subside + - If secondary infection present: Antibiotics (Phenoxymethyl penicillin) + - Antifungal: 1 week + 1 week (Nystatin cream(Topical)-candida or clotrimazole cream(Broad spectrum systemic) + - ### Lifestyle and Dietary Recommendations + - Ear must be kept dry +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Papillary Carcinoma of Thyroid/2024-12-10T00_17_06.936Z.Desktop.md b/logseq/bak/pages/Papillary Carcinoma of Thyroid/2024-12-10T00_17_06.936Z.Desktop.md new file mode 100644 index 0000000..e7b9a68 --- /dev/null +++ b/logseq/bak/pages/Papillary Carcinoma of Thyroid/2024-12-10T00_17_06.936Z.Desktop.md @@ -0,0 +1,75 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 49ee1cd7-ce1f-4c21-a273-6e222282ac02 + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Investigatiosn #ent-prof-card #card + deck:: #ENT + id:: 6756b6b8-254c-446c-b927-42fa2a1c0e7d + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 90c38ac3-b1b0-4c9d-b6f0-463912e4337a + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Parotid Tumor/2024-12-10T00_17_06.937Z.Desktop.md b/logseq/bak/pages/Parotid Tumor/2024-12-10T00_17_06.937Z.Desktop.md new file mode 100644 index 0000000..74bac38 --- /dev/null +++ b/logseq/bak/pages/Parotid Tumor/2024-12-10T00_17_06.937Z.Desktop.md @@ -0,0 +1,72 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification #ent-prof-card #card + deck:: #ENT + id:: d09c577a-17fa-48ed-b6e3-82de031dddac + - ### Diagnostic Criteria +- ## Diagnosis #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: f4f1779a-dab1-46c2-9796-df3f92e1cedd + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Perichondritis/2024-12-10T00_17_06.940Z.Desktop.md b/logseq/bak/pages/Perichondritis/2024-12-10T00_17_06.940Z.Desktop.md new file mode 100644 index 0000000..b6a9a6b --- /dev/null +++ b/logseq/bak/pages/Perichondritis/2024-12-10T00_17_06.940Z.Desktop.md @@ -0,0 +1,114 @@ +- alias:: + ICD-11_Code:: +- #definition It is defined as inflammation of the perichondrium of the pinna #ent-prof-card #card + deck:: #ENT + id:: 67542d40-7651-40c8-92c2-cf87ac1d55e6 +- ## Etiology + background-color:: blue + - ### Causative Agents + - Secondary infections from [[Hematoma Auris]] + logseq.order-list-type:: number + - Surgical incision + logseq.order-list-type:: number + - Trauma(Laceration) + logseq.order-list-type:: number + - It can result from extension of infection from [[Diffuse Otitis Externa]] or [[Furunculosis]] + logseq.order-list-type:: number + - Organism + logseq.order-list-type:: number + - _[[Pseudomona]]_ + logseq.order-list-type:: number + - _[[Staphylococcus aureus]]_ + logseq.order-list-type:: number + - _[[Proteus]]_ + logseq.order-list-type:: number + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 6733ccee-0f47-4280-ba92-ee43d6ab6408 + - ### Signs and Symptoms + - #### Symptoms + - Severe Pain + - Thickening and reddening of pinna + - #### Signs + - Tenderness + - High rise of temperature + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 6733ccee-4031-4bf4-accb-1e06b3adf1bd + - ### Medical Treatment with [[Hospitalization]] + - [[Broad Spectrum Antibiotics]] + logseq.order-list-type:: number + - IV - [[Ciprofloxacin]] + logseq.order-list-type:: number + - Oral - [[Ceftazidime]] + logseq.order-list-type:: number + - Analgesics + logseq.order-list-type:: number + - Antipyretics + logseq.order-list-type:: number + - Local Application of 4% aluminum acetate compress + logseq.order-list-type:: number + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications + - Cauliflower like pinna due to necrosis of cartilage (abscess formation) + - #### Management + - Incision and drainage of abscess followed by obliteration of space by pressure with bandage (dental roll) + - Incision & drainage of abscess + logseq.order-list-type:: number + - Removal of devitalized cartilage + logseq.order-list-type:: number + - Continuous drip of antibiotics according to [[C/S]] of pus for 7-10 days + logseq.order-list-type:: number + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Placenta Praevia/2024-12-10T00_17_06.990Z.Desktop.md b/logseq/bak/pages/Placenta Praevia/2024-12-10T00_17_06.990Z.Desktop.md new file mode 100644 index 0000000..3cd0de3 --- /dev/null +++ b/logseq/bak/pages/Placenta Praevia/2024-12-10T00_17_06.990Z.Desktop.md @@ -0,0 +1,122 @@ +title:: Placenta Praevia +ICD-11_Code:: + +- #definition When the placenta is implanted partially or completely over the lower uterine segment (over and adjacent to the internal os) it is called placenta previa #obspc +- # Morbidly Adherent Placenta #obspw #unanswered + - q : name 3 morbidly adherent placenta +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + collapsed:: true + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification #obspc + - # Types #obspc + based-on:: depending upon the degree of extension of placenta to the lower segment + - Type-I Placenta Previa + alias:: Low-lying + id:: 6718ed4b-6eb7-4b4e-95dd-8f20299e0de4 + - The major part of the placenta is attached to the upper segment and only the lower margin encroaches onto the lower segment not up to the os + - Type-II Placenta Previa + alias:: Marginal + - Types + - Type-II Anterior Placenta Previa + id:: 671a1d74-4cb2-492a-8f5f-8e33260d1f1c + - Type-II Posterior Placenta Previa + id:: 671a1d7f-856e-44e4-8e7d-faf35ac5e699 + - The placenta reaches the margin of the internal os but does not cover it. + - Type-III Placenta Previa + alias:: Incomplete or partial central + id:: 6718ed85-3d32-46f7-b74c-40c0cfe78d98 + - The placenta covers the internal os partially (covers the internal os when closed but does not entirely do so when fully dilated) + - {{embed [[Central Placenta Praevia]]}} + - # Clinical Classification + - Mild Degree + include:: ((6718ed4b-6eb7-4b4e-95dd-8f20299e0de4)), ((671a1d74-4cb2-492a-8f5f-8e33260d1f1c)) + - Major Degree + include:: ((671a1d7f-856e-44e4-8e7d-faf35ac5e699)), ((671a1d7f-856e-44e4-8e7d-faf35ac5e699)), ((6718ed85-3d32-46f7-b74c-40c0cfe78d98)), [[Type-IV Placenta Previa]] + - ### Diagnostic Criteria +- ## Diagnosis #obspw #unanswered + background-color:: blue + - ### Clinical Diagnosis + - ((671a158b-14d5-41ea-bc14-924f7589074d)) + - ### Laboratory Tests + - ### Imaging Studies + collapsed:: true + - [[Abdominal Ultrasonography]] + - ### Differential Diagnosis + collapsed:: true + - [[Abruptio Placentae]] #obspc + id:: 6718edc1-f69a-40e0-9826-ec8d0995a444 + - |Parameters|Placenta Previa|Abruptio Placentae| + |--|--|--| + |Clinical Features||| + |Nature of Bleeding|-Painless, apprently causeless and recurrent[:br]- Bleeding is always revealed|- Painful, often attributed to pre-eclampsia or trauma and continuous[:br]- Revealed, concealed or usually mixed| + |Character of Blood|Bright Red|Dark Colored| + |General condition and anemia|Proportionate to visible blood loss|Out of proportion to the visible blood loss in concealed or mixed variety| + |Features of pre-eclampsia|Not relevant|Present in one-third ases| + |Abdominal examniation||| + |Height of Uterus|Proprtionate height to gestational age|May be disproportionately enlarged in concealed type| + |Feel of Uterus|Soft and relaxed|May be tense, tender and rigid| + |Malpresentation|Malpresentation is common. The head is high floating.|Unrelated, the head may be engaged.| + |FHS|Usually present|Usually absent especially in concealed type| + |Placentography (USG)|Placenta in lower segment|Placenta in upper segment| + |Vaginal Examination|Placenta is felt on the lower segment|Placenta is not felt on lower segment. Blood clots should not be confused with placenta| + - # [[Accidental Hemorrhage]] #obspw #unanswered + - |Accidental hemorrhage |Placenta Preveia| + |--|--| + ||| + ||| + ||| + ||| +- ## Management and Treatment #obspw #unanswered + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Pleomorphic Adenoma/2024-12-10T00_17_06.991Z.Desktop.md b/logseq/bak/pages/Pleomorphic Adenoma/2024-12-10T00_17_06.991Z.Desktop.md new file mode 100644 index 0000000..fe93c08 --- /dev/null +++ b/logseq/bak/pages/Pleomorphic Adenoma/2024-12-10T00_17_06.991Z.Desktop.md @@ -0,0 +1,76 @@ +- alias:: + ICD-11_Code:: +- #definition {{c1 }} #ent-prof-card #card + deck:: #ENT + id:: 6756b95e-c2cb-4c5b-98a5-1736584258e7 +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Investigation #ent-prof-card #card + deck:: #ENT + id:: 6756b97c-6c6c-4459-9c57-5dbcac986175 + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: aa5e61b8-45db-43ca-9c6a-a542ea363e06 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Pleural Effusion/2024-12-10T00_17_06.992Z.Desktop.md b/logseq/bak/pages/Pleural Effusion/2024-12-10T00_17_06.992Z.Desktop.md new file mode 100644 index 0000000..e66d031 --- /dev/null +++ b/logseq/bak/pages/Pleural Effusion/2024-12-10T00_17_06.992Z.Desktop.md @@ -0,0 +1,69 @@ +alias:: +ICD-11_Code:: + +- #definition The accumulation of serous fluid within the pleural space is termed pleural effusion +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - [[Chest X-Ray PA view]] : blunting of costophrenic angle and or cardiophrenic angle, This may progress to form a dense white area within a meniscus + - ### Differential Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Pneumonia/2024-12-10T00_17_06.993Z.Desktop.md b/logseq/bak/pages/Pneumonia/2024-12-10T00_17_06.993Z.Desktop.md new file mode 100644 index 0000000..8519c3f --- /dev/null +++ b/logseq/bak/pages/Pneumonia/2024-12-10T00_17_06.993Z.Desktop.md @@ -0,0 +1,86 @@ +alias:: +ICD-11_Code:: +tags:: #Paediatrics + +- #definition Pneumonia is infection of lung parenchyma +- ## Etiology + background-color:: blue + - ### Causative Agents + - MC cause in neonates? GBS, E. coli, Lysteria + - MC cause 1 mo-3 mo? C. trachomatis, RSV, parainfluenza, strep pneumoniae + - MC cause in kids 4 mo- 5 y/o? VIRAL! (RSV) then s. pneumoniae + - MC cause in kids > 5 y/o ? Mycoplasma, s. pneumoniae + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - Kid comes w/ cough productive of yellow-green sputum, runny nose and T=100.8. Lung exam reveals coarse rhonchi, decreased breaths sounds and crackles in the LL and WBC = 16K + - Next best step? CXR to confirm. Typical vs atypical + - #### Probable Diagnosis + - ### Laboratory Tests + - CBC + - eosinophilia (chlamydia pneumonia) C/S : Staccato cough + - ### Imaging Studies + - CXR + - ### Differential Diagnosis + - Acute Bronchiotis + - Kid comes w/ cough productive of yellow-green sputum, runny nose and T=100.8, Lung exam only reveals coarse rhonchii. + - ### Confirmation of Diagnosis + - CXR +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue + - [[IMCI]] ((6735a475-3d7f-40d0-a0a5-0902740b38ba)) \ No newline at end of file diff --git a/logseq/bak/pages/Pre-Eclampsia/2024-12-10T00_17_07.000Z.Desktop.md b/logseq/bak/pages/Pre-Eclampsia/2024-12-10T00_17_07.000Z.Desktop.md new file mode 100644 index 0000000..445f4f1 --- /dev/null +++ b/logseq/bak/pages/Pre-Eclampsia/2024-12-10T00_17_07.000Z.Desktop.md @@ -0,0 +1,154 @@ +alias:: PE +source:: ((671a2f95-31d1-4ec3-8576-8f636115a1a5)) [[Dutta Obs]] +ICD-11_Code:: + +- #definition Multisystem disorder characterized by denovo onset of HTN with proteinuria developed beyond 20 weeks of gestation or accompanied by neurological, hematological, lymphatic, hepatic, renal manifestations or Fetal growth restriction in absence of proteinuria. +- ## Etiology + background-color:: blue + - ### Risk Factors + - Primigravidia + - Family History: Hypertension, pre-eclampsia + - Placental abnormalities + - [[Hyperplacentosis]] + - Placental ischemia + - Obesity, Insulin Resistance + - Pre-existing vascular disease + - New paternity, pregnancy following ART + - Thrombophilias +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - Failure of trophoblast invasion + logseq.order-list-type:: number + - Imbalance of angiogenic and antiangiogenic proteins + logseq.order-list-type:: number + - Genetic predisposition + logseq.order-list-type:: number + - Aberrant natural immune response to fetus + logseq.order-list-type:: number + - Vascular endothelial damage + - Inflammatory mediators (cytokines) + - Immunological intolerance between maternal and fetal tissues + - Coagulation abnormalities + - Increased oxygen-free radicals + - Dietary deficiency or excess + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - Acute Fulminant Pre-Eclampsia + alias:: Acute Fulminant Pre-Eclampsia, Impending Eclampsia + - Features #obGyn-prof-OSPE + - Severe headache + - blurring of vision + - vomiting + - epigastric pain + - oligourea + - Management + - Principles of General Management #obGyn-prof-OSPE + - Immediate hospitalization + - Prevention of convulsion/ prophylactic anticonvulsant + - Control of hypertension + - Delivery of baby + - Complication + - Maternal Complication #obGyn-prof-OSPE + - Eclampsia + - Pulmonary edema + - Renal Failure + - Heart Failure + - DIC + - based-on:: gestational age + - Early Pre-Eclampsia + time:: <34 weeks + - Late Pre-Eclampsia + time:: >34 weeks + - ### Diagnostic Criteria + - BP : > 110/90 mm Hg in more than one occasion + - Either + - Urine Protein : ++ + - and/or : Evidence of Organ Damage +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - ### Laboratory Tests #obGyn-prof-OSPE + - CBC + - Renal Function Test/ Serum Creatinine Level + - Liver Function Test + - Platelet count/ Coagulation Profile + - USG + - ### Imaging Studies + - ### Differential Diagnosis +- ## Antenatal Fetal monitoring + background-color:: blue + - Daily fetal kick count + - Ultrasonography for fetal growth and liquor pockets + - Cardiotocography + - Umbilical artery flow velocimetry and biophysical profile +- ## Management and Treatment + background-color:: blue + - ### Lifestyle and Dietary Recommendations + - Rest + - Admission in hospital is helpful + - Lying in left-lateral position + - Diet + - daily protein : 100g + - Total calorie: 1600 cal/day + - ### Medical Treatment + - Diuretics (if compelling reasons) + - Cardiac Failure + - Pulmonary edema + - Antihypertensive drug therapy induced fluid retention + - Massive edema + - Antihypertensives + - [[Labetalol]] + - [[Nifedipine]] + - [[Methyl-dopa]] + - [[Hydralazine]] + - If Systolic Blood Pressure > 150 mm Hg + - Diazepam & phenobarbitone prophylaxis + - ### Obstetric Management #obGyn-prof-OSPE + - BP is controlled, wait and continue until term + - If BP not controlled terminate pregnancy at 37 weeks + - if, <34 weeks : steroid + - If chance of delivery within 2 hours, then allow vaginal delivery otherwise [[Caesarean Section]] +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Presbycusis/2024-12-10T00_17_07.001Z.Desktop.md b/logseq/bak/pages/Presbycusis/2024-12-10T00_17_07.001Z.Desktop.md new file mode 100644 index 0000000..be9c4ac --- /dev/null +++ b/logseq/bak/pages/Presbycusis/2024-12-10T00_17_07.001Z.Desktop.md @@ -0,0 +1,75 @@ +- alias:: + ICD-11_Code:: +- #definition {{c2 }} #ent-prof-card #card + deck:: #ENT + id:: 6756c1ba-ec8e-4c85-a213-861eb86f84c2 +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 036db9d5-059f-4959-9ae3-58c26281be65 + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 5485cb47-0f03-40ad-bd9d-6927cb2e6752 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Ptosis/2024-12-10T00_17_07.002Z.Desktop.md b/logseq/bak/pages/Ptosis/2024-12-10T00_17_07.002Z.Desktop.md new file mode 100644 index 0000000..8f849fb --- /dev/null +++ b/logseq/bak/pages/Ptosis/2024-12-10T00_17_07.002Z.Desktop.md @@ -0,0 +1,70 @@ +alias:: +ICD-11_Code:: + +- #definition #eye-prof-written +- ## Etiology + background-color:: blue + - ### Causative Agents #eye-prof-written + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options #eye-prof-written + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Purulent Conjunctivitis/2024-12-10T00_17_07.003Z.Desktop.md b/logseq/bak/pages/Purulent Conjunctivitis/2024-12-10T00_17_07.003Z.Desktop.md new file mode 100644 index 0000000..e943944 --- /dev/null +++ b/logseq/bak/pages/Purulent Conjunctivitis/2024-12-10T00_17_07.003Z.Desktop.md @@ -0,0 +1,68 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents #eye-prof-written + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #eye-prof-written + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Quinsy/2024-12-10T00_17_07.004Z.Desktop.md b/logseq/bak/pages/Quinsy/2024-12-10T00_17_07.004Z.Desktop.md new file mode 100644 index 0000000..df687a5 --- /dev/null +++ b/logseq/bak/pages/Quinsy/2024-12-10T00_17_07.004Z.Desktop.md @@ -0,0 +1,79 @@ +alias:: peritonsillar abscess +ICD-11_Code:: + +- #definition {{c1 }} #ent-prof-card #card + deck:: #ENT + id:: 6756b260-7501-42a1-9738-3d39be0fe940 +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis #ent-prof-written #card + deck:: #ENT + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Cardinal Features #ent-prof-card #card + deck:: #ENT + id:: 6756b2ed-83ee-4754-a88d-f345b31725c0 + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #ent-prof-written #card + background-color:: blue + deck:: #ENT + id:: 482c2fd5-0fa6-4908-a26b-7c5429aa5d14 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue +- SN: #ent-prof-written #card + deck:: #ENT \ No newline at end of file diff --git a/logseq/bak/pages/Renal Failure/2024-12-10T00_17_07.005Z.Desktop.md b/logseq/bak/pages/Renal Failure/2024-12-10T00_17_07.005Z.Desktop.md new file mode 100644 index 0000000..a89ba6f --- /dev/null +++ b/logseq/bak/pages/Renal Failure/2024-12-10T00_17_07.005Z.Desktop.md @@ -0,0 +1,74 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - Oligouria + - Anuria + - Vomiting + - Drowsiness + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Retropharyngeal abscess/2024-12-10T00_17_07.006Z.Desktop.md b/logseq/bak/pages/Retropharyngeal abscess/2024-12-10T00_17_07.006Z.Desktop.md new file mode 100644 index 0000000..d0a6781 --- /dev/null +++ b/logseq/bak/pages/Retropharyngeal abscess/2024-12-10T00_17_07.006Z.Desktop.md @@ -0,0 +1,70 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - [[Acute Retropharyngeal Abscess]] + - [[Chronic Retropharyngeal Abscess]] + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Rhinolith/2024-12-10T00_17_07.007Z.Desktop.md b/logseq/bak/pages/Rhinolith/2024-12-10T00_17_07.007Z.Desktop.md new file mode 100644 index 0000000..0ae63da --- /dev/null +++ b/logseq/bak/pages/Rhinolith/2024-12-10T00_17_07.007Z.Desktop.md @@ -0,0 +1,75 @@ +- alias:: + ICD-11_Code:: +- #definition {{c1 }} #ent-prof-card #card + deck:: #ENT + id:: 6756bc19-9869-4c08-8bee-2956ca0a5160 +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 0e9c95cd-92e1-4b2d-bc81-91c7d30a49b1 + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: e188ef27-6e92-4c7f-9887-a63b4aea04eb + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Rhinoscleroma/2024-12-10T00_17_07.007Z.Desktop.md b/logseq/bak/pages/Rhinoscleroma/2024-12-10T00_17_07.007Z.Desktop.md new file mode 100644 index 0000000..3a48a4a --- /dev/null +++ b/logseq/bak/pages/Rhinoscleroma/2024-12-10T00_17_07.007Z.Desktop.md @@ -0,0 +1,72 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 22db0673-3a72-4e8c-9996-5f6605f6e1e0 + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 7e1a56a4-3d8e-49d2-a962-a124c29a790a + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Rhinosporidiosis/2024-12-10T00_17_07.008Z.Desktop.md b/logseq/bak/pages/Rhinosporidiosis/2024-12-10T00_17_07.008Z.Desktop.md new file mode 100644 index 0000000..4acfcb0 --- /dev/null +++ b/logseq/bak/pages/Rhinosporidiosis/2024-12-10T00_17_07.008Z.Desktop.md @@ -0,0 +1,74 @@ +- alias:: + ICD-11_Code:: +- ## Etiology #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 120242e6-8089-4346-a09b-24c41a65d894 + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: d15cc573-58c4-4954-9664-4ee4841c91f8 + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 95047ab4-df72-4522-9526-e1fe19c4e9b6 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Ruptured Tympanic Membrane/2024-12-10T00_17_07.009Z.Desktop.md b/logseq/bak/pages/Ruptured Tympanic Membrane/2024-12-10T00_17_07.009Z.Desktop.md new file mode 100644 index 0000000..06ccd5c --- /dev/null +++ b/logseq/bak/pages/Ruptured Tympanic Membrane/2024-12-10T00_17_07.009Z.Desktop.md @@ -0,0 +1,76 @@ +alias:: Perforation of Tympanic Membrane +ICD-11_Code:: + +- ## Etiology + background-color:: blue + - ### Causative Agents #ent-prof-card #card + deck:: #ENT + id:: a0ae438b-8af2-41f9-99f1-35110c1bbdc3 + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Types #ent-prof-card #card + deck:: #ENT + id:: 67dcf02d-c10d-442d-9e1a-05ee98a38fc7 + - Differences between [[Central Perforation]] & [[Marginal Perforation]] + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: a39f3760-165f-4df9-9ff9-71d86d50049e + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/SLE/2024-12-10T00_17_07.016Z.Desktop.md b/logseq/bak/pages/SLE/2024-12-10T00_17_07.016Z.Desktop.md new file mode 100644 index 0000000..b4ac783 --- /dev/null +++ b/logseq/bak/pages/SLE/2024-12-10T00_17_07.016Z.Desktop.md @@ -0,0 +1,112 @@ +alias:: +ICD-11_Code:: + +- ## Etiology + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + - ### Incidence + - ### Prevalence + - ### Demographics + - **90% women** + - frequently starting at **childbearing age** + - ### Geographic Distribution +- ## Pathophysiology + - ### Mechanism of Disease + - ### Affected Systems/Organs + almost any organ, but mainly involves + - [[Skin]] + - [[Joints]] + - [[Kidneys]] + - [[Blood cells]] + - [[Nervous System]] +- ## Clinical Features + - ### Signs and Symptoms + - #### Symptoms + - [[Seizures]] and [[Fever]] in **children** + :LOGBOOK: + CLOCK: [2024-10-18 Fri 12:10:47] + :END: + - [[Raynaud's Phenomenon]] and [[Pleuritis]] } **twice** as common in **adults** + - #### Signs + - [[Malar Rash]] + - [[Ulcers]] + - [[Proteinurea]] + - [[Urinary Cellular Casts]] + - [[Thrombocytopenia]] + - [[Hemolytic Anemia]] + - [[Lymphadenopathy]] + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + - ### Clinical Diagnosis + - Classical Triad of [[Fever]], [[Join Pain]], [[Rash]] in a woman of child bearing age + - **Constitutional** (eg, fatigue, fever, arthralgia, weight changes) + - **Musculoskeletal** (eg, arthralgia, arthropathy, myalgia, frank arthritis, avascular necrosis) + - **Dermatologic** (eg, malar rash, photosensitivity, discoid lupus) + - **Renal** (eg, acute or chronic kidney failure, acute nephritic disease) + - **Neuropsychiatric** (eg, seizure, psychosis) + - **Pulmonary** (eg, pleurisy, pleural effusion, pneumonitis, pulmonary hypertension, interstitial lung disease) + - **Gastrointestinal** (eg, nausea, dyspepsia, abdominal pain) + - **Cardiac** (eg, pericarditis, myocarditis) + - **Hematologic** (eg, cytopenias such as leukopenia, lymphopenia, anemia, or thrombocytopenia) + - ### Laboratory Tests + - [[CBC with differential]] + - [[Serum Creatinine]] + - [[Urine RME]] + - [[ESR]] or [[CRP level]] + - [[Complement levels]] + - [[Liver Function Tests]] + - [[Creatine Kinase Assay]] + - [[Spot Protein/Spot Creatinine Ratio]], [[Autoantibody Tests]] + - ### Imaging Studies + - [[Joint Radiography]] + - [[Chest Radiography and Chest CT Scanning]] + - [[Echocardiography]] + - [[Brain MRI]] + - [[Cardiac MRI]] + - ### Differential Diagnosis + - [[Adult-Onset Still Disease]] + - [[Behçet Syndrome]] + - [[Chronic Fatigue Syndrome]] + - [[Endocarditis]] + - [[Fibromyalgia]] + - [[HIV Infection]] + - [[Inflammatory Bowel Disease]] + - [[Lyme Disease]] + - [[Mixed Connective Tissue Disease]] + - [[Psoriatic Arthritis]] + - [[Reactive Arthritis]] + - [[Rheumatoid Arthritis]] + - [[Sarcoidosis]] + - [[Systemic Sclerosis]] +- ## Management and Treatment + - ### Medical Treatment + - **[[Antimalarials]]** eg, [[Hydroxychloroquine]] + - **[[Corticosteroids]]** eg, [[Methylprednisolone]], [[Prednisone]], short-term use recommended + - **[[Nonbiologic DMARDs]]** [[Cyclophosphamide]], [[Methotrexate]], [[Azathioprine]], [[Mycophenolate]], [[Cyclosporine]] + - **[[NSAIDS]]** eg, [[Ibuprofen]], [[Naproxen]], [[Diclofenac]] + - **[[Biologic DMARDs]]** eg, [[Belimumab]], [[Rituximab]], [[Anifrolumab]], and/or [[IV Immune Globulin]] + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations +- ## Prognosis + - ### Expected Course + - ### Survival Rates + - ### Quality of Life Considerations +- ## Complications + - ### Possible Complications + - ### Long-term Effects +- ## Prevention + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + - ## Ongoing Clinical Trials + - ## Recent Advances +- ## Key Literature + - ## Guidelines and Protocols \ No newline at end of file diff --git a/logseq/bak/pages/Sensorineural Deafness/2024-12-10T00_17_07.011Z.Desktop.md b/logseq/bak/pages/Sensorineural Deafness/2024-12-10T00_17_07.011Z.Desktop.md new file mode 100644 index 0000000..4396282 --- /dev/null +++ b/logseq/bak/pages/Sensorineural Deafness/2024-12-10T00_17_07.011Z.Desktop.md @@ -0,0 +1,70 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents #ent-prof-card #card + deck:: #ENT + id:: dfded0b2-61c3-405f-b82f-52ebcc9b7283 + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Septal Abscess/2024-12-10T00_17_07.012Z.Desktop.md b/logseq/bak/pages/Septal Abscess/2024-12-10T00_17_07.012Z.Desktop.md new file mode 100644 index 0000000..06e5f1c --- /dev/null +++ b/logseq/bak/pages/Septal Abscess/2024-12-10T00_17_07.012Z.Desktop.md @@ -0,0 +1,77 @@ +- alias:: + ICD-11_Code:: +- #definition {{c1 }} #ent-prof-card #card + deck:: #ENT + id:: 6756c537-1205-46d8-91a0-cc1915f6ae4e +- ## Etiology #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 6756cf32-bc6a-478e-b20d-f7f4b03ce19c + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 9cf87f7c-b5ea-4dd9-a176-292616919594 + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: da63716d-c270-4810-9403-4f1b6f1c1073 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Septal Hematoma/2024-12-10T00_17_07.013Z.Desktop.md b/logseq/bak/pages/Septal Hematoma/2024-12-10T00_17_07.013Z.Desktop.md new file mode 100644 index 0000000..6c06fe7 --- /dev/null +++ b/logseq/bak/pages/Septal Hematoma/2024-12-10T00_17_07.013Z.Desktop.md @@ -0,0 +1,75 @@ +- alias:: + ICD-11_Code:: +- #definition +- ## Etiology + background-color:: blue + - ### Causative Agents #ent-prof-card #card + deck:: #ENT + id:: 64266b0a-1aaa-42f1-8753-bdefd8d0e31a + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 932292be-6531-4121-a91b-8f88bd317a67 + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: a9a2e6bf-5e0f-4758-9453-efb3537e2918 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Stridor/2024-12-10T00_17_07.016Z.Desktop.md b/logseq/bak/pages/Stridor/2024-12-10T00_17_07.016Z.Desktop.md new file mode 100644 index 0000000..f796d43 --- /dev/null +++ b/logseq/bak/pages/Stridor/2024-12-10T00_17_07.016Z.Desktop.md @@ -0,0 +1,9 @@ +tags:: #Signs + +- #definition {{c1 }} #ent-prof-card #card + deck:: #ENT + id:: 6756b3b2-dc1f-4fe6-8ec0-16f71c98fa2a +- # Causes #ent-prof-card #card + deck:: #ENT + id:: 6756b3bf-1f1a-4151-a1a2-dee3068c5861 +- \ No newline at end of file diff --git a/logseq/bak/pages/Stye/2024-12-10T00_17_07.019Z.Desktop.md b/logseq/bak/pages/Stye/2024-12-10T00_17_07.019Z.Desktop.md new file mode 100644 index 0000000..8b7802d --- /dev/null +++ b/logseq/bak/pages/Stye/2024-12-10T00_17_07.019Z.Desktop.md @@ -0,0 +1,89 @@ +- alias:: + ICD-11_Code:: +- #definition {{c1 It is an acute suppurative inflammation of a lash follicle and its associated gland of Zeis or moll by staphylococcus aureus}} #eye-prof-written #eye-prof-card #card + deck:: #Eye + id:: 6750248f-e0c3-40ee-aad7-420afc818616 +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - [[Chalazion]] + - Differences #eye-prof-card #card + deck:: #Eye + id:: 6755ec28-400f-46f7-bb1d-43f78a1921d9 + - | **Feature** | **Stye** | **Chalazion** | + | ---- | ---- | ---- | + | **Infection** | Bacterial | No | + | **Signs of Inflammation** | Present(Red, Painful) | Absent | + | **Location** | Near the Base of Eyelid | Away from the lash line | + | **Onset** | Rapid (acute) | Gradual (chronic) | + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment #eye-prof-card #card + deck:: #Eye + id:: de9abaed-5a1e-4cfd-9878-9857c4d3a34d + - [[Topical Antibiotic]] + - [[Epilation]] of the affected hair follicle + - Hot Compression(3-4 times daily) + - Topical Antibiotics {{c1 Chloramphenicol}} eye drop (4-6 times a day) + {{c1 Chloramphenicol}} eye ointment at bedtime #eye-prof-card #card + deck:: #Eye + id:: 6755e5b6-c3e7-4d29-bbd2-0696f6a0f8e0 + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Thyroglossal Cyst/2024-12-10T00_17_07.020Z.Desktop.md b/logseq/bak/pages/Thyroglossal Cyst/2024-12-10T00_17_07.020Z.Desktop.md new file mode 100644 index 0000000..5b4893e --- /dev/null +++ b/logseq/bak/pages/Thyroglossal Cyst/2024-12-10T00_17_07.020Z.Desktop.md @@ -0,0 +1,73 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Investigation #ent-prof-card #card + deck:: #ENT + id:: 6756b884-4e02-415f-ace0-864c4a99519f + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 5de64e21-03bc-464b-a190-56d00aee7332 + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Thyroid Neoplasm/2024-12-10T00_17_07.021Z.Desktop.md b/logseq/bak/pages/Thyroid Neoplasm/2024-12-10T00_17_07.021Z.Desktop.md new file mode 100644 index 0000000..9d3fecf --- /dev/null +++ b/logseq/bak/pages/Thyroid Neoplasm/2024-12-10T00_17_07.021Z.Desktop.md @@ -0,0 +1,73 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification #ent-prof-card #card + deck:: #ENT + id:: cf7127fe-8d80-4a80-ade1-8a7577b8b3c4 + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Investigation #ent-prof-card #card + deck:: #ENT + id:: 6756b676-e1f2-426c-9a92-ca8cd58d1a70 + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Tonsilitis/2024-12-10T00_17_07.022Z.Desktop.md b/logseq/bak/pages/Tonsilitis/2024-12-10T00_17_07.022Z.Desktop.md new file mode 100644 index 0000000..3393055 --- /dev/null +++ b/logseq/bak/pages/Tonsilitis/2024-12-10T00_17_07.022Z.Desktop.md @@ -0,0 +1,88 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + collapsed:: true + - ### Causative Agents + - Bacterial + - Beta streptococcal hemolyticus + - Staphylococcus + - Haemophillus influenza beta + - Pseudomonas + - Virus + - Influenza + - Parainfluenza + - Adenovirus + - Rhinovirus + - ### Risk Factors +- ## Epidemiology + background-color:: blue + collapsed:: true + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + collapsed:: true + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - [[Acute Tonsilitis]] + - [[Chronic Tonsilitits]] + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + collapsed:: true + - ### Clinical Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis +- ## Management and Treatment + background-color:: blue + collapsed:: true + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations +- ## Prognosis + background-color:: blue + collapsed:: true + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + collapsed:: true + - ### Possible Complications + - ### Long-term Effects +- ## Prevention + background-color:: blue + collapsed:: true + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + collapsed:: true + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + collapsed:: true + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Tonsillectomy/2024-12-10T00_17_07.023Z.Desktop.md b/logseq/bak/pages/Tonsillectomy/2024-12-10T00_17_07.023Z.Desktop.md new file mode 100644 index 0000000..a82fe9d --- /dev/null +++ b/logseq/bak/pages/Tonsillectomy/2024-12-10T00_17_07.023Z.Desktop.md @@ -0,0 +1,38 @@ +# Indications #ent-prof-card #card +card-last-score:: 1 +card-repeats:: 1 +card-next-schedule:: 2024-12-07T18:00:00.000Z +card-last-interval:: -1 +id:: 6733ccee-2ae1-4595-b0f6-5f09375b1b25 +card-ease-factor:: 2.5 +card-last-reviewed:: 2024-12-07T09:10:10.080Z +deck:: #ENT + - [[Recurrent Tonsillitis]] + logseq.order-list-type:: number + - [[Quinsy]]: for the first time and also second time without tonsillitis + logseq.order-list-type:: number + - Huge enlargement of the tonsil that causes obstructive symptoms like snoring, dyspnea, dysphagia etc + logseq.order-list-type:: number + - Suspected malignancy (unilateral enlargement of tonsil, ulceration of tonsil) + logseq.order-list-type:: number + - Other operative procedure like avulsion of styloid process, glossopharyngeal neurectomy + logseq.order-list-type:: number +- # Contraindication of tonsillectomy #ent-prof-card #card + deck:: #ENT + id:: 6733ccee-0b37-4719-b633-2a9135cb80fd + - Acute upper respiratory infection because bleeding is more in the presence of acute infection (after resolution of infection, wait for 2 weeks) + - Bleeding disorder like hemophilia, aplastic anemia, ITP, leukemia + - Uncontrolled DM + - Uncontrolled hypertension + - Epidemic like disease - polio (it causes bulbar palsy) + - Overt or submucous +- # Complications #ent-prof-card #card + deck:: #ENT + id:: 6756b151-9329-4f14-b5ad-804173e6d0dc + - [[Reactionary Hemorrhage]] +- # Management of Reactionary hemorrhage in Tonsillectomy #ent-prof-card #card + deck:: #ENT + id:: 6756b167-b5d3-45e4-a37e-8bda72a3ba58 +- # Management of Secondary hemorrhage in Tonsillectomy #ent-prof-card #card + deck:: #ENT + id:: 6756b183-ce0e-472b-9132-ca01bec19dae \ No newline at end of file diff --git a/logseq/bak/pages/Tubotympanic Chronic Suppurative Otitis Media/2024-12-10T00_17_07.024Z.Desktop.md b/logseq/bak/pages/Tubotympanic Chronic Suppurative Otitis Media/2024-12-10T00_17_07.024Z.Desktop.md new file mode 100644 index 0000000..c3b83d9 --- /dev/null +++ b/logseq/bak/pages/Tubotympanic Chronic Suppurative Otitis Media/2024-12-10T00_17_07.024Z.Desktop.md @@ -0,0 +1,69 @@ +alias:: Tubotympanic variety CSOM +ICD-11_Code:: + +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Uveitis/2024-12-10T00_17_07.025Z.Desktop.md b/logseq/bak/pages/Uveitis/2024-12-10T00_17_07.025Z.Desktop.md new file mode 100644 index 0000000..a730200 --- /dev/null +++ b/logseq/bak/pages/Uveitis/2024-12-10T00_17_07.025Z.Desktop.md @@ -0,0 +1,76 @@ +- alias:: + ICD-11_Code:: +- #definition {{c1 Uveitis is the Inflammation of the uveal tract, which may involve the adjacent Structure.}} #eye-prof-card #card + id:: 6755b9b4-8bc4-4688-8f1d-d401a0a9969e + deck:: #Eye +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - [[Mydriatics]] -> [[Atropine 1% Sulphate]] + collapsed:: true + - Relief of pain + - Prevention & breakdown of ((674abd95-5b79-4a8e-9b98-77b688e6b19a)) + - [[Topical Steroid]] + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Varicella/2024-12-10T00_17_07.026Z.Desktop.md b/logseq/bak/pages/Varicella/2024-12-10T00_17_07.026Z.Desktop.md new file mode 100644 index 0000000..405c49e --- /dev/null +++ b/logseq/bak/pages/Varicella/2024-12-10T00_17_07.026Z.Desktop.md @@ -0,0 +1,75 @@ +alias:: Chicken Pox +ICD-11_Code:: + +- ## Etiology + background-color:: blue + - ### Causative Agent + - Causative Agent : Varicella-Zoster Virus + - Mode of Transmission + - Respiratory Droplet + - Direct Contact + - Transplacental + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - almost all susceptible children before adolescence + - ### Prevalence + - ### Demographics + - pre-adolescent children + - Infection confers lifelong immunity, exception: there have been reinfections in healthy children + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Vertigo/2024-12-10T00_17_07.027Z.Desktop.md b/logseq/bak/pages/Vertigo/2024-12-10T00_17_07.027Z.Desktop.md new file mode 100644 index 0000000..fa0eb16 --- /dev/null +++ b/logseq/bak/pages/Vertigo/2024-12-10T00_17_07.027Z.Desktop.md @@ -0,0 +1,73 @@ +- alias:: + ICD-11_Code:: +- #definition {{c1 }} #ent-prof-card #card + deck:: #ENT + id:: 6756c26e-8c76-4f88-9f40-061bbefc10dd +- ## Etiology + background-color:: blue + - ### Causative Agents #ent-prof-card #card + deck:: #ENT + id:: e11cf2f0-ae51-4057-a4e7-d30365595c1a + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment + background-color:: blue + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Vocal Cord Nodule/2024-12-10T00_17_07.028Z.Desktop.md b/logseq/bak/pages/Vocal Cord Nodule/2024-12-10T00_17_07.028Z.Desktop.md new file mode 100644 index 0000000..2090156 --- /dev/null +++ b/logseq/bak/pages/Vocal Cord Nodule/2024-12-10T00_17_07.028Z.Desktop.md @@ -0,0 +1,72 @@ +- alias:: + ICD-11_Code:: +- ## Etiology + background-color:: blue + - ### Causative Agents + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 8b3e6e6f-9d19-4cbc-96bc-80175be22817 + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: f3f5c671-2d29-4788-8045-fdd1376019cc + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/Wax/2024-12-10T00_17_07.032Z.Desktop.md b/logseq/bak/pages/Wax/2024-12-10T00_17_07.032Z.Desktop.md new file mode 100644 index 0000000..6779240 --- /dev/null +++ b/logseq/bak/pages/Wax/2024-12-10T00_17_07.032Z.Desktop.md @@ -0,0 +1,133 @@ +- #definition It is composed of desquamated epithelium, dirt, secretions of sebaceous (watery secretion) and seruminous gland (fatty secretion) +- ## Composition + - Desquamated Epithelium + logseq.order-list-type:: number + - Dirt + logseq.order-list-type:: number + - Secretion of (Formation) #ent-prof-card #card + logseq.order-list-type:: number + deck:: #ENT + id:: 6733ccef-2563-4b05-b5ae-48913f93e037 + - Sebaceous gland + logseq.order-list-type:: number + - Serimunous gland + logseq.order-list-type:: number +- ## Excretion of Wax + - By movement of jaw during eating, talking, chewing, etc + logseq.order-list-type:: number + - Expelled in flakes but in certain individuals & children the wax accumulates -> external canal obstruction + logseq.order-list-type:: number +- ## Consistency + - Soft -> if secretion increased + - Hard -> if secretion decreased +- ## Function of normal wax + - Lubrication + logseq.order-list-type:: number + - Antibacterial (Bacteriostatic & Fungistatic -> due to acidic pH) + logseq.order-list-type:: number + - Protection of ear from insect (foreign material) & dust + logseq.order-list-type:: number +- alias:: + ICD-11_Code:: +- ## Etiology #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 6733ccef-7988-48c3-99dc-0de47e748645 + - ### Causative Agents + - Long standing impacted wax may ulcerate the meatal skin & result in granuloma formation (_wax granuloma_) + logseq.order-list-type:: number + - Excessive formation (hyper-secretion of gland) + logseq.order-list-type:: number + - Excessive desquamation of canal wall + logseq.order-list-type:: number + - ### Risk Factors + - Narrowing of external auditory canal + - Hairy external ear + - Frequent use of cotton bud - it hampers the normal cleaning + - Hot Humid climate +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology + background-color:: blue + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - ## Clinical Features + - #### Symptoms + - Sensation of blockage of the ear + logseq.order-list-type:: number + - Impairment of hearing + logseq.order-list-type:: number + - Tinnitus & giddiness + logseq.order-list-type:: number + - Aural fullness + logseq.order-list-type:: number + - Deafness (When blocks [[EAC]]) + logseq.order-list-type:: number + - Ear ache (when impacted wax cause [[Diffuse Otitis Externa]] ) + logseq.order-list-type:: number + - Refex Cough + logseq.order-list-type:: number + - #### Signs + - Impacted wax is seen in auroscopic findings + - brownish, hard or soft mass in the [[EAC]] + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - Otoscopy is contraindicated due to severe pain + background-color:: red + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis +- ## Management and Treatment #ent-prof-card #card + background-color:: blue + deck:: #ENT + id:: 6733ccef-220c-4ac9-8b57-a1bd92422057 + - ### Medical Treatment : no medical treatment + background-color:: red + - ### Surgical Options + - ## Treatment + - If wax is soft : Aural toileting by micro suction, Jobson's Horne Probe + - If children : GA + antibiotic + - If wax is hard: Making it soft by 7.5% $$\ce{NaHCO3}$$ (or olive oil or coconut oil) 3-4 drops twice daily 5-7 days. Then micro suction is given + - ### Lifestyle and Dietary Recommendations +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Complications + background-color:: blue + - ### Possible Complications + - ### Long-term Effects +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/logseq/bak/pages/White Patches on the tonsil/2024-12-10T00_17_07.033Z.Desktop.md b/logseq/bak/pages/White Patches on the tonsil/2024-12-10T00_17_07.033Z.Desktop.md new file mode 100644 index 0000000..cd796fc --- /dev/null +++ b/logseq/bak/pages/White Patches on the tonsil/2024-12-10T00_17_07.033Z.Desktop.md @@ -0,0 +1,5 @@ +tags:: #Signs + +- # Differential Diagnosis #ent-prof-card #ent-prof-written #card + deck:: #ENT + id:: 6756b1ae-51e0-4ba9-9220-dc162ef3b54e \ No newline at end of file diff --git a/logseq/bak/pages/unanswered/2024-12-10T00_17_07.024Z.Desktop.md b/logseq/bak/pages/unanswered/2024-12-10T00_17_07.024Z.Desktop.md new file mode 100644 index 0000000..808d124 --- /dev/null +++ b/logseq/bak/pages/unanswered/2024-12-10T00_17_07.024Z.Desktop.md @@ -0,0 +1 @@ +- diid \ No newline at end of file diff --git a/pages/Carcinoma Esophagus.md b/pages/Carcinoma Esophagus.md index f5c5af8..5d74737 100644 --- a/pages/Carcinoma Esophagus.md +++ b/pages/Carcinoma Esophagus.md @@ -3,78 +3,78 @@ tags:: #Disease - ## Etiology background-color:: blue - - ### Causative Agents - - ### Risk Factors + - ### Causative Agents + - ### Risk Factors - ## Epidemiology background-color:: blue - - ### Incidence - - ### Prevalence - - ### Demographics - - ### Geographic Distribution + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution - ## Pathophysiology background-color:: blue - - ### Mechanism of Disease - - ### Affected Systems/Organs + - ### Mechanism of Disease + - ### Affected Systems/Organs - ## Clinical Features #ent-prof-card #unanswered #card background-color:: blue deck:: #ENT id:: 464b6633-91a4-428a-b619-da2aa496c4e9 - - ### Signs and Symptoms - - #### Symptoms - - #### Signs - - ### Stages or Classification - - ### Diagnostic Criteria + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria - ## Diagnosis background-color:: blue - - ### Clinical Diagnosis - - #### Classical Presentation - - #### Probable Diagnosis - - ### Investigation #ent-prof-card #unanswered #card - deck:: #ENT - id:: 6756b5b4-3bc1-4867-9de8-8fa712fb4021 - - ### Laboratory Tests - - ### Imaging Studies - - ### Differential Diagnosis - - [[Achalasia Cardia]] - - Differences #ent-prof-card #unanswered #card - deck:: #ENT - id:: 6756aebe-94f6-4540-bb8d-48b5a674608e - - ### Confirmation of Diagnosis + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Investigation #ent-prof-card #unanswered #card + deck:: #ENT + id:: 6756b5b4-3bc1-4867-9de8-8fa712fb4021 + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - [[Achalasia Cardia]] + - Differences #ent-prof-card #unanswered #card + deck:: #ENT + id:: 6756aebe-94f6-4540-bb8d-48b5a674608e + - ### Confirmation of Diagnosis - ## Management and Treatment #ent-prof-card #unanswered #card background-color:: blue deck:: #ENT id:: 1f402519-98a7-48ea-a65a-27f7915cd7ab - - ### Medical Treatment - - ### Surgical Options - - ### Lifestyle and Dietary Recommendations - - ### Follow-up + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up - ## Prognosis background-color:: blue - - ### Expected Course - - #### With Treatment - - #### Without Treatment - - ##### Possible Complications - - ##### Long-Term Effects - - ### Survival Rates - - #### With Treatment - - #### Without Treatment - - ### Quality of Life Considerations + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations - ## Prevention background-color:: blue - - ### Health Education - - ### Community Approach - - ### Screening Programs - - ### Lifestyle Modifications + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications - ## Patient Education and Support background-color:: blue - - ### Educational Resources - - ### Support Groups - - ### Counseling Options + - ### Educational Resources + - ### Support Groups + - ### Counseling Options - ## Recent Research and Developments background-color:: blue - - ### Ongoing Clinical Trials - - ### Recent Advances + - ### Ongoing Clinical Trials + - ### Recent Advances - ## Key Literature background-color:: blue - ## Guidelines and Protocols - background-color:: blue + background-color:: blue \ No newline at end of file diff --git a/pages/Diptheria.md b/pages/Diptheria.md index 5700777..149fcd2 100644 --- a/pages/Diptheria.md +++ b/pages/Diptheria.md @@ -3,69 +3,71 @@ tags:: #Disease - ## Etiology background-color:: blue - - ### Causative Agents - - ### Risk Factors + - ### Causative Agents + - ### Risk Factors - ## Epidemiology background-color:: blue - - ### Incidence - - ### Prevalence - - ### Demographics - - ### Geographic Distribution + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution - ## Pathophysiology background-color:: blue - - ### Mechanism of Disease - - ### Affected Systems/Organs + - ### Mechanism of Disease + - ### Affected Systems/Organs - ## Clinical Features background-color:: blue - - ### Signs and Symptoms - - #### Symptoms - - #### Signs - - ### Stages or Classification - - ### Diagnostic Criteria + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria - ## Diagnosis #ent-prof-written #card deck:: #ENT - - ### Clinical Diagnosis - - #### Classical Presentation - - #### Probable Diagnosis - - ### Laboratory Tests - - ### Imaging Studies - - ### Differential Diagnosis - - ### Confirmation of Diagnosis + id:: 79c1fc72-f8ea-436f-8b0d-1b74ddbc6290 + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis - ## Management and Treatment background-color:: blue - - ### Medical Treatment - - ### Surgical Options - - ### Lifestyle and Dietary Recommendations - - ### Follow-up + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up - ## Prognosis background-color:: blue - - ### Expected Course - - #### With Treatment - - #### Without Treatment - - ##### Possible Complications - - ##### Long-Term Effects - - ### Survival Rates - - #### With Treatment - - #### Without Treatment - - ### Quality of Life Considerations + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations - ## Prevention background-color:: blue - - ### Health Education - - ### Community Approach - - ### Screening Programs - - ### Lifestyle Modifications + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications - ## Patient Education and Support background-color:: blue - - ### Educational Resources - - ### Support Groups - - ### Counseling Options + - ### Educational Resources + - ### Support Groups + - ### Counseling Options - ## Recent Research and Developments background-color:: blue - - ### Ongoing Clinical Trials - - ### Recent Advances + - ### Ongoing Clinical Trials + - ### Recent Advances - ## Key Literature background-color:: blue - ## Guidelines and Protocols background-color:: blue - SN : #ent-prof-written #card deck:: #ENT + id:: 6756d13b-1c1c-4d5a-aa14-1e1684683519 \ No newline at end of file diff --git a/pages/External Ear.md b/pages/External Ear.md index 1bb6df1..8770666 100644 --- a/pages/External Ear.md +++ b/pages/External Ear.md @@ -1,6 +1,5 @@ - [[Anatomy of External Ear]] - ### Importance of Important landmarks of Pinna - collapsed:: true - tragus - reconstructive surgery - repair the tympanic membrane diff --git a/pages/Foreign Body in Ear.md b/pages/Foreign Body in Ear.md index ff01a5a..8ec7057 100644 --- a/pages/Foreign Body in Ear.md +++ b/pages/Foreign Body in Ear.md @@ -1,11 +1,50 @@ -# Types #ent-prof-card #unanswered #card - -deck:: #ENT +# Types #ent-prof-card #card #[[External Ear]] id:: 6756a934-1410-48f2-b1a9-99cdf6a75c0c - deck:: #ENT -id:: 6756a934-1410-48f2-b1a9-99cdf6a75c0c - -- # Management #ent-prof-card #unanswered #card - deck:: #ENT + - Nonliving + logseq.order-list-type:: number + - Children inserted + logseq.order-list-type:: number + - piece of paper or sponge + logseq.order-list-type:: number + - grain seeds (rice, wheat, maize) + logseq.order-list-type:: number + - slate pencil + logseq.order-list-type:: number + - piece of chalk or metallic ball bearings + logseq.order-list-type:: number + - Adults inserted + logseq.order-list-type:: number + - broken end of matchstick + logseq.order-list-type:: number + - overlooked cotton swab + logseq.order-list-type:: number + - Living + logseq.order-list-type:: number + - Flycing or crawling insects like + logseq.order-list-type:: number + - mosquitoes + logseq.order-list-type:: number + - beetles + logseq.order-list-type:: number + - cockroach + logseq.order-list-type:: number + - ant + logseq.order-list-type:: number + - maggots from flies + logseq.order-list-type:: number +- # Management of a case of Living Body in ear #ent-prof-card #card #[[External Ear]] id:: 6756cf39-f53f-48c4-b651-e41c2953306b + deck:: #ENT + - No attempt should be made to catch them alive + background-color:: pink + - Insect killed by + - oil (household remedy) + - spirit + - chloroform water + - Removed by + - Forceps removal + - Syrining + - Suction + - Microscopic removal with special instruments + - Postaural approach \ No newline at end of file diff --git a/pages/Furuncle.md b/pages/Furuncle.md new file mode 100644 index 0000000..677a0fa --- /dev/null +++ b/pages/Furuncle.md @@ -0,0 +1,92 @@ +alias:: Localized Acute Otitis Externa +ICD-11_Code:: +tags:: #Disease + +- #definition {{c1 A furuncle is a staphylococcal infection of the hair follicle}} #ent-prof-card #card #[[External Ear]] + deck:: #ENT + id:: 67579687-462c-4d72-a007-b7aabc820878 +- ## Etiology + background-color:: blue + - ### Causative Agents #ent-prof-card #card #[[External Ear]] + deck:: #ENT + id:: c3ed9276-100a-4ae9-8b22-5374b5db6310 + - [[Staphylococcus aureus]] + - ### Risk Factors +- ## Epidemiology + background-color:: blue + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution +- ## Pathophysiology #ent-prof-card #card #[[External Ear]] + background-color:: blue + deck:: #ENT + id:: bcf7efa7-463f-4fe6-af30-cee75433b2ed + - ### Mechanism of Disease + - infection of the hair follicles of external ear by [[Staphylococcus aureus]] + - ### Affected Systems/Organs + - only the cartilagenous part comprises the hair follicles, hence Furuncle is confined to cartilagenous part of external ear +- ## Clinical Features + background-color:: blue + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria +- ## Diagnosis + background-color:: blue + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card #[[External Ear]] + background-color:: blue + deck:: #ENT + id:: 3af07f85-c7db-408f-a49b-e78a42fe5ebd + - ### Medical Treatment + - Systemic Antibiotics + - Analgesics + - Local Heat + - Ear pack of 10% ichthammol glycerine provides splintage and reduces pain + - Hygroscopic action of glycerine reduces oedema + - ichammol is mildly antiseptic + - ### Surgical Options + if abscess formed + - incision and drainage of abscess + - If recurrent [[Furunculosis]] + - Exclude diabetes + - Attention paid to the patient's nasal vestibules which may harbour staphylococci and the infection transferred by patient's fingers + - Staphylococcal infections of the skin as a possible source should also be excluded and suitably treated +- ## Prognosis + background-color:: blue + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations +- ## Prevention + background-color:: blue + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications +- ## Patient Education and Support + background-color:: blue + - ### Educational Resources + - ### Support Groups + - ### Counseling Options +- ## Recent Research and Developments + background-color:: blue + - ### Ongoing Clinical Trials + - ### Recent Advances +- ## Key Literature + background-color:: blue +- ## Guidelines and Protocols + background-color:: blue \ No newline at end of file diff --git a/pages/Furunculosis.md b/pages/Furunculosis.md index 314e1a8..3d21524 100644 --- a/pages/Furunculosis.md +++ b/pages/Furunculosis.md @@ -1,80 +1,78 @@ - alias:: ICD-11_Code:: tags:: #Disease -- #definition {{c1 }} #ent-prof-card #unanswered #card - deck:: #ENT +- #definition {{c1 Recurrent or multiple [[Furuncle]]s is called Furunculosis }} #ent-prof-card #unanswered #card id:: 6756a8ab-4837-43bd-8f2a-5e5a48df80fa -- ## Etiology #ent-prof-card #unanswered #card - background-color:: blue deck:: #ENT +- ## Etiology + background-color:: blue id:: 6756cf33-62f1-4697-b808-6abef9e42e55 - - ### Causative Agents - - ### Risk Factors + - ### Causative Agents + - ### Risk Factors - ## Epidemiology background-color:: blue - - ### Incidence - - ### Prevalence - - ### Demographics - - ### Geographic Distribution + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution - ## Pathophysiology #ent-prof-card #unanswered #card background-color:: blue deck:: #ENT id:: f0515a7d-e1eb-4340-981b-5b843b5bb246 - - ### Mechanism of Disease - - ### Affected Systems/Organs + - ### Mechanism of Disease + - ### Affected Systems/Organs - ## Clinical Features #ent-prof-card #unanswered #card background-color:: blue deck:: #ENT id:: e445fb66-0f09-4bbf-a956-f1602db091af - - ### Signs and Symptoms - - #### Symptoms - - #### Signs - - ### Stages or Classification - - ### Diagnostic Criteria + - ### Signs and Symptoms + - #### Symptoms + - #### Signs + - ### Stages or Classification + - ### Diagnostic Criteria - ## Diagnosis background-color:: blue - - ### Clinical Diagnosis - - #### Classical Presentation - - #### Probable Diagnosis - - ### Laboratory Tests - - ### Imaging Studies - - ### Differential Diagnosis - - ### Confirmation of Diagnosis -- ## Management and Treatment #ent-prof-card #unanswered #card + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment background-color:: blue - deck:: #ENT id:: 0103a3c3-347d-4f75-8dfc-57f0e330cc30 - - ### Medical Treatment - - ### Surgical Options - - ### Lifestyle and Dietary Recommendations - - ### Follow-up + - ### Medical Treatment + - ### Surgical Options + - ### Lifestyle and Dietary Recommendations + - ### Follow-up - ## Prognosis background-color:: blue - - ### Expected Course - - #### With Treatment - - #### Without Treatment - - ##### Possible Complications - - ##### Long-Term Effects - - ### Survival Rates - - #### With Treatment - - #### Without Treatment - - ### Quality of Life Considerations + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations - ## Prevention background-color:: blue - - ### Health Education - - ### Community Approach - - ### Screening Programs - - ### Lifestyle Modifications + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications - ## Patient Education and Support background-color:: blue - - ### Educational Resources - - ### Support Groups - - ### Counseling Options + - ### Educational Resources + - ### Support Groups + - ### Counseling Options - ## Recent Research and Developments background-color:: blue - - ### Ongoing Clinical Trials - - ### Recent Advances + - ### Ongoing Clinical Trials + - ### Recent Advances - ## Key Literature background-color:: blue - ## Guidelines and Protocols - background-color:: blue + background-color:: blue \ No newline at end of file diff --git a/pages/Hematoma Auris.md b/pages/Hematoma Auris.md index 19dcd94..1e138d3 100644 --- a/pages/Hematoma Auris.md +++ b/pages/Hematoma Auris.md @@ -3,73 +3,76 @@ tags:: #Disease - ## Etiology background-color:: blue - - ### Causative Agents #ent-prof-card #unanswered #card - deck:: #ENT - id:: 267a035d-50dd-44af-9166-b7cd518c61af - - ### Risk Factors + - ### Causative Agents #ent-prof-card #card #[[External Ear]] + id:: 267a035d-50dd-44af-9166-b7cd518c61af + deck:: #ENT + - Blunt Trauma + - ### Risk Factors - ## Epidemiology background-color:: blue - - ### Incidence - - ### Prevalence - - ### Demographics - - ### Geographic Distribution + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution - ## Pathophysiology background-color:: blue - - ### Mechanism of Disease - - ### Affected Systems/Organs -- ## Clinical Features #ent-prof-card #unanswered #card + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card #[[External Ear]] background-color:: blue - deck:: #ENT id:: 675e005b-0dc4-4250-8c48-872b210a4b86 - - ### Signs and Symptoms - - #### Symptoms - - #### Signs - - ### Stages or Classification - - ### Diagnostic Criteria + deck:: #ENT + - ### Cauliflower Ear + alias:: Pugilistic Ear, Boxer's Ear + - If Haemotoma gets infected, severe [[Perichondritis]] may set in - ## Diagnosis background-color:: blue - - ### Clinical Diagnosis - - #### Classical Presentation - - #### Probable Diagnosis - - ### Laboratory Tests - - ### Imaging Studies - - ### Differential Diagnosis - - ### Confirmation of Diagnosis -- ## Management and Treatment #ent-prof-card #unanswered #card + - ### Clinical Diagnosis + - #### Classical Presentation + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card #[[External Ear]] background-color:: blue - deck:: #ENT id:: f7071a4f-91ab-45e9-a9ee-7701520e4996 - - ### Medical Treatment - - ### Surgical Options - - ### Lifestyle and Dietary Recommendations - - ### Follow-up + deck:: #ENT + - ### Surgical Options + - Aspiration of the haematoma under strict aseptic precautions + - Pressure dressing, carefully packing all concavities of the auricle to prevent reaccumulation + - Aspiration may need to be repeated, when ails, incision and drainage. Then Pressure applied by dental rolls tied through and through sutures. + - ### Medical Treatment + - Prophylactic Antibiotic + - ### Lifestyle and Dietary Recommendations + - ### Follow-up - ## Prognosis background-color:: blue - - ### Expected Course - - #### With Treatment - - #### Without Treatment - - ##### Possible Complications - - ##### Long-Term Effects - - ### Survival Rates - - #### With Treatment - - #### Without Treatment - - ### Quality of Life Considerations + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations - ## Prevention background-color:: blue - - ### Health Education - - ### Community Approach - - ### Screening Programs - - ### Lifestyle Modifications + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications - ## Patient Education and Support background-color:: blue - - ### Educational Resources - - ### Support Groups - - ### Counseling Options + - ### Educational Resources + - ### Support Groups + - ### Counseling Options - ## Recent Research and Developments background-color:: blue - - ### Ongoing Clinical Trials - - ### Recent Advances + - ### Ongoing Clinical Trials + - ### Recent Advances - ## Key Literature background-color:: blue - ## Guidelines and Protocols - background-color:: blue + background-color:: blue \ No newline at end of file diff --git a/pages/Malignant Otitis Externa.md b/pages/Malignant Otitis Externa.md index fd6a0e8..17d4f4f 100644 --- a/pages/Malignant Otitis Externa.md +++ b/pages/Malignant Otitis Externa.md @@ -1,76 +1,89 @@ - alias:: ICD-11_Code:: tags:: #Disease -- #definition {{c1 }} #ent-prof-card #unanswered #card - deck:: #ENT +- #definition {{c1 It is an inflammatory condition caused by pseudomonas infection usually in the elderly diabetics, or in those on immunosuppressive drugs. }} #ent-prof-card #card #[[External Ear]] id:: 6756ab5c-a4c8-488c-abee-6ae8f0386aa9 + deck:: #ENT - ## Etiology background-color:: blue - - ### Causative Agents - - ### Risk Factors + - ### Causative Agents + - [[Pseudomonas]] + - ### Risk Factors + - Elderly [[Diabetes Mellitus]] + - [[Immunosuppressive Drugs]] - ## Epidemiology background-color:: blue - - ### Incidence - - ### Prevalence - - ### Demographics - - ### Geographic Distribution + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution - ## Pathophysiology background-color:: blue - - ### Mechanism of Disease - - ### Affected Systems/Organs -- ## Clinical Features #ent-prof-card #unanswered #card + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card #[[External Ear]] background-color:: blue - deck:: #ENT id:: 7cb04bbd-1833-4b20-951c-15e69c28556d - - ### Signs and Symptoms - - #### Symptoms - - #### Signs - - ### Stages or Classification - - ### Diagnostic Criteria + deck:: #ENT + - ### Signs and Symptoms + - #### Symptoms + - Excruciating pain + - Appearance of granulations in the ear canal + - Facial paralysis is common - ## Diagnosis background-color:: blue - - ### Clinical Diagnosis - - #### Classical Presentation - - #### Probable Diagnosis - - ### Laboratory Tests - - ### Imaging Studies - - ### Differential Diagnosis - - ### Confirmation of Diagnosis -- ## Management and Treatment #ent-prof-card #unanswered #card + - ### Clinical Diagnosis + - #### Classical Presentation + - ((6757a239-0aec-4435-8ab3-621cbd1d9117)) + - #### Probable Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis + - ### Confirmation of Diagnosis +- ## Management and Treatment #ent-prof-card #card #[[External Ear]] background-color:: blue - deck:: #ENT id:: 28d9b3b0-29e5-42da-ae87-1173fb90808d - - ### Medical Treatment - - ### Surgical Options - - ### Lifestyle and Dietary Recommendations - - ### Follow-up + deck:: #ENT + - ### Medical Treatment + - Control of Diabetes + - Antibiotic Treatment against *P. aeruginosa* or changed after C/S + - IV Gentamicin combined with Ticarcillin + - Third generation cephalosporins + - Oral Quinolones (Ciprofloxacin, Olfloxacin and Levofloxacin) + - Antibiotic treatment is continued for 6-8 weeks, sometimes more + - ### Surgical Options + - Toilet of ear canal. REmoev discharge, debris and granulations or any dead tissue or bone + - ### Lifestyle and Dietary Recommendations + - Control of Diabetes + - ### Follow-up + - ((6757a3e7-9b44-4101-a82f-5c6b79cc4fba)) - ## Prognosis background-color:: blue - - ### Expected Course - - #### With Treatment - - #### Without Treatment - - ##### Possible Complications - - ##### Long-Term Effects - - ### Survival Rates - - #### With Treatment - - #### Without Treatment - - ### Quality of Life Considerations + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ##### Possible Complications + - ##### Long-Term Effects + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations - ## Prevention background-color:: blue - - ### Health Education - - ### Community Approach - - ### Screening Programs - - ### Lifestyle Modifications + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications - ## Patient Education and Support background-color:: blue - - ### Educational Resources - - ### Support Groups - - ### Counseling Options + - ### Educational Resources + - ### Support Groups + - ### Counseling Options - ## Recent Research and Developments background-color:: blue - - ### Ongoing Clinical Trials - - ### Recent Advances + - ### Ongoing Clinical Trials + - ### Recent Advances - ## Key Literature background-color:: blue - ## Guidelines and Protocols - background-color:: blue + background-color:: blue \ No newline at end of file diff --git a/pages/Otitis Externa.md b/pages/Otitis Externa.md index 426dbc1..81ddbeb 100644 --- a/pages/Otitis Externa.md +++ b/pages/Otitis Externa.md @@ -1,7 +1,22 @@ -# Classification #ent-prof-card #unanswered #card - -deck:: #ENT - [[Malignant Otitis Externa]] - [[Diffuse Otitis Externa]] -id:: 6756a805-64ab-44e4-aee0-a28c733812b3 - -deck:: #ENT - [[Malignant Otitis Externa]] - [[Diffuse Otitis Externa]] +# Classification #ent-prof-card #card #[[External Ear]] id:: 6756a805-64ab-44e4-aee0-a28c733812b3 +deck:: #ENT + - [[Malignant Otitis Externa]] - [[Diffuse Otitis Externa]] + - Infective Group + logseq.order-list-type:: number + - [[Furuncle]] + logseq.order-list-type:: number + - [[Diffuse Otitis Externa]] + logseq.order-list-type:: number + - [[Malignant Otitis Externa]] + logseq.order-list-type:: number + - Reactive Group + logseq.order-list-type:: number + - [[Otomycosis]] + logseq.order-list-type:: number + - [[Herpes Zoster Oticus]] + logseq.order-list-type:: number + - [[Otitis Externa Haemorrhagica]] + logseq.order-list-type:: number +- Others + - \ No newline at end of file diff --git a/pages/Otomycosis.md b/pages/Otomycosis.md index dc46d3e..6c89306 100644 --- a/pages/Otomycosis.md +++ b/pages/Otomycosis.md @@ -4,99 +4,106 @@ tags:: #Disease - ## Etiology background-color:: blue - - ### Causative Agents - - _[[Aspergillus niger]]_ (black fungal ball) - - _[[Aspergillus fumigatus]]_ (green) - - _[[Candida albicans]]_ (whitish) - - ### Risk Factors - - Hot and humid climate - - More in summer, DM, topical use of antibiotics - - Secondary to bacterial infection diffuse otitis externa and suppurative otitis media - - At that time antibiotic should not be given because antibiotic solution support the growth of fungus + - ### Causative Agents + - _[[Aspergillus niger]]_ (black fungal ball) + - _[[Aspergillus fumigatus]]_ (green) + - _[[Candida albicans]]_ (whitish) + - ### Risk Factors + - Hot and humid climate + - More in summer, DM, topical use of antibiotics + - Secondary to bacterial infection diffuse otitis externa and suppurative otitis media + - At that time antibiotic should not be given because antibiotic solution support the growth of fungus - ## Epidemiology background-color:: blue - - ### Incidence - - ### Prevalence - - ### Demographics - - ### Geographic Distribution + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution - ## Pathophysiology background-color:: blue - - ### Mechanism of Disease - - ### Affected Systems/Organs + - ### Mechanism of Disease + - ### Affected Systems/Organs - ## Clinical Features #ent-prof-card #unanswered #card background-color:: blue deck:: #ENT id:: 6733ccee-2abe-4542-a82e-a7e5755b34d6 - - ### Signs and Symptoms - - #### Symptoms - - Intense itching & irritation - - Mild pain associated with secondary bacterial infection - - Blockage of ear - - Otorrhoea-straw coloured serous discharge due to increase secretion of gland of external auditory canal - - Blockage & heaviness in the ear - - Impairment of hearing(conductive type) - - #### Signs - - Aural discharge-watery or purulent - - Peculiar musty odor - - On auriscopic findings - - Fungal ball or otomycotic plug - wet filter paper/ newspaper color of the ball - - Mucous membrane **swollen**, **reddish**, **congested** - - ### Stages or Classification - - ### Diagnostic Criteria + - ### Signs and Symptoms + - #### Symptoms + - Intense Itching + - Discomfort + - Pain + - #### Signs + - Watery Discharge with a musty odour + - Ear blockage + - fungal mass may appear white, brown or black and has been likened to a wet piece of filter paper + - On auriscopic findings + - Fungal ball or otomycotic plug - wet filter paper/ newspaper color of the ball + - Mucous membrane **swollen**, **reddish**, **congested** + - ### Stages or Classification + - ### Diagnostic Criteria - ## Diagnosis background-color:: blue - - ### Clinical Diagnosis : S/S - - ### Laboratory Tests - - Wet film preparation - - Hyphae are found in aspergillus - - Small ovoid budding is found in candida - - Aural swab for C/S - - ### Imaging Studies - - ### Differential Diagnosis -- ## Management and Treatment + - ### Clinical Diagnosis : S/S + - ### Investigations + - Otoscope Findings + - A. niger appears black headed filamentous growth + - A. fumigatus as pale blue or green + - Candida as white or creamy deposit + - Meatal skin appear, *sodden, red * and *oedematous* + - Wet film preparation + - Hyphae are found in aspergillus + - Small ovoid budding is found in candida + - Aural swab for C/S + - ### Imaging Studies + - ### Differential Diagnosis +- ## Management and Treatment #ent-prof-card #card #[[External Ear]] background-color:: blue - - ### Surgical Options - - For blockage: {{c1 Removal of the fungal mass by forceps, suction or by syringe}} #ent-prof-card #unanswered #card - deck:: #ENT - id:: 6733ccee-7980-4895-ad56-952edb6147b4 - - ### Medical Treatment #ent-prof-card #unanswered #card - deck:: #ENT - id:: 6756cf36-e0de-4456-8c77-c1efbe134db8 - - For itching : Antihistamine (Chlorpheniramine) - - If pain: Tab. Paracetamol(500 mg) three times daily till pain subside - - If secondary infection present: Antibiotics (Phenoxymethyl penicillin) - - Antifungal: 1 week + 1 week (Nystatin cream(Topical)-candida or clotrimazole cream(Broad spectrum systemic) - - ### Lifestyle and Dietary Recommendations - - Ear must be kept dry + deck:: #ENT + id:: 6733ccee-2f53-4849-b192-14e354d05c13 + - ### Surgical Options + - For blockage: + id:: 6733ccee-7980-4895-ad56-952edb6147b4 + Thorough Ear toilet to remove all discharge and epithelial debris which are conductive to the growth of fungus by syringing, suction or mopping + - ### Medical Treatment + id:: 6756cf36-e0de-4456-8c77-c1efbe134db8 + - Antifungal + - They are + - Nystatin against Candida + - Other borad-spectrum antifungal agents : Cotrimazole and Povidone Iodine + - Two percent salicylic acid in alcohol is also effective + - Antifungal treatment should be continued for a week even after apparent cure to avoid recurrences + - Antibiotic/steroid preparation for secondary bacterial infections + - ### Lifestyle and Dietary Recommendations + - Ear must be kept dry - ## Prognosis background-color:: blue - - ### Expected Course - - #### With Treatment - - #### Without Treatment - - ### Survival Rates - - #### With Treatment - - #### Without Treatment - - ### Quality of Life Considerations + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations - ## Complications background-color:: blue - - ### Possible Complications - - ### Long-term Effects + - ### Possible Complications + - ### Long-term Effects - ## Prevention background-color:: blue - - ### Health Education - - ### Community Approach - - ### Screening Programs - - ### Lifestyle Modifications + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications - ## Patient Education and Support background-color:: blue - - ### Educational Resources - - ### Support Groups - - ### Counseling Options + - ### Educational Resources + - ### Support Groups + - ### Counseling Options - ## Recent Research and Developments background-color:: blue - - ### Ongoing Clinical Trials - - ### Recent Advances + - ### Ongoing Clinical Trials + - ### Recent Advances - ## Key Literature background-color:: blue - ## Guidelines and Protocols - background-color:: blue + background-color:: blue \ No newline at end of file diff --git a/pages/Perichondritis.md b/pages/Perichondritis.md index 2e195ee..44e794b 100644 --- a/pages/Perichondritis.md +++ b/pages/Perichondritis.md @@ -1,115 +1,111 @@ - alias:: ICD-11_Code:: tags:: #Disease -- #definition It is defined as inflammation of the perichondrium of the pinna #ent-prof-card #unanswered #card - deck:: #ENT +- #definition {{c1 It is defined as inflammation of the perichondrium of the pinna #ent-prof-}}card #card #[[External Ear]] id:: 67542d40-7651-40c8-92c2-cf87ac1d55e6 + deck:: #ENT - ## Etiology background-color:: blue - - ### Causative Agents - - Secondary infections from [[Hematoma Auris]] - logseq.order-list-type:: number - - Surgical incision - logseq.order-list-type:: number - - Trauma(Laceration) - logseq.order-list-type:: number - - It can result from extension of infection from [[Diffuse Otitis Externa]] or [[Furunculosis]] - logseq.order-list-type:: number - - Organism - logseq.order-list-type:: number - - _[[Pseudomona]]_ - logseq.order-list-type:: number - - _[[Staphylococcus aureus]]_ - logseq.order-list-type:: number - - _[[Proteus]]_ - logseq.order-list-type:: number - - ### Risk Factors + - ### Causative Agents + - Secondary infections from [[Hematoma Auris]] + logseq.order-list-type:: number + - Surgical incision + logseq.order-list-type:: number + - Trauma(Laceration) + logseq.order-list-type:: number + - It can result from extension of infection from [[Diffuse Otitis Externa]] or [[Furunculosis]] + logseq.order-list-type:: number + - Organism + logseq.order-list-type:: number + - _[[Pseudomona]]_ + logseq.order-list-type:: number + - _[[Staphylococcus aureus]]_ + logseq.order-list-type:: number + - _[[Proteus]]_ + logseq.order-list-type:: number + - ### Risk Factors - ## Epidemiology background-color:: blue - - ### Incidence - - ### Prevalence - - ### Demographics - - ### Geographic Distribution + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution - ## Pathophysiology background-color:: blue - - ### Mechanism of Disease - - ### Affected Systems/Organs -- ## Clinical Features #ent-prof-card #unanswered #card + - ### Mechanism of Disease + - ### Affected Systems/Organs +- ## Clinical Features #ent-prof-card #card #[[External Ear]] background-color:: blue - deck:: #ENT id:: 6733ccee-0f47-4280-ba92-ee43d6ab6408 - - ### Signs and Symptoms - - #### Symptoms - - Severe Pain - - Thickening and reddening of pinna - - #### Signs - - Tenderness - - High rise of temperature - - ### Stages or Classification - - ### Diagnostic Criteria + deck:: #ENT + - ### Signs and Symptoms + - #### Symptoms + - Red, hot and painful pinna which feels stiff + - #### Signs + - Tenderness + - Stiff (feel 😊) - ## Diagnosis background-color:: blue - - ### Clinical Diagnosis - - ### Laboratory Tests - - ### Imaging Studies - - ### Differential Diagnosis + - ### Clinical Diagnosis + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis - ## Management and Treatment #ent-prof-card #unanswered #card background-color:: blue deck:: #ENT id:: 6733ccee-4031-4bf4-accb-1e06b3adf1bd - - ### Medical Treatment with [[Hospitalization]] - - [[Broad Spectrum Antibiotics]] - logseq.order-list-type:: number - - IV - [[Ciprofloxacin]] - logseq.order-list-type:: number - - Oral - [[Ceftazidime]] - logseq.order-list-type:: number - - Analgesics - logseq.order-list-type:: number - - Antipyretics - logseq.order-list-type:: number - - Local Application of 4% aluminum acetate compress - logseq.order-list-type:: number - - ### Surgical Options - - ### Lifestyle and Dietary Recommendations + - ### Medical Treatment with [[Hospitalization]] + - [[Broad Spectrum Antibiotics]] + logseq.order-list-type:: number + - IV - [[Ciprofloxacin]] + logseq.order-list-type:: number + - Oral - [[Ceftazidime]] + logseq.order-list-type:: number + - Local Application of 4% aluminum acetate compresses + logseq.order-list-type:: number + - ### Surgical Options + if abscess formed + - Drain abscess + - Culture and Sensitivity of pus + - ### Lifestyle and Dietary Recommendations - ## Prognosis background-color:: blue - - ### Expected Course - - #### With Treatment - - #### Without Treatment - - ### Survival Rates - - #### With Treatment - - #### Without Treatment - - ### Quality of Life Considerations + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations - ## Complications background-color:: blue - - ### Possible Complications - - Cauliflower like pinna due to necrosis of cartilage (abscess formation) - - #### Management - - Incision and drainage of abscess followed by obliteration of space by pressure with bandage (dental roll) - - Incision & drainage of abscess - logseq.order-list-type:: number - - Removal of devitalized cartilage - logseq.order-list-type:: number - - Continuous drip of antibiotics according to [[C/S]] of pus for 7-10 days - logseq.order-list-type:: number - - ### Long-term Effects + - ### Possible Complications + - Cauliflower like pinna due to necrosis of cartilage (abscess formation) + - #### Management + - Incision and drainage of abscess followed by obliteration of space by pressure with bandage (dental roll) + - Incision & drainage of abscess + logseq.order-list-type:: number + - Removal of devitalized cartilage + logseq.order-list-type:: number + - Continuous drip of antibiotics according to [[C/S]] of pus for 7-10 days + logseq.order-list-type:: number + - ### Long-term Effects - ## Prevention background-color:: blue - - ### Health Education - - ### Community Approach - - ### Screening Programs - - ### Lifestyle Modifications + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications - ## Patient Education and Support background-color:: blue - - ### Educational Resources - - ### Support Groups - - ### Counseling Options + - ### Educational Resources + - ### Support Groups + - ### Counseling Options - ## Recent Research and Developments background-color:: blue - - ### Ongoing Clinical Trials - - ### Recent Advances + - ### Ongoing Clinical Trials + - ### Recent Advances - ## Key Literature background-color:: blue - ## Guidelines and Protocols - background-color:: blue + background-color:: blue \ No newline at end of file diff --git a/pages/Syringing the Ear.md b/pages/Syringing the Ear.md new file mode 100644 index 0000000..cd276ef --- /dev/null +++ b/pages/Syringing the Ear.md @@ -0,0 +1 @@ +# Procedure \ No newline at end of file diff --git a/pages/Wax.md b/pages/Wax.md index b0a5757..29b0f6c 100644 --- a/pages/Wax.md +++ b/pages/Wax.md @@ -3,132 +3,133 @@ tags:: #Disease - #definition It is composed of desquamated epithelium, dirt, secretions of sebaceous (watery secretion) and seruminous gland (fatty secretion) - ## Composition - - Desquamated Epithelium - logseq.order-list-type:: number - - Dirt - logseq.order-list-type:: number - - Secretion of (Formation) #ent-prof-card #unanswered #card - logseq.order-list-type:: number - deck:: #ENT - id:: 6733ccef-2563-4b05-b5ae-48913f93e037 - - Sebaceous gland - logseq.order-list-type:: number - - Serimunous gland - logseq.order-list-type:: number + - Desquamated Epithelium + logseq.order-list-type:: number + - Dirt + logseq.order-list-type:: number + - Secretion of (Formation) #ent-prof-card #unanswered #card + logseq.order-list-type:: number + deck:: #ENT + id:: 6733ccef-2563-4b05-b5ae-48913f93e037 + - Sebaceous gland + logseq.order-list-type:: number + - Ceriminous gland + logseq.order-list-type:: number - ## Excretion of Wax - - By movement of jaw during eating, talking, chewing, etc - logseq.order-list-type:: number - - Expelled in flakes but in certain individuals & children the wax accumulates -> external canal obstruction - logseq.order-list-type:: number + - By movement of jaw during eating, talking, chewing, etc + logseq.order-list-type:: number + - Expelled in flakes but in certain individuals & children the wax accumulates -> external canal obstruction + logseq.order-list-type:: number - ## Consistency - - Soft -> if secretion increased - - Hard -> if secretion decreased + - Soft -> if secretion increased + - Hard -> if secretion decreased - ## Function of normal wax - - Lubrication - logseq.order-list-type:: number - - Antibacterial (Bacteriostatic & Fungistatic -> due to acidic pH) - logseq.order-list-type:: number - - Protection of ear from insect (foreign material) & dust - logseq.order-list-type:: number + - Lubrication + logseq.order-list-type:: number + - Antibacterial (Bacteriostatic & Fungistatic -> due to acidic pH) + logseq.order-list-type:: number + - Protection of ear from insect (foreign material) & dust + logseq.order-list-type:: number - ## Etiology #ent-prof-card #unanswered #card background-color:: blue deck:: #ENT id:: 6733ccef-7988-48c3-99dc-0de47e748645 - - ### Causative Agents - - Long standing impacted wax may ulcerate the meatal skin & result in granuloma formation (_wax granuloma_) - logseq.order-list-type:: number - - Excessive formation (hyper-secretion of gland) - logseq.order-list-type:: number - - Excessive desquamation of canal wall - logseq.order-list-type:: number - - ### Risk Factors - - Narrowing of external auditory canal - - Hairy external ear - - Frequent use of cotton bud - it hampers the normal cleaning - - Hot Humid climate + - ### Causative Agents + - Long standing impacted wax may ulcerate the meatal skin & result in granuloma formation (_wax granuloma_) + logseq.order-list-type:: number + - Excessive formation (hyper-secretion of gland) + logseq.order-list-type:: number + - Excessive desquamation of canal wall + logseq.order-list-type:: number + - ### Risk Factors + - Narrowing of external auditory canal + - Hairy external ear + - Frequent use of cotton bud - it hampers the normal cleaning + - Hot Humid climate - ## Epidemiology background-color:: blue - - ### Incidence - - ### Prevalence - - ### Demographics - - ### Geographic Distribution + - ### Incidence + - ### Prevalence + - ### Demographics + - ### Geographic Distribution - ## Pathophysiology background-color:: blue - - ### Mechanism of Disease - - ### Affected Systems/Organs -- ## Clinical Features + - ### Mechanism of Disease + - ### Affected Systems/Organs + - ((675798b9-1c47-4d4e-bf3f-f0e918a2c78c)) + - ((67579897-adbd-4590-b33f-139f936b8701)) +- ## Clinical Features #ent-prof-card #card #[[External Ear]] background-color:: blue - - ### Signs and Symptoms - - ## Clinical Features - - #### Symptoms - - Sensation of blockage of the ear - logseq.order-list-type:: number - - Impairment of hearing - logseq.order-list-type:: number - - Tinnitus & giddiness - logseq.order-list-type:: number - - Aural fullness - logseq.order-list-type:: number - - Deafness (When blocks [[EAC]]) - logseq.order-list-type:: number - - Ear ache (when impacted wax cause [[Diffuse Otitis Externa]] ) - logseq.order-list-type:: number - - Refex Cough - logseq.order-list-type:: number - - #### Signs - - Impacted wax is seen in auroscopic findings - - brownish, hard or soft mass in the [[EAC]] - - ### Stages or Classification - - ### Diagnostic Criteria + deck:: #ENT + id:: 6733ccef-f88b-470f-b61d-dee5132df0ff + - ### Signs and Symptoms + - #### Symptoms + - Impariment of Hearing or Sense of Blocked ear + logseq.order-list-type:: number + - Tinnitus and giddiness + logseq.order-list-type:: number + - Reflex cough + logseq.order-list-type:: number + - ((6757990b-3ecb-42ca-b341-621c427e9a82)) + logseq.order-list-type:: number + - ((67579917-c01b-4bbc-afc5-c1fcbe54be4f)) + logseq.order-list-type:: number + - #### Signs + - Impacted wax is seen in auroscopic findings + - brownish, hard or soft mass in the [[EAC]] + - ### Stages or Classification + - ### Diagnostic Criteria - ## Diagnosis background-color:: blue - - ### Clinical Diagnosis - - Otoscopy is contraindicated due to severe pain - background-color:: red - - ### Laboratory Tests - - ### Imaging Studies - - ### Differential Diagnosis -- ## Management and Treatment #ent-prof-card #unanswered #card + - ### Clinical Diagnosis + - Otoscopy is contraindicated due to severe pain + background-color:: red + - ### Laboratory Tests + - ### Imaging Studies + - ### Differential Diagnosis +- ## Management and Treatment #ent-prof-card #card #[[External Ear]] background-color:: blue - deck:: #ENT id:: 6733ccef-220c-4ac9-8b57-a1bd92422057 - - ### Medical Treatment : no medical treatment - background-color:: red - - ### Surgical Options - - ## Treatment - - If wax is soft : Aural toileting by micro suction, Jobson's Horne Probe - - If children : GA + antibiotic - - If wax is hard: Making it soft by 7.5% $$\ce{NaHCO3}$$ (or olive oil or coconut oil) 3-4 drops twice daily 5-7 days. Then micro suction is given - - ### Lifestyle and Dietary Recommendations + deck:: #ENT + - ### Medical Treatment : no medical treatment + background-color:: red + - ### Surgical Options + - Removal by [[Syringing the Ear]] or Instrumental manipulation + - Hard imapced mass may sometimes require prior softening with wax solvents + - 5% $$\ce{NaHCO3}$$ in equal parts of glycerine and water instilled two or three times a day for a few days + - Hydrogen peroxide, liquid paraffin or olive oil may also achieve the same result + - Commercial drops containing ceruminolytic agents like paradichlorobenzene 2% can also be sued and above methods tried again + - Any ulceration seen in meatal wall as a result of impacted wax is protected by application of suitable antibiotic ointment + - ### Lifestyle and Dietary Recommendations - ## Prognosis background-color:: blue - - ### Expected Course - - #### With Treatment - - #### Without Treatment - - ### Survival Rates - - #### With Treatment - - #### Without Treatment - - ### Quality of Life Considerations + - ### Expected Course + - #### With Treatment + - #### Without Treatment + - ### Survival Rates + - #### With Treatment + - #### Without Treatment + - ### Quality of Life Considerations - ## Complications background-color:: blue - - ### Possible Complications - - ### Long-term Effects + - ### Possible Complications + - ### Long-term Effects - ## Prevention background-color:: blue - - ### Health Education - - ### Community Approach - - ### Screening Programs - - ### Lifestyle Modifications + - ### Health Education + - ### Community Approach + - ### Screening Programs + - ### Lifestyle Modifications - ## Patient Education and Support background-color:: blue - - ### Educational Resources - - ### Support Groups - - ### Counseling Options + - ### Educational Resources + - ### Support Groups + - ### Counseling Options - ## Recent Research and Developments background-color:: blue - - ### Ongoing Clinical Trials - - ### Recent Advances + - ### Ongoing Clinical Trials + - ### Recent Advances - ## Key Literature background-color:: blue - ## Guidelines and Protocols - background-color:: blue + background-color:: blue \ No newline at end of file diff --git a/pages/hls__P_L_Dhingra_Diseases_of_Ear,_Nose_and_Throat_&_Head_and_Neck_Surgery_1730589599933_0.md b/pages/hls__P_L_Dhingra_Diseases_of_Ear,_Nose_and_Throat_&_Head_and_Neck_Surgery_1730589599933_0.md index 7313855..4070425 100644 --- a/pages/hls__P_L_Dhingra_Diseases_of_Ear,_Nose_and_Throat_&_Head_and_Neck_Surgery_1730589599933_0.md +++ b/pages/hls__P_L_Dhingra_Diseases_of_Ear,_Nose_and_Throat_&_Head_and_Neck_Surgery_1730589599933_0.md @@ -1,2 +1,39 @@ file:: [P_L_Dhingra_Diseases_of_Ear,_Nose_and_Throat_&_Head_and_Neck_Surgery_1730589599933_0.pdf](../assets/P_L_Dhingra_Diseases_of_Ear,_Nose_and_Throat_&_Head_and_Neck_Surgery_1730589599933_0.pdf) file-path:: ../assets/P_L_Dhingra_Diseases_of_Ear,_Nose_and_Throat_&_Head_and_Neck_Surgery_1730589599933_0.pdf + +- Reflex cough due to stimulation of auricular branch of vagus may sometimes occur + ls-type:: annotation + hl-page:: 71 + hl-color:: yellow + id:: 67579897-adbd-4590-b33f-139f936b8701 +- Tinnitus and giddiness may result from impaction of wax against the tympanic membrane + ls-type:: annotation + hl-page:: 71 + hl-color:: yellow + id:: 675798b9-1c47-4d4e-bf3f-f0e918a2c78c + hl-stamp:: 1733793979736 +- The onset of these symptoms may be sudden when water enters the ear canal during bathing or swimming and the wax swells up. + ls-type:: annotation + hl-page:: 71 + hl-color:: red + id:: 6757990b-3ecb-42ca-b341-621c427e9a82 +- Long standing impacted wax may ulcerate the meatal skin and result in granuloma formation (wax granuloma) + ls-type:: annotation + hl-page:: 71 + hl-color:: yellow + id:: 67579917-c01b-4bbc-afc5-c1fcbe54be4f +- It is an inflammatory condition caused by pseudomonas infection usually in the elderly diabetics, or in those on immunosuppressive drugs. + ls-type:: annotation + hl-page:: 70 + hl-color:: yellow + id:: 6757a108-63bf-437c-9a95-dfe16bd2f7ea +- Severe otalgia in an elderly diabetic patient with granulation tissue in the external ear canal at its cartilaginous–bony junction + ls-type:: annotation + hl-page:: 70 + hl-color:: yellow + id:: 6757a239-0aec-4435-8ab3-621cbd1d9117 +- If patient is not responsive, culture and sensitivity of ear discharge should guide the surgeon + ls-type:: annotation + hl-page:: 70 + hl-color:: yellow + id:: 6757a3e7-9b44-4101-a82f-5c6b79cc4fba \ No newline at end of file